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Abstract 
Valvular heart disease is a major cause of mortality worldwide. Mitral valve regurgitation 
represents the second major valvular disorder in the western world. Current strategies for 
mitral valve reconstruction are imperfect. The aim of this study was to investigate the tissue 
engineering of mitral valve leaflets for mitral valve leaflets reconstruction. The approach taken 
was to utilise decellularised porcine pericardium seeded with porcine mesenchymal stem cells 
(pMSCs) and to mechanically condition the cell seeded constructs using biaxial strain in a 
bespoke bioreactor. 
The biomechanical and biological properties of porcine mitral valve leaflets and native and 
decellularised porcine pericardium were studied for comparative purposes. The porcine 
pericardium was decellularised using a propriety method based upon low concentration 
sodium dodecyl sulphate (SDS) and proteinase inhibitors. Histological characterisation 
showed the four and three layered structure of leaflets and fresh/decellularised pericardium, 
respectively. Histological analysis of decellularised pericardium did not reveal any remaining 
cells. Moreover, the histoarchitecture of collagen and elastic fibres appeared to be well 
preserved. Biochemical analysis showed that the mitral valve leaflets and the fresh 
pericardium had hydroxyproline and glycosaminoglycan (GAG) contents similar to those 
reported in the literature. Decellularised pericardium had higher hydroxyproline content than 
that of fresh pericardium but lower GAG content. The levels of deoxyribonucleic acid (DNA) in 
fresh and decellularised pericardium were determined and this showed that there was a 99% 
reduction in the DNA content following decellularisation. In vitro biocompatibility studies 
showed that the decellularised pericardium was not cytotoxic to porcine skin fibroblasts and 
pMSCs. Biomechanical properties were determined using low strain rate uniaxial loading to 
failure. Both fresh and decellularised pericardium demonstrated rather isotropic behaviours, 
possessing similar mechanical properties along the two orthogonal directions studied. Anterior 
leaflet specimens cut circumferentially were stiffer than those cut radially and the posterior 
leaflets. This anisotropic mechanical behaviour of the anterior leaflet was related to the main 
orientation of the collagen fibres along the circumferential direction. Conversely, the posterior 
leaflets were more isotropic.  
The optimum seeding density for culturing decellularised pericardial samples was 1×105 
cells·cm-2 for pMSCs and the ideal time for culturing prior to loading the reseeded scaffold in 
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the bioreactor stations was 3 days. With regards to fibroblasts and porcine smooth muscle 
cells (pSMCs), the optimum seeding density was 2×105 cells·cm-2 at 1 week culture for 
fibroblasts, whereas pSMCs had the tendency of forming agglomerates on the surface of 
tissue rather than penetrating throughout the thickness of the scaffold, thus, they were not 
considered ideal for remodelling the histoarchitecture of tissue during dynamic experiments. 
The actuator of the bioreactor was calibrated and the general set up of the system was 
completed. Suitable conditions to apply during static culture in the bioreactor, in terms of 
oxygen and pH control, in order to maintain the ECM integrity and cell viability in the 
bioreactor, were initially determined using fresh pericardium, however this proved problematic 
due to the variability in the tissue that was available.   
One day static experiment performed with the bioreactor by using decellularised pericardium 
reseeded with pMSCs showed that there was no difference in terms of viability when keeping 
the tissue statically in the tissue holders and in the bioreactor stations. Thus, tissue holders 
could be used as positive static controls during dynamic experiments. 
One day dynamic experiments (10% strain) performed with the bioreactor by using 
decellularised pericardium reseeded with pMSCs showed that cells were viable both when 
kept dynamically in the bioreactor and statically in the tissue holders. Cells started aligning 
along specific directions when kept dynamically in the bioreactor.  
Overall porcine mitral valve leaflets and porcine fresh/decellularised pericardium shared 
similar histoarchitectures, but had different biochemical composition and biomechanics. 
Decellularised pericardium was shown to be an optimum material for cell repopulation, 
delivering the necessary biological and biomechanical cues to seeded cells. The bioreactor 
was optimised for both static and dynamic culture and is now ready for further investigation at 
longer time points. This research provided the basics into the optimal strategy for 
mechanostimulation of cell-seeded pericardial scaffolds in vitro in order to generate heart-
valve like tissue. 
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Chapter 1 
Introduction & literature review 
1.1 Introduction 
Valvular disease represents one of the major causes of mortality worldwide, causing disability, 
reduced quality of life, and early mortality (Chockalingam et al., 2004; Otto and Bonow, 2009). 
Valvular disease is most commonly manifested by two dysfunctional effects; valvular stenosis, 
which occurs when the valve opening is smaller than normal due to stiff or fused leaflets, and 
valvular deficiency, also called regurgitation, which occurs when a valve leaflets do not close 
tightly. In the United States alone, there are roughly 100,000 valve replacement or repair 
operations each year, and 20,000 valvular-disease-related deaths (Otto and Bonow, 2009). 
Mitral valve (MV) regurgitation represents the second major valvular disorder in the Western 
world, after aortic valve dysfunction (Otto and Bonow, 2009). Current treatment strategies for 
MV dysfunction include MV repair and replacement. Repair is the gold standard and usually 
employs synthetic biomaterials, such as expanded polytetrafluoethylene (ePTFE), for chordal 
reconstruction, or chemically-treated xenograft tissue, such as pericardium, for annular, 
cuspal or chordal reconstruction (Salati et al., 1997; Bevilaqua et al., 2003; Acar et al., 2004; 
David et al., 2013). Both approaches only deliver inert or biocompatible material solutions that 
cannot regenerate or grow with the patient. In addition, glutaraldehyde-treated tissue with cell 
remnants will calcify, become rigid and eventually degenerate (Boskey, 1981). Ideally, 
surgeons would prefer autologous tissue since it will retain viability and regenerate. In most 
cases, however, autologous tissue is not available, and even if it is available, this is not an 
ideal solution since it involves the sacrifice of the patient’s healthy pericardium. Although less 
advantageous than repair, valve replacement with bioprosthetic, mechanical or homograft 
valves have also been employed for MV dysfunction (Moon et al., 2001). However, this 
approach is associated with limited durability of the bioprostheses, the need for 
anticoagulation with the mechanical valves and the limited availability and immunogenicity of 
the homograft mitral apparatus (Chauvaud et al., 2003). 
The disadvantages associated with the current strategies for MV repair and replacement, 
have motivated the investigation of new approaches for the treatment of MV dysfunction. 
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Tissue engineering (TE) has recently emerged as an exciting alternative to conventional 
strategies for valvular repair and replacement. The ultimate goal of TE is to develop implants, 
which will not only be fully compatible, but will also be able to grow (in the young patient), 
remodel and regenerate in vivo. In general, there are two main TE strategies, namely in vivo 
TE and in vitro TE. In vivo TE involves the use of bioresorbable scaffolds that rely on the 
patient’s cellular response in vivo, with the intention of developing functionality after 
implantation. In vitro TE, or functional TE (FTE), employs scaffolds that are seeded with 
autologous cells in vitro, and physically conditioned with a view to producing in-vivo-equivalent 
functionality prior to implantation. In this fashion, FTE simulates the type of physical 
environment that native tissues encounter in the body with a view to engineering functional 
constructs in the laboratory. The development of FTE simulation systems for the growth of 
tissues in response to physiological mechanical stimulation has the potential not only to 
provide alternative strategies for tissue reconstructions, but also important model systems for 
the enhancement of understanding into mechanotransduction, the process by which the cells 
transduce mechanical stresses into biochemical signals to regulate their function (Ulbricht et 
al., 2013).  
The aim of this study was to develop, optimise and evaluate FTE simulation models for the 
future development of MV-leaflet-equivalents for MV reparative surgery. The approach 
adopted was to utilise decellularised porcine pericardium seeded with porcine mesenchymal 
stem cells (pMSCs). The long term strategy was envisaged as the production of decellularised 
xenogeneic donor pericardial scaffolds seeded with the patient’s own MSCs, isolated from the 
bone marrow, and mechanically conditioned in the bioreactor, to allow for the remodelling of 
the scaffold in order to obtain a MV-leaflet-equivalent tissue prior to implantation. Human cells 
were not used in this study due to the limited availability of human tissue.  
The biomechanical and biological properties of porcine MV leaflets were studied with a view to 
understanding the histoarchitectural, biomechanical and functional requirements of the TE 
constructs. The properties of native and decellularised porcine pericardium were also studied 
to assess the effects of decellularisation on the histoarchitecture, biomechanics and function 
of the pericardium, as well as to assess the suitability of pericardium for MV leaflet repair. 
Subsequently, the optimum conditions for seeding the pericardial scaffolds with pMSCs were 
investigated in static cultures. The pMSCs-seeded scaffolds were then dynamically cultured in 
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the bioreactor, with a view to investigating the effect of MV-relevant stimuli on the function and 
morphology of the pMSCs, and on the histoarchitecture of the TE constructs.  
 
1.2 Literature review 
1.2.1 The cardiovascular system 
The cardiovascular system (CVS) consists of the heart and the blood vessels; from the 
arteries, arterioles, and capillaries, to the venules and veins. The heart and blood vessels 
transport nutrients to and remove waste products from the cells. In particular, the CVS is 
responsible for the rapid convective transport of oxygen, glucose, amino acids, fatty acids, 
vitamins, drugs and water to the tissues, and the rapid washout of metabolic waste products 
such as carbon dioxide, urea (soluble compound) and creatinine (the anhydride of creatine). 
The heart consists of two intermittent muscular pumps; the right and left ventricles. Each 
pump is filled from a contractile reservoir; the right or left atrium. The right ventricle pumps 
deoxygenated blood through the pulmonary artery to the lungs. The pulmonary veins return 
oxygenated blood from the lungs to the left side of the heart, completing the pulmonary 
circulation. The left ventricle pumps out an equal volume of oxygenated blood to the rest of 
the body. Deoxygenated blood returns to the right atrium of the heart via the two main veins, 
the superior and inferior vena cava, to complete the systemic circulation (Figure 1.1), (Levick, 
2003; Martini and Nath, 2009; Tortora and Nelsen, 2009).  
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Figure 1.1: The pulmonary and systemic circulation. From http://nursingcrib.com/nursing-notes-
reviewer/maternal-child-health/from-fetal-circulation-to-pulmonary-circulation/ (accessed on 
05/11/2013). 
 
1.2.2 Anatomy, structure & function of the heart 
The human heart is a cone-shaped muscle of around 12 cm long and 9 cm wide (Levick, 
2003). Unlike most other muscles in the body, the heart never rests. It beats approximately 
100,000 times each day pumping roughly 8000 litres of blood (Martini and Nath, 2009).  The 
heart consists of four muscular chambers; the left and right atrium, and the left and right 
ventricle (Figure 1.2). It lies obliquely across the midline of the chest, with the tip of the cone 
(apex) located directly posterior to the sternum. The apex moves mainly during the contraction 
producing the heartbeat (apex beat) that is felt through the chest wall. 
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Figure 1.2:  The human heart. Adapted from: http://planetearth.nerc.ac.uk/news/story.aspx?id=369 
(accessed on 05/11/2013). 
 
The atria and the ventricles are separated by muscular partitions, called septa; the atria by the 
inter-atrial septum, and the ventricles by the much thicker inter-ventricular septum. The atria 
and ventricles of each side of the heart communicate via the atrioventricular (AV) valves 
(tricuspid valve and mitral valve). The AV valves permit the unidirectional blood flow from the 
atria to the ventricles (Martini and Nath, 2009). Blood passes from the right atrium into the 
right ventricle through the tricuspid AV valve, which is composed of three fibrous cusps or 
leaflets. The tricuspid valve closes when the right ventricle contracts, preventing the backflow 
of blood into the right atrium. The blood exits the right ventricle into the pulmonary circulation 
through the pulmonary valve, or pulmonary semilunar valve, which is located at the superior 
part of the right ventricle. The left atrium receives blood from the lungs via the pulmonary 
veins. The left AV valve, or bicuspid valve, or mitral valve (MV), regulates the blood inflow 
from the pulmonary circulation into the left heart, allowing blood from the left atrium into the 
left ventricle and also preventing the backflow of blood to the left atrium during systole. 
The left ventricle is the thickest part of the heart (averaging 10 - 15 mm thickness) and it forms 
the apex of the heart. Similarly to the right ventricle, the left ventricle accommodates the 
papillary muscles, which are active muscular extensions in the internal wall of the ventricles, 
and anchor the AV leaflets via the chordae tendineae. The latter are tendinous structures that 
act in a similar manner to the strings of a parachute, preventing the AV leaflets from 
overshooting (prolapse) into the atria during ventricular contraction. The blood exits the left 
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ventricle through the aortic valve, entering the largest artery of the body, the ascending aorta. 
Some of the blood in the aorta flows into the coronary arteries, carrying blood to the 
myocardium (Tortora and Nelsen, 2009). The four heart valves are illustrated in Figure 1.3. 
 
Figure 1.3: The four heart valves acting in the human heart. Modified from 
http://www.indiana.edu/~nimsmsf/P215/p215notes/LabManual/Lab10.pdf (accessed on 
05/11/2013). 
 
1.2.3 The pericardium 
The pericardium is the membrane that surrounds and protects the heart. It restricts the heart 
in its position, allowing at the same time sufficient freedom of movement for strong and rapid 
contraction. The pericardium can be divided in two main portions: the fibrous and serous 
pericardium (Figure 1.4). The superficial fibrous pericardium is a tough, inelastic, dense and 
irregular connective tissue, which resembles a bag attached to the diaphragm. The fibrous 
pericardium prevents overstretching of the heart, and provides protection and anchoring of the 
heart to the mediastinum. 
The deeper serous pericardium is a thinner and more delicate membrane that forms a double 
layer around the heart. The serous pericardium is in turn divided into three main components; 
the parietal layer, pericardial cavity and visceral layer. The outer parietal layer is fused to the 
fibrous pericardium. The inner visceral layer, also called the epicardium, adheres tightly to the 
heart and consists of the mesothelium (cell layer of mesodermal origin) and an underlying 
layer of areolar connective tissue, attached to the myocardium. Between the parietal and 
visceral layers is the pericardial cavity that contains a thin film of lubricating fluid. This fluid is 
known as pericardial fluid and it is secreted by the pericardial cells (Tortora and Nelsen, 
2009). 
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The differentiation among the layers varies in the literature. In a study by Mirsadraee (2005), 
the parietal pericardium is referred to as the fibrous layer and the parietal layer considered 
together. The study described the parietal pericardium as a sac consisting microscopically of 
three layers (Figure 1.5). These layers included: the serosa, consisting of a layer of 
mesothelial cells and a narrow submesothelial space, the middle thick fibrosa, containing 
variously oriented layers of collagen fibrils and small elastic fibres, and the outer epipericardial 
layer, containing mainly large bundles of collagen (Ishihara et al., 1980). In this thesis, the 
definition of parietal pericardium described by Mirsadraee (2005) is used. 
 
Figure 1.4: The human pericardium. Adapted from Martini and Nath (2009). 
 
 
Figure 1.5: Alcian blue-periodic acid-Schiff (PAS) staining of a human parietal pericardium 
sample isolated along the direction of the collagen fibres. A: Mesothelial layer and cells; B: 
Connective tissue cells; C: Fibrosa and epipericardial layers. Scale bar indicates 100 µm. 
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1.2.4 Heart physiology & the cardiac cycle 
Every heart beat is a single cardiac contraction during which the entire heart contracts in 
series (first the atria and then the ventricles). The heart beat is initiated by an electrical system 
within the heart called the sinoatrial (SA) node which discharges spontaneously at regular 
intervals (Figure 1.6). This system is composed of modified cardiomyocytes, not nervous 
tissue (Levick, 2003). The electrical discharge reaches the atrioventricular (AV) node from 
which, the electrical impulse reaches the ventricular wall. The period between the start of one 
heartbeat and the start of the next is called the cardiac cycle. The cardiac cycle includes 
alternating periods of contraction and relaxation. For each chamber of the heart, the cardiac 
cycle can be described into two phases; systole and diastole (Figure 1.7). 
 
 
Figure 1.6: The conducting system of the heart. The stimulus is generated in the SA node, then it is 
propagated to the AV node via the atria and then spreads into the ventricles. Adapted from: 
http://www.mda.org/publications/quest/q123edmd.html (accessed on 05/11/2013). 
 
Systole represents the contraction during which the chamber contracts and pushes blood into 
the adjacent artery (pulmonary or aorta). Diastole represents the relaxation during which the 
ventricles fill with blood from the atria and prepare for the next cardiac cycle. During the 
cardiac cycle the pressure within each chamber rises during systole and falls during diastole. 
The valves between adjacent chambers ensure the unidirectional flow of blood from one 
chamber to the next when the pressure in the first chamber exceeds the one in the second. 
Although the pressure is lower in the right atrium and right ventricle, both sides of the heart 
contract at the same time, and they eject equal volumes of blood. 
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Figure 1.7: The cardiac cycle. Description of the four phases of the cardiac cycle: atrial systole, atrial 
diastole, ventricular systole and ventricular diastole. Modified from Martini and Nath (2009). 
 
The cardiac cycle begins with the atrial systole, during which the atrial pressure raises 
pushing blood into the ventricles through the open AV valves. At start of atrial systole, the 
ventricles are already filled to about 70 per cent of their normal capacity, due to the passive 
blood flowing during the end of the previous cardiac cycle. Following the atrial systole, the 
atrial diastole and the ventricular systole begin. During ventricular systole, the pressure in the 
ventricles rises above the one in the atria, causing the AV valves to close. When the 
ventricular pressure exceeds that in the arterial trunks, the semilunar valves open and blood 
flows into the pulmonary and aortic trunks. At the end of the ventricular systole, there is a 
rapid fall of the ventricular pressure. Blood in the aorta and pulmonary trunk flows back 
towards the ventricles, causing the semilunar valves to start closing, and a gradual decrease 
in the aortic and pulmonary pressure. Subsequently, the ventricular diastole starts and is 
followed by the atrial systole of the next cycle.  
1.2.5 The mitral valve  
The MV is situated between the left atrium and left ventricle and its function is to direct the 
blood flow from the left atrium towards the left ventricle. Its orifice is smaller than the tricuspid 
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orifice, with a mean circumference of 9 cm in males and 7.2 cm in females. When the leaflets 
of the MV close, they form a single coaptation zone. 
 
Figure 1.8: Anatomy of the mitral valve. Adapted from http://www.heart-valve-surgery.com/heart-
surgery-blog/2008/09/02/mitral-valve-annulus-definition-diagrams-prolapse-calcification-treatment/ 
(accessed on 05/11/2013). 
 
There are two valve commissures, or junctional zones, between the leaflets of the normal MV, 
which resemble deep folds in the leaflets. These include the anteromedial and the 
posterolateral commissures (Figure 1.8). The MV annulus is made of fibrocollagenous 
elements of varying consistency from which the fibrous core of the leaflet (fibrosa) originates. 
This architecture allows for significant changes in the shape and dimensions of the annulus at 
different stages of the cardiac cycle, which ensure valve competence (Gray, 2008). The two 
MV leaflets constitute a veil, which is attached around the circumference of the mitral annulus. 
Although the MV leaflets are more like a single continuous leaflet, they are usually referred to 
as the anterior and posterior leaflets. On the ventricular side, the leaflets have a “rough” zone 
which includes the insertions of the chordae tendinae to the leaflet tissue. Between the 
“rough” zone and the annulus, there is a macroscopically “smooth” leaflet zone, free of 
chordae insertions, whose fibrous core incorporates extensions attached to the rough zone. 
During passive ventricular filling and atrial systole, the smooth atrial surface of the anterior 
leaflet is important in directing the blood towards the ventricle body and apex. The posterior 
leaflet has a longer attachment to the annulus than the anterior leaflet. From the papillary 
muscle, the chordae attach to the free edge of the leaflets. The two MV papillary muscles vary 
in length and width and may be bifid. The chordae tendinae usually arise from the tip and 
apical zone of each papillary muscle, but sometimes originate from near their base.  
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The principal components of the extracellular matrix (ECM) of the MV leaflets are collagen 
(60%), elastin (10%) and proteoglycans (20%) (Kunzelman et al., 1993a). Each component 
contributes to the valve’s unique physical properties. Collagen provides mechanical strength 
and it is predominantly type I and III (74% and 24%) with 2% of type V (Cole et al., 1984). The 
collagen fibres are surrounded by an elastin matrix, which provides interconnections between 
the collagen (Scott and Vesely, 1995). These fibres can withstand high tensile forces, with low 
torsional and flexural stiffness. The fibres are oriented along the circumferential direction in 
which the tissue is able to withstand the greatest tensile stresses (Sacks and Yoganathan, 
2007). The glycosaminoglycan (GAG) side-chains of proteoglycans are negatively charged 
leading to a significant water-binding capacity and the formation of a porous gel. An important 
function is the ability to resist compressive forces (Culav et al., 1999). These components 
constitute the four layers of the leaflet, including the atrialis, spongiosa, fibrosa and 
ventricularis (Gross and Kugel, 1931; Kunzelman et al., 1993a; Flanagan and Pandit, 2003). 
The arrangement of these layers is different between the semilunar and AV valves. In 
particular, the AV valves possess an additional layer called atrialis (Flanagan and Pandit, 
2003), (Figure 1.9). 
 
 
 
Figure 1.9: MV location (a) and Masson's trichrome staining of anterior leaflet (radial) (b). 
Collagen stained blue, blood vessels and cytoplasm stained red). Scale bar indicates 500 µm. (a) 
Modified from: http://www.drugdevelopmenttechnology.com/projects/xarelto/xarelto1.html (accessed 
on 05/11/2013). 
 
The fibrosa of the MV leaflet is the central layer and it forms the load- bearing backbone, 
consisting of sheets of collagen bundles (Kunzelman et al., 1993a) aligned mainly along the 
circumferential direction and arranged in a crimped manner to allow expansion during valve 
closure (ventricular systole). This layer is continuous with the collagen core of the chordae 
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tendineae. The atrialis layer is mainly made of well organised multiple layers of elastin fibres, 
whereas the spongiosa is formed by loose connective tissue, including proteoglycans and 
randomly oriented collagen. The atrialis and spongiosa are able to absorb stresses generated 
during valve closure (ventricular systole) through GAG presence. The ventricularis is the 
inferior layer and thinnest one. It is abundant of elastin, allowing the leaflets to withstand cyclic 
deformation/reformation during the cardiac cycle (Culav et al., 1999; Kunzelman et al., 
1993a). 
At the cellular level, heart valves are sheathed by a layer of valve endothelial cells (VECs). 
These cells are aligned circumferentially with the collagen architecture. Valve interstitial cells 
(VICs) are spread throughout the three layers of the leaflets, and their purpose is to remodel 
the valve ECM. They respond to the deformation of the leaflets during the cardiac cycle, 
repairing the damage occurred in the lealfets during cyclic loading. VICs also act as signal 
transduction sites, transducing the mechanical information from the ECM to chemical signals 
to regulate their function, a process that is known as mechanotransduction (Weber et al., 
2002). The key components of the heart valves and their function is summarised in Table 1.1. 
Element Sub-structure Function 
ECM Collagen 
 
Elastin 
GAGs 
Provides strength and stiffness to maintain coaptation during diastole, 
when leaflet has maximal area. 
Extends in diastole; contracts in systole to minimize leaflet area. 
Accommodates shear of cuspal layers, cushions shock during valve cycle. 
Cells Interstitial 
 
Endothelial 
Synthesize ECM; express MMPs and TIMPs that mediate matrix 
remodelling. 
Maintain non-thrombogeneicity; blood-tissue interface; 
Blood 
vessels 
- Few and focal; valve leaflets and leaflets sufficiently thin to be nourished 
by diffusion from the heart's blood. 
Nerves - Present, with uncertain function. 
Anisotropy - Permits differences in radial and circumferential extensibility. 
Table 1.1: Key elements of the heart valves. MMPs: matrix metalloproteinases; TIMPs: tissue 
inhibitors of metalloproteinases. Modified from Mendelson and Schoen (2006). 
 
1.2.6 Biomechanics of the heart valves 
Understanding the interaction between the heart valves and the local haemodynamic and 
biomechanical environment is critical to understanding native valve function and structure. 
During the cardiac cycle, the valves undergo large dynamic deformations. One of the best 
methods to understand the key characteristics of valve deformation is to examine it in relation 
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with the transvalvular pressures (TVPs). The maximum physiological TVPs of a heart at rest, 
for the tricuspid, pulmonary, mitral and aortic valves are 25, 10, 120 and 80 mm Hg, 
respectively (Guyton, 1976). Therefore, the valves in the left side of the heart experience 
higher TVPs. Owing to this, the mitral and aortic valves are more prone to disease. Sacks et 
al. (2009a) reported large changes in anterior MV leaflet area (30 %) under minimal TVP, 
(Figure 1.10), followed by a sharp transition to a highly stiff region. This stiff region 
corresponded to the fully coapted state of the MV when it is closed. A peak areal strain rate of 
1000 % per second was observed during the MV closing phase. Other studies reported that 
the anterior MV leaflet experienced large, anisotropic strains during closure and that once 
closed, during systolic ejection, further leaflet deformation ceased (Sacks et al., 2002; 2007). 
Mean peak strain rates of 300-400 % per second were observed along the radial direction and 
100-130 % per second along the circumferential direction. The authors reported that the 
closing deformation behaviour was symmetrically reversed during valve opening (Sacks et al., 
2002, 2007). 
 
Figure 1.10: Area changes of the anterior MV leaflet during the cardiac cycle. (a) Relationship 
between left ventricular (LV) pressure and MV areal strain. (b) Representative areal strain traces, with 
the corresponding strain rate.  From Sacks et al. (2009a). 
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During the cardiac cycle, the MV leaflets experience tension, shear, and flexure (Sacks et al., 
2009a). These loading modes are imposed cyclically during valve opening and closing 
(flexure), during blood flow through the valve (shear), and when the valve is fully closed 
(tension) (Mendelson and Schoen, 2006; Merryman et al., 2006). These macroscopic forces 
are translated to the microscale level, and then transduced by VICs at the cellular level. Heart 
valves respond in normal and pathological conditions to the surrounding environmental 
stimuli, especially mechanical loading, by cell activation (VICs switch to their activated 
myofibroblast phenotype) and consequent ECM remodelling and synthesis. This interrelation 
between the physical environment of the heart valves and the function of their cellular 
populations has an inevitable effect on the constitution of their ECM. This in turn affects the 
mechanical behaviour of the tissue. Mechanical behaviour is concerned with the deformation 
that occurs under loading. The simplest experiment that can be carried out to determine the 
mechanical behaviour of a tissue, and to understand the relation between mechanics and 
histoarchitecture, is the uniaxial tensile test. During such a test, the stress as a response to 
the straining of the tissue sample is recorded. The typical stress-strain behaviour of soft tissue 
under uniaxial tensile loading to failure is shown in Figure 1.11. 
 
 
Figure 1.11: A typical stress-strain behaviour of soft tissue. UTS: ultimate tensile strength. 
Adapted from Fung (1984). 
 
Such a behaviour has three distinct phases before failure, including an initial linear phase 
(elastin phase), an intermediate transition phase and a final linear phase (collagen phase) 
(Fung, 1984). During the elastin phase, the tissue offers little resistance to elongation since 
force transmission and load bearing is provided mainly by the elastin fibres. During this phase 
the tissue behaves almost as a Hookean elastic solid with the stress increasing linearly with 
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the strain. In the transition phase, collagen uncrimping occurs and gradually more collagen 
fibres become uncoiled and aligned (recruited), increasingly contributing to force transmission. 
In the collagen phase, all the collagen fibres are uncoiled and the load is entirely borne by 
them. The slope of the stress-strain curve for this phase is steep and almost constant, 
reflecting the material properties of the collagen fibres, which allow limited elongation to 
fracture (Korossis, 2002). The collagen phase of a tissue usually continues well beyond the 
physiological range, corresponding to its reserve strength. At the end of the collagen phase 
the slope starts decreasing and a further increase of the load will finally result in tissue failure. 
This stress-strain behaviour varies among tissues, depending on the structure and quantity of 
the various tissue components, (Fung, 1984; Auricchio, 2003). Moreover, the stress-strain 
behaviour of biological tissue shows non-linear viscoelasticity, so that when the tissue is 
subjected to cyclic loading, the stress-strain response demonstrates a hysteresis between 
loading and unloading (Figure 1.12). With succeeding cycles the hysteresis loop decreases, 
tending to a steady state after a number of cycles. This period of adjustment is common to all 
tissues, and it is called preconditioning. The reason that preconditioning occurs is that the 
internal structure of the tissue changes during the cycling. By repeated cycling, a steady state 
is reached at which no further change will occur unless the cycling routine is changed. 
 
 
Figure 1.12: Hysteresis loop between loading and unloading. From Fung (1984). 
 
1.2.7 Valvular cells 
Two types of cells are found in valve leaflets, including VECs, which cover the surfaces of the 
leaflets, and VICs, which populate the ECM of the leaflets. Both cell types exhibit unique 
functions that are different from those of other endothelial (ECs) and interstitial (ICs) cells 
found throughout the body.  VECs are located on the outflow and inflow surfaces of the valve, 
and they differ from one surface to another since they are influenced by different pressure and 
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flow patterns (Sacks et al., 2009b). Chester and Taylor (2007) reported that although valvular 
cells play an important role in maintaining the integrity of the leaflets, in cases where 
inappropriate stimuli occurs, VICs and VECs may also participate in processes that lead to 
valve degeneration and calcification. The VECs form a continuous layer with the endocardium 
of the heart and they are involved in the regulation of vascular tone, inflammation, thrombosis 
and remodelling (Leask et al., 2003). At a basic structural and functional level, VECs resemble 
ECs present elsewhere in the circulation. The primary role of the ECs is to form a semi-
permeable membrane able to exclude the plasma and other biomolecules of the blood while 
allowing nutrients to move rapidly (Levick, 2003). ECs have an important role in the 
maintenance of a non-thrombogenic blood-tissue interface, the regulation of immune and 
inflammatory reactions, and in the regulation of the function of other cell types. In fact VECs 
are part of the EC family, but since they are subjected to the valvular mechanical 
environment, they assume different phenotypes to other ECs (Rabkin-Aikawa et al., 2005).  
VICs comprise different cell populations, which are able to synthesize several types of ECM 
molecules and degrading enzymes, such as matrix metalloproteinases (MMPs), as well as 
their inhibitors (TIMPs), which allow for the ECM remodelling and repair (Rabkin-Aikawa et al., 
2005). The different functions of VICs are illustrated in Figure 1.13. VICs are present 
throughout the leaflet and express three different phenotypes of VICs; fibroblasts, smooth 
muscle cells (SMCs) and myofibroblasts (Taylor et al., 2003; Sacks and Yoganathan, 2007). 
These different VIC phenotypes are believed to be plastic and reversible (Rabkin et al., 2002; 
Rabkin-Aikawa et al., 2004). Contractile VICs (expressed by the SMC phenotype) may have a 
function in aiding adaptation to altered haemodynamic forces via the generation of valvular 
forces (Rabkin-Aikawa et al., 2004). The myofibroblastic phenotype is thought to be involved 
in the rapid remodelling of the ECM, whereas the fibroblastic phenotype is thought to be 
important in regulation and stabilisation of the ECM structure. Rabkin-Aikawa et al. (2005) 
reported that under mechanical equilibrium the majority of the VIC population is composed of 
quiescent fibroblast-like cells. When stimulated by mechanical loading or other environmental 
stimuli (during valve development, adaptation, pathology and substitution), the fibroblastic 
phenotype becomes activated (myofibroblastic) and mediates rapid connective tissue 
remodelling through collagen biosynthesis and other cellular activities (Rabkin-Aikawa et al., 
2005). 
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Figure 1.13: Cellular functions of valve interstitial cells. From Taylor et al. (2003).  
 
The ability of fibroblasts to readily adapt to their environment could be very useful in tissue 
engineering. These cells synthesise collagen, elastin, proteoglycans, fibronectin, growth 
factors, cytokines, chemokines, MMPs and TIMPs. MMPs play a vital role in ECM remodelling 
and maintenance in health and disease (Segura et al., 1998). They also control the release of 
growth factors. Myofibroblasts are unique mesenchymal cells found in many tissues and have 
both fibroblast and SMC characteristics (Schmitt-Graff et al.,1994). Studies of organ cultures 
of valves, as well as animal studies, have demonstrated that although VICs play an important 
role in repair, they may also have a detrimental role in mediating valve calcification (Mohler et 
al., 1999).  
In addition, and in studies by Liu et al. (2007) and Schoen (2008), five identifiable VIC 
phenotypes were suggested. These include embryonic progenitor endothelial/mesenchymal 
cells, quiescent VICs (qVICs), activated VICs (aVICs), progenitor VICs (pVICs), and 
osteoblastic VICs (obVICs). The embryonic progenitor endothelial/mesenchymal cells 
undergo endothelial-to-mesenchymal transformation (EMT) that initiate the process of valve 
formation in the embryo to give rise to qVICs and/or aVICs. The qVICs are at rest in the adult 
valve and maintain normal valve physiology. In the case of haemodynamic/mechanical stress 
or pathological injury, qVICs become aVICs that participate in repair and remodelling of the 
valve. In conditions promoting valve calcification, such as in the presence of osteogenic and 
chondrogenic factors, qVICs can undergo osteoblastic differentiation into obVICs.  
1.2.8 Heart valve dysfunction 
The most common aetiologies of heart valve disease are classified to congenital abnormalities 
(disruption in the formation of the valve architecture due to incorrect gene expression), 
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myxomatous valve degeneration (damage to or inadequate collagen leading to weakness of 
the leaflets), acquired disease (such as valve calcification or endocarditis) or a mixture of 
congenital and acquired disease (such as calcification or endocarditis of a congenitally 
malformed valve) (Schoen, 2005a, 2008; Otto and Bonow, 2009). Calcification involves the 
impregnation of the leaflets or surrounding tissue with calcium or calcium salts, which harden 
the tissue. Endocarditis is the inflammation of the endocardium due to an infectious or non-
infectious cause. Acquired valvular heart disease can be either of rheumatic or non-rheumatic 
origin (Otto and Bonow, 2009). Valve pathology is often mediated through abnormal and 
complex interactions between the VICs, VECs, ECM and their environment (Schoen, 2008). 
During the last century, there has been a dramatic decline in the incidence of rheumatic fever 
in developed countries to less than 1 per 100,000, whereas in developing countries, rheumatic 
heart valve disease still remains one of the major clinical conditions. Rheumatic fever is an 
acute inflammatory disease that induces a progressive immune reaction and causes the 
thickening and fibrosis of the valve with fusion of the commissures, reduced leaflet mobility 
and a small orifice. Moreover the chordae may be matted together with heavy calcification of 
the valve (Otto and Bonow, 2009). Although the incidence of rheumatic fever has declined in 
the developed countries, the overall burden of valvular heart disease has not followed the 
same trend due to the increase in age-related degenerative valve disease (World Health 
Organization, 2004; Carapetis, 2007). Over the last 30 years there has been a considerable 
change in the frequency of various valvular disorders in the Western world. Currently, MV 
regurgitation represents the second major valvular disorder, after aortic valve dysfunction. 
Other common types of MV disease include MV prolapse and MV stenosis (Otto and Bonow, 
2009). 
1.2.8.1 Mitral valve regurgitation 
Mitral valve regurgitation (MVR) is one of the most common valvular disorders and it may be 
caused by a wide variety of aetiologies (Otto and Bonow, 2009). MVR occurs when the MV is 
not capable of closing completely during left ventricle contraction, causing blood flowing back 
into the atrium (Turi, 2004; Figure 1.14). MVR can be caused by the malfunction of the valve 
leaflets, valve annulus, chordae, papillary muscles or ventricular myocardium. 
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Figure 1.14: Pathology of MV regurgitation. Blue arrow indicates blood regurgitating back to the 
atrium. From: http://www.uofmhealth.org/health-library/zm6291 (accessed on 05/11/13).  
 
MVR can be caused by mitral valve prolapse (Turi, 2004), or rheumatic fever. The latter 
causes distortion the leaflets and shortening of the chordae (Buchbinder and Roberts, 1972; 
Arnett and Roberts, 1976; Turi, 2004). Other types of MVR include ischaemic MVR, which can 
be either acute (due to papillary muscle rupture or myocardial infarction), or chronic (due to 
shape alterations of the left ventricular; Otto and Bonow, 2009). MVR may also be caused by 
endocarditis, which involves damage of the leaflets or rupture of the chordae, producing acute 
or chronic MVR (Otto and Bonow, 2009), and by cardiomyopathy (Virmani, 1980; Ross and 
Roberts, 1986; Roberts et al., 1987; Klues et al., 1992). Moreover, the enlargement of the left 
ventricle can cause dilation of the mitral annulus, resulting in inadequate closing of the valve 
orifice by the leaflets and, consequently leading to MVR (Turi, 2004). 
1.2.8.2 Mitral valve prolapse 
Mitral valve prolapse (MVP), also called “click murmur syndrome” or “Barlow's syndrome”, 
represents the displacement of enlarged, thickened, mitral leaflets back into the left atrium 
during ventricular systole (Hayek et al., 2005; Figure 1.15). Owing to this, the valve does not 
close tightly during systole, allowing blood back to the left atrium. MVP is equally common in 
men and women and has an occurrence in the general population of about 2-3%. MVP can be 
classified as classic (when the thickening is greater than 5 mm), or non-classic prolapse 
(Freed et al., 1999). The underlying cause of MVP can be histological abnormalities in the 
valvular tissue, geometric disparities between the left ventricle and the MV, or various 
connective tissue disorders, such as myxomatous degeneration (Schoen, 2008). Myxomatous 
degeneration, which is the most common cause of MVP, is associated with inadequate 
chordal support (elongation or rupture), excessive leaflet tissue and annular dilatation in 
conjunction with leaflet thickening (Otto and Bonow, 2009).  Leaflet thickening is usually 
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caused by excessive deposition of proteoglycans in the spongiosa (Schoen, 2008). In 
addition, there is an attenuation of the collagen-rich fibrosa layer of the valve, together with 
development of structurally abnormal chordae (Hayek et al., 2005). As a result, a decrease in 
stiffness and an increase in extensibility occur in the valvular tissue (Barber et al., 2001a, 
2001b). In myxomatous degeneration, the VICs alter the synthesis and/or remodelling of the 
ECM by increasing the expression of MMPs and other enzymes responsible for ECM protein 
degradation (Rabkin et al., 2001), and by increasing GAG synthesis (Hayek et al., 2005; 
Schoen 2008). MVP causes chest pain, palpitations, fatigue, weakness, anxiety and panic 
attacks (Turi, 2004; Hayek et al., 2005). One of the most serious complications of MVP is 
severe MVR. 
 
Figure 1.15: MV prolapse. From: http://www.nhlbi.nih.gov/health/health-topics/topics/mvp/ (accessed 
on 05/11/13). 
 
1.2.8.3 Mitral valve stenosis 
Mitral valve stenosis (MVS) involves the narrowing of the MV orifice (Figure 1.16), which 
reduces the efficiency of the heart to filling the left ventricle during diastole (Turi, 2004). The 
most usual cause of MVS is rheumatic heart disease (Roberts et al., 1973, 1987; Otto and 
Bonow, 2009), whereas less common, non-rheumatic causes include severe calcification of 
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the mitral annulus and leaflets (Hammer et al., 1978; Theleman et al., 2006), congenital 
anomalies (Roberts et al., 1973, 1987), infective endocarditis (Roberts et al., 1967), 
neoplasms (particularly myxoma) protruding through the mitral orifice (Roberts, 2001), and a 
mismatched prosthesis used to replace the native MV (Roberts et al., 1973). MVS is 
uncommon in most industrialized nations, due to the dramatic decrease of rheumatic fever. 
However, it remains relatively common in developing countries (Turi, 2004). 
 
 
Figure 1.16: Pathology of MV stenosis: the MV orifice is narrowed during stenosis.  From: 
http://www.heart-valve-surgery.com/mitral-valve-disorders-symptoms.php (accessed on 05/11/13). 
 
The symptoms of MVS include breathlessness and palpitations. The latter are caused by a 
dysfunction in the stability of the heart beat (Turi, 2004; Otto and Bonow, 2009). Other 
symptoms may include fatigue, chest pain and occasional coughing up of blood (Turi, 2004). 
In patients with MVS the valve has a domed appearance, restricted opening, and is thickened 
with an enlarged left atrium (Turi, 2004). 
1.2.9 Conventional mitral valve reconstruction strategies 
Current surgical interventions for MV dysfunction include MV repair and replacement (Otto 
and Bonow, 2009). Similarly to the case of the other heart valves, reconstruction strategies for 
MV dysfunction need to employ materials and devices that are non-thrombogenic, provide 
resistance to infection, have adequate mechanical properties and structural integrity and, 
ideally, support cell infiltration and viability (Mendelson and Schoen, 2006). 
1.2.9.1 Mitral valve repair 
Currently, repair of the MV is the gold standard for treating MV dysfunction and involves open 
heart surgery. In the last 50 years, MV repair techniques have undergone many modifications 
and improvements (Spiegelstein et al., 2007). Depending on the underlying cause of MV 
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dysfunction, different types of MV repair techniques are applied. MV repair in degenerative 
MVR is associated with very good short- and long-term outcomes (Gillinov et al., 1998; 
Spiegelstein et al., 2007). Repair techniques used to treat this condition include quadrangular 
(Figure 1.17), trapezoid, or triangular resection of the segment of the posterior leaflet 
demonstrating prolapse or ruptured chords (Carpentier et al., 1983; Deloche et al., 1990; 
Braunberger et al., 2001; Daimon et al., 2006; Spiegelstein et al., 2007). The posterior leaflet 
is repaired with either plication of the annulus, or with sliding plasty. The former involves the 
suturing of the annulus at the level of the resection in order to make the two leaflet remnants 
come in close apposition with a little overlap. The latter is associated with excess tissue, as in 
the case of Barlow's diseases, and involves the detachment of part of the two remnants of the 
posterior leaflet from the annulus, followed by the reattachment of the segments to the 
annulus, allowing the close apposition of the leaflet remnants with a little overlap (Perier, 
2005). Commonly, after a quadrangular resection the insertion of a ring completes the repair. 
MV repair in rheumatic disease remains controversial due to the high possibility of re-
operation after repair, and the risks associated with the advanced age of the patients and the 
presence of active rheumatic endocarditis (Duran et al., 1991). 
 
 
 
Figure 1.17: Quadrangular resection in MV repair. Part of the posterior leaflet is resected (a, b); 
final suturing involving either plication of the annulus or sliding plasty (c). From Otto and Bonow 
(2009). 
 
In anterior leaflet prolapse or ruptured chords, ePTFE chord replacements have become quite 
popular in the past decade (Von Oppel and Mohr, 2000; David, 2004; Dreyfus et al., 2006; 
Lawrie, 2006). Chordal transfer is performed in patients with myxomatous disease and 
involves the transfer of chords from a healthy portion of the leaflet to the prolapsing one. This 
technique has demonstrated excellent clinical outcomes (Smedira et al., 1996; Salati et al., 
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1997; Duran et al., 1999; Gillinov et al., 2005a). Shortening of the anterior leaflet (Quigley et 
al. 2005), or anterior leaflet chord (Dreyfus et al., 2006), have also been used. 
Annuloplasty of the posterior part of the annulus has been performed using untreated (Salati 
et al., 1991) and glutaraldehyde-treated (Borghetti et al., 2000) autologous pericardium. 
Comparative studies with rigid prosthetic rings have shown that autologous pericardium 
provided more favourable annulus dynamics (Borghetti et al., 2000). Prosthetic annuloplasty 
rings have also been used in conjunction with glutaraldehyde-treated autologous pericardium 
for the augmentation of the anterior leaflet (Acar et al., 2004; Chavaud et al., 1998). Studies 
have shown that this technique is associated with decreased re-operation risk compared to 
using an annuloplasty ring alone. Further studies with glutaraldehyde-treated autologous 
pericardium used in MV leaflet extension, have shown late deterioration and calcification of 
the tissue with minimal risk of thromboembolic events (Chauvad et al., 1991; 2001). 
Autologous pericardium has the most favourable characteristics for cardiovascular 
implantation since it is a low-cost biomaterial, free of donor derived pathogens, non-
immunogenic, easily accessed (Duran and Gometza, 1993; Mirsadraee et al., 2006) and may 
remodel in the patient. However, it is not an ideal solution since it requires sacrifice of the 
pericardium of the patient, and involves inflammatory changes after pericardiotomy (Duran 
and Gometza, 1993). Glutaraldehyde-treated bovine pericardium has also been used to close 
MV leaflet perforations (Muhercke et al., 1997). However, glutaraldehyde-treated tissue with 
cell remnants can cause calcification. The calcific deposits enlarge and coalesce, leading to 
the formation of mineralized nodules, which can cause tissue stiffening and weakening, 
ultimately leading to deterioration of the bioprosthesis (Boskey et al., 1981). 
In the case of chronic ischemic MVR, the most commonly used surgical procedure is 
restrictive mitral annuloplasty (Dion et al., 1995; Bolling et al., 1998; Daimon et al., 2006; 
Spiegelstein et al., 2007; Braun et al., 2008). Generally, almost all MV repairs are completed 
with annuloplasty, which involves the reconstruction of the annulus. Its role is to reduce the 
size of the annulus and the tension caused by the repairing sutures (Tuladhar et al., 2006). 
Different types of annuloplasty rings have been employed clinically. These include rigid or 
flexible and complete or incomplete rings (Spiegelstein et al., 2007). Additional MV repair 
techniques include the edge-to-edge, or Alfieri technique, and commisuroplasty. The former 
involves the localised suturing of the two leaflets at the site of regurgitation (Alfieri et al., 1999, 
2004; Spiegelstein et al., 2007) (Figure 1.18). The latter is used for patients with small leaflet 
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prolapse, adjacent to the commissure, and provides a localised closure of the commissure 
without altering the valve orifice (Gillinov et al., 2005b; Aubert et al., 2005). The recently-
developed Mitraclip system, which has been adapted to the edge-to-edge technique 
(Gaemperli et al., 2013), and has been shown to be less invasive by employing a catheter 
inserted in the femoral vein to reach the heart. 
 
Figure 1.18: Edge-to-edge technique; single suture on the free edges. From Otto and Bonow 
(2009). 
 
MV repair has many advantages over mitral replacement including, lower operative mortality, 
reduced incidence of thromboembolism and reduced need for anticoagulation (Perier et al., 
1984; Gillinov et al., 1998; Yau et al., 2000), lower risk of endocarditis (Galloway et al., 1988; 
Duran, 1993), and improved long-term results (Galloway et al., 1989; Akins et al., 1994). 
Nevertheless, there are several cases of recurrent MV dysfunction following MV repair, which 
require reoperation. Failed repair can be divided into two groups, namely early failure and late 
failure. Early failure is caused by factors related to the procedure used. These factors include 
rupture of shortened chordae, haemolysis, and incomplete repair with residual mitral 
regurgitation. Late failure is caused by new valvular pathologic lesions and progressive 
disease (Otto and Bonow, 2009). Overall, less than half of MV repair reoperations have a 
successful outcome (Shekar et al., 2005; Dumont et al., 2007). 
1.2.9.2 Mitral valve replacement 
Although MV repair is generally the most common choice for degenerative MVR, MV 
replacement is still preferred for some specific conditions of MV dysfunction. Specifically, 
replacement is preferred in patients with rheumatic MV disease, degenerative disease with 
annulus and leaflet calcification, and endocarditis with extensive valve deterioration and repair 
(Gillinov et al., 2001; Jokinen et al., 2007; Fedak et al., 2008). Heart valve replacement 
involves the substitution of the diseased valve with either a mechanical or a tissue valve. 
Mechanical prostheses are made entirely of artificial components. Based on their design, 
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these valves are classified into three types (Figure 1.19), including ball and cage, tilting disc 
and bileaflet valves. Mechanical valves are associated with enhanced durability, but generate 
large regurgitation volumes during valve closing and require life-long anticoagulation 
treatment (Warfarin). The latter is necessary in order to avoid thromboembolic complications 
associated with blood clotting caused by turbulent-flow-induced high fluid stresses (Edmunds 
et al., 1987; Wurzinger and Schmid-Schönbein, 1990; Korossis et al., 2002).  Owing to the 
need of anticoagulation, one of the major problems with mechanical heart valves are 
haemorrhagic disorders (Grunkemeier and Rahimtoola, 1990; Schoen et al., 1992). The use 
of mechanical valves in children and young adults is problematic due to their inability to grow 
with the patient, leading to costly re-operations. In addition, patients with mechanical 
prosthesis are prone to increased incidence of endocarditis (Otto and Bonow, 2009). 
 
Figure 1.19: Mechanical valves: (a) ball & cage; (b) tilting disc; (c) bileaflet. From Korossis 
(2002). 
 
Tissue valves include bioprosthetic valves, made of chemically-treated porcine or bovine 
tissue (xenografts), and cadaveric valves (allografts or homografts). Tissue valves are 
associated with significantly lower thromboembolic risks, thus they do not require 
anticoagulation treatment, and have a haemodynamic performance comparable to that of the 
native valve (Russo et al., 2008). However, tissue deterioration and structural dysfunction, 
due to both calcification and non-calcific mechanisms, represent serious drawbacks with 
tissue valves (Hammermeister et al., 1993). In addition, valve infection and non-structural 
dysfunction affect both tissue and mechanical valves almost equally (Korossis, 2002). 
Bioprosthetic valves are cross-linked with low-concentration glutaraldehyde solutions in order 
to reduce their antigenicity and to stabilise the tissue against structural degradation (Korossis, 
2002). In addition, studies have described treatment of these valves with anticalcific agents to 
minimize the risk of calcification (Schoen et al., 2005a, 2005b). Porcine bioprosthetic valves 
are usually made from intact pig aortic valves (with or without the valve root). These valves 
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are cross-linked under various boundary conditions (degree of valve pressurisation), which 
have shown to affect the haemodynamic performance of the prostheses (Korossis et al., 
2002). Stinson et al. (1974, 1977) reported that the use of glutaraldehyde-treated porcine 
aortic valves for MV replacement provided overall durability comparable to that of mechanical 
prostheses. Other works reported on the use of porcine and bovine xenografts for MV 
replacement and concluded that bovine pericardial valves were associated with lower risk of 
thromboembolism, due to their superior haemodynamics (Gonzalez-Lavin et al., 1984).  
Bioprosthetic valves are subjected to structural deterioration due to chemical, mechanical, and 
morphological changes occurring during cross-linking and fabrication. This, in conjunction with 
the lack of a regeneration mechanism makes these valves prone to structural dysfunction. In 
addition, the lack of an endothelial barrier, causes increase permeability of the xenograft 
tissue (Schoen et al., 2008), whereas internal rearrangements, involving collagen crimp and 
alignment, are not possible due to the fixation of the ECM proteins (Vesely et al., 1988; Fisher 
and Davies, 1989). Moreover, cell remnants in the tissue act as foci for calcification. However, 
new generation bioprostheses have demonstrated 64 - 98 % freedom from structural valve 
deterioration after 10 years (Marchand et al., 1998; Masters et al., 2004). In addition, recent 
studies have suggested that development of improved GAG cross-linking techniques, to limit 
GAG degradation, may improve valve longevity (Lovekamp et al., 2006; Shah et al., 2008).  
Homografts are usually intact mitral, aortic and pulmonary valves, obtained from human 
donors and cryopreserved. Chauvaud et al. (2003) reported on MV homografts and showed 
that papillary muscle in the subvalvular apparatus caused an increased immunogenic 
reaction. The authors concluded that this kind of replacement was not suitable for young 
patients. Doty et al. (2001) used homograft MVs and reported that successful replacement 
requires secure fixation to the papillary muscles. Moreover, mismatch between the homograft 
and the patient’s valve can cause early dysfunction (Ali et al., 2004). Homografts have been 
reported to demonstrate good haemodynamics, low thrombogeneicity and low infection rates. 
However, although homografts are subject to decreased degeneration compared to 
bioprostheses, their long-term performance is limited by progressive degeneration due to 
absence of a repair mechanism.  
According to Schoen et al. (1982), the criteria for an ideal valve substitute is ease of 
implantation, quick healing in the implanted position, long life cycles with minimal wear or 
degenerative change, high flow with minimal turbulence when opened and no regurgitation 
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when closed, limited risk of thrombosis and biocompatibility. None of the currently available 
valve substitutes meet all these criteria. In addition, none of the current valve replacements, or 
indeed valve repair materials (with the exception of autologous pericardium), have an inherent 
remodelling/repair mechanism and thus, they cannot regenerate or grow with the patient.  
1.2.10 The tissue engineering concept 
Tissue engineering (TE) has emerged as a promising alternative for tissue reconstructions. 
The ultimate goal of TE is to provide tissue-equivalents, which will not only be fully 
compatible, but will also remodel, regenerate and ultimately grow with the patient. TE involves 
the development of biological or synthetic substitutes for implantation into the body with the 
purpose of fostering remodelling and regeneration of diseased tissue. In the past few years, a 
number of different TE strategies have been developed (Rabkin and Schoen, 2002). These 
are summarised in Figure 1.20. In vivo TE involves the use of bioresorbable scaffolds that rely 
on the patient’s cellular response in vivo, with the intention of developing functionality after 
implantation. This approach has been investigated for a range of tissues (Brown et al., 2013; 
Del Gaudio et al., 2013; Manassero et al., 2013). However, this approach is limited by the 
patient response in terms of scaffold recellularisation and regeneration. This can lead to the 
development of inappropriate properties of the implant in vivo. Utilisation of passive in vitro 
recellularisation prior to implantation has also been attempted but its success is limited since 
cell differentiation and tissue matrix remodelling may not progress physiologically. 
In vitro TE, or functional TE (FTE), employs scaffolds that are recellularised with appropriate 
autologous cells in vitro, and physically conditioned with a view to producing in-vivo-equivalent 
functionality prior to implantation. In this fashion, FTE simulates the type of physical 
environment that native tissues encounter in the body with a view to generating functional 
tissue-engineered constructs in the laboratory, prior to implantation (Langer and Vacanti, 
1993; Vacanti and Langer, 1999; Rabkin and Schoen, 2002). Compared to in vivo 
transplantation of dissociated cells and/or biodegradable scaffolds alone, the implantation of 
functional tissue has the potential to promote graft fixation and survival. 
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Figure 1.20: The four main different TE approaches: (a) The cell-seeded scaffold is implanted 
without in vitro conditioning/maturation; (b) Cells introduced directly into the host without a scaffold; (c) 
Scaffolds attract endogenous cells in vivo to repopulate and remodel; (d) Functional tissue-equivalents 
are engineered in vitro, prior to implantation. Modified from Rabkin and Schoen (2002). 
 
1.2.10.1 Progress in valvular tissue engineering 
Tissue engineering approaches emerged 20 years ago, as a potential solution to overcome 
the problems associated with the limited availability of human donor tissues (Fuchs et al., 
2001). The term TE was coined by Fung in 1987, although early attempts appear to originate 
as early as in the 1960s, in an attempt to propagate skin cells in vitro, and in the 1970s with 
the work of Rheinwald and Green at Massachusetts Institute of Technology (MIT), who 
successfully developed skin grafts using sheets of cultured keratinocytes, and dermal cells 
(Rheinwald and Green, 1975). Over the past few years, there has been a considerable 
interest in the TE of heart valves, especially for the aortic and pulmonary positions. Rabkin-
Aikawa et al. (2005) reported that to achieve the challenge of heart valve TE, a deep 
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understanding of both normal and pathological tissue function is necessary, including 
mechanisms of embryological development and functional tissue biomechanics.  
To date, there have been two main strategies for the development of TE heart valves. These 
include the transplantation of unseeded scaffolds, with a view to attracting endogenous cells, 
and cell-seeded scaffolds, which have been physically conditioned in vitro, with a view to 
developing valve-equivalent functionality prior to implantation.  
Decellularised scaffolds have been implanted to investigate the in vivo autologous 
regeneration potential of the unseeded scaffolds. Theodoridis et al. (2013) compared the 
recellularisation potential of decellularised pulmonary valves, unseeded or seeded, prior to 
implantation into elderly sheeps. Ovine pulmonary valves decellularised unseeded and 
decellularised re-endothelialized with autologous endothelial cells, were implanted in the 
orthotopic position in sheep. Explantation after six and twelve months showed no signs of 
degradation of the ECM, minimal calcification and cell repopulation, but to various degrees. 
Only one valve showed complete repopulation, and a slight tendency of better repopulation 
was observed in the re-endothelialized pulmonary valves implants, however no significant 
difference in the cell densities was found among the groups. Elkins et al. (2001) decellularised 
human and sheep pulmonary valves using the SynerGraft treatment process and implanted 
these in human patients and sheeps, respectively. The decellularised sheep allograft valves 
were monitored echocardiographically and histologically at 3 and 6 months; they became 
functional during the implantation period, and were progressively repopulated with recipient 
cells. The decellularised human allografts implanted in humans did not seem to provoke 
reactive antibody response.  
According to the cell-seeded scaffolds approach, mechanical loading has been considered to 
be necessary to stimulate the growth and maturation of the seeded cells and the formation of 
the ECM. As such valvular constructs have been conditioned using dynamic flow or strain, or 
a combination of both (Filova et al., 2009). Engelmayr et al. (2006) reported that mechanical 
stimulation had fundamental effects on the differentiation of sheep bone-marrow-derived stem 
cells on polyglycolic acid/ poly L-lactic acid (PGA/PLLA) valvular scaffolds. Moreover, fibrin-
based valvular constructs cultivated with porcine VICs under 15% cyclic distension were 
shown to have increased collagen content and ultimate strength (Syedain et al., 2008). In a 
study by Ku et al. (2006), VICs and MSCs stretched on collagen-coated substrates increased 
their collagen synthesis. In general, mechanical conditioning has been demonstrated to 
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improve the properties of valvular constructs when compared to static cultures (Hoerstrup et 
al., 2002; Mol et al., 2003; Engelmayr et al., 2005). Moreover, cell-seeded and in-vitro-
conditioned valvular scaffolds were shown to be fully functional in the pulmonary position in 
the study of Hoerstrup et al. (2000a). They seeded ovine myofibroblasts and ECs onto 
fabricated bioresorbable polymeric scaffolds and cultured them in a pulse duplicator prior to 
implantationt. They reported the formation of a layered leaflet tissue structure and efficient 
functionality after 20 weeks in lambs.  
1.2.10.2 Valvular tissue engineering scaffolds 
Typically, a TE scaffold is a porous, bioresorbable polymer of either synthetic or natural origin, 
which can support appropriate cell function (Bianco and Robey, 2001; Blau et al., 2001). 
Depending on the approach used, degradation and remodelling of the scaffold starts either in 
vitro or in vivo. Three main types of scaffolds have been used in valvular TE. These include: 
decellularised xenogeneic or allogeneic valvular scaffolds, synthetic scaffolds, and scaffolds 
fabricated from reconstituted ECM proteins, such as collagen and elastin. Decellularised 
xenogeneic or allogeneic scaffolds together with scaffolds fabricated from reconstituted ECM 
proteins are considered natural scaffolds. The advantages and disadvantages of the different 
scaffold types are presented in Table 1.2.  
 
 Synthetic scaffolds Natural scaffolds 
Advantages 
Control over structure and properties (pore 
size, stability, and degradation rate); Easily 
reproduced; Potentially resorbable. 
Natural histoarchitecture; Maintain 
biological cues (reactive sites, growth 
factors); Resorbable. 
Disadvantages 
Difficulty in controlling cell adhesion and 
tissue reorganisation; Inflammation due to 
incomplete polymer degradation; Limited 
diffusion in thick scaffolds (> 2mm) 
Decellularisation may alter physical 
properties; May induce immunologic 
reaction; Calcification potential; 
Limited diffusion in thick scaffolds (> 
2mm). 
Table 1.2: Advantages and disadvantages of synthetic and natural scaffolds. Adapted from 
Mendelson and Schoen 2006. 
 
Ideally, a valvular scaffold should closely mimic the ECM of the native valve and have the 
following characteristics: 1) have mechanical and biological integrity; 2) allow and support cell 
attachment and migration; 3) transfer appropriate mechanical and biochemical cues to the 
cells; 4) allow sufficient diffusion of nutrients and cell metabolites; 5) allow dynamic changes 
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in its architecture (Dohmen and Konertz, 2009). Moreover, the scaffold should be 
biocompatible, and biodegradable into non-toxic products. Scaffolds may be combined with 
growth factors (GFs), cytokines (regulatory proteins) and hormones, which can regulate cell 
function and tissue formation (Flanagan and Pandit, 2003). Moreover, cell adhesion onto the 
scaffold can be improved by modifying its surface with covalently attached adhesion peptide 
sequences, such as arginine-glycine-aspartic (RGD; Hubbell, 1995). These peptide 
sequences allow the formation of a physical link between the scaffold and the cells via integrin 
cell surface receptors (Van der Flier and Sonnenberg, 2001).  
Natural materials 
Natural scaffolds are usually made of reconstituted ECM proteins, such as fibrin, elastin and 
collagen, or decellularised homograft or xenograft tissue. Decellularisation was first used as a 
means of reducing the cell-debris-induced immunogenicity and calcification of bioprosthetic 
valves. Decellularised xenogeneic or homogeneic tissue scaffolds have been used in a 
number of studies over the past few years. The commercially available SynerGraft valve 
(CryoLife Inc., USA) was a decellularised porcine valve, which was used in clinical trials (O' 
Brien et al., 1999). However, early failure in humans resulted in the withdrawing of this implant 
(Simon et al., 2003). Specifically, the decellularised valve caused a strong inflammatory 
response, which was non-specific and was followed by a lymphocyte response, and rapid 
structural failure within one year. This failure was attributed to incomplete decellularisation of 
the graft. Rieder et al. (2005) compared decellularised porcine and cryopreserved 
decellularised human pulmonary valves to investigate whether decellularisation was more 
effective on xenograft or homograft valves. The authors reported that decellularisation was 
more effective on human tissue. Indeed, a considerable amount of antigenic content was still 
detectable within xenogeneic tissue after decellularisation. This acute immunogeneic reaction 
induced by the SynerGraft implant was associated to the presence of the α-gal (Galα1,3-
Galβ1-4GlcNAc-R) epitope. This epitope represents the major xenogeneic antigen which 
causes hyperacute rejection of animal tissue in Man. 
A decrease in immunogeneic response for decellularised homografts, compared to 
cryopreserved homografts, was observed in vivo in human patients with good short-term 
results (Hawkins et al., 2003; Sievers et al., 2003). Da Costa et al. (2009) reported that the 
Ross operation completed with decellularised pulmonary valves homografts in the pulmonary 
position was associated with good functional recovery and low incidence of reoperation up to 
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13 years. An important consideration with decellularised scaffolds is the fact that the 
decellularisation treatment itself most likely causes alteration in the biomechanical properties 
of the scaffolds compared to the starter tissue (Korossis, 2002). The potential toxicity of the 
decellularisation agents is another important factor that needs to be taken into account in the 
development of such scaffolds. 
The reconstituted ECM protein-based scaffolds are probably the least explored approach. 
Collagen based constructs seeded with vascular SMCs and/or ECs have been used for the 
generation of tubular blood vessels (Weinberg and Bell, 1986), aortic valve leaflets (Tranquillo 
and Girton, 2003), and chordae tendineae (Shi and Vesely, 2003, 2004). Shi and Vesely 
(2003) fabricated MV chordae through collagen gel contraction by casting a collagen-cell 
suspension into silicone rubber wells. The authors reported that gel contraction increased with 
increasing cell-seeding density, whereas fibril density increased with culture time as the gel 
contracted. The authors also reported that insufficient mechanical properties have been the 
main limitation for the application of collagen-based constructs, and that the mechanical 
strength of the constructs can be enhanced by optimizing the cell type, seeding density, 
culture time, and initial collagen concentration. Ye et al. (2000) used a similar approach by 
encapsulating cells in autologous fibrin gel, and reported the generation of new ECM. 
Ramamurthi and Vesely (2005), used crosslinked hyaluronan (GAG) gels, seeded with 
neonatal rat aortic SMCs, and reported that these gels are useful as substrates to induce 
elastin synthesis in culture to obtain structures that resemble the elastin matrix of the native 
aortic valve. Flanagan et al. (2006) investigated a type I collagen-GAG (chondroitin sulphate) 
hydrogel for the creation of MV tissue. They isolated porcine MV VICs and VECs, and they 
co-cultured them for 4 weeks in the hydrogels. The authors reported that both collagen alone 
and collagen-GAG constructs contracted to form tissue-like structures in vitro. They also 
noted that the addition of GAGs resulted in a more porous construct, positively influencing the 
bioactivity of the seeded cells and tissue remodelling. They also reported that further 
optimisation was necessary to improve construct structure and mechanical strength. In 
addition to inadequate mechanical properties, other limitations associated with reconstituted 
protein scaffolds include excessive shrinkage of the construct and the possibility of necrosis 
and apoptosis of the entrapped cells (Mendelson and Schoen, 2006).  
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Synthetic materials 
Synthetic polymer scaffolds have the advantage of possessing well controlled and 
reproducible properties. In addition, they are bioresorbable, serving as temporary ECMs until 
the seeded cells are capable of producing their own ECM proteins. Synthetic, biodegradable 
polymers most widely used in valvular TE include PGA, polylactic acid (PLA) and their 
copolymers. PGA was used as the first totally synthetic resorbable suture, commercially 
available under the name of Dexon. PGA has been used by Hoerstrup et al. (2002) to produce 
trileaflet valvular scaffolds for pulmonary valve replacement. These scaffolds were coated with 
poly 4-hydroxybutyrate (P4HB) and seeded with human bone-marrow-derived MSCs. 
Following 14 days of dynamic culture in a bioreactor, the cellular tissue was organised in a 
layered fashion, in contrast to the static controls that looked loose and less organized. 
However, PGA is rapidly resorbable and loses its mechanical strength rapidly (Grayson et al., 
2004). Copolymers formed by the polymerisation of PGA with the much more hydrophobic 
PLA, have been shown to possess a lower rate of degradation, due to the decreased rate of 
hydrolysis and, therefore, better mechanical properties. These polymers are considered 
biocompatible, and they have been used successfully in a number of FDA-approved implants 
(Grayson et al., 2004). Sutherland et al. (2005) seeded ovine bone-marrow-derived MSCs 
onto 50:50 poly(lactide-co-glycolide) (PGLA)/PGA blend biodegradable scaffolds to create 
semilunar valves, which were implanted into the pulmonary position in sheep. The explanted 
TE valves (4 and 8 months) demonstrated ECM deposition and cell distribution similar to the 
native pulmonary valves.  
Nevertheless, in spite of the positive results there are a number of disadvantages associated 
with the use of scaffolds made of these polymers. These disadvantages are mainly related to 
cell regulation and 3D tissue reorganization, since such materials are usually isotropic 
whereas native valves present a significant anisotropy in their structure and mechanical 
properties (Merryman et al., 2006). Towards this end, many studies have focused on 
overcoming the problem with the isotropy of these scaffolds by producing PGA/PLA 
electrospun scaffolds that resemble the structural anisotropy and fibre orientation of the native 
valve leaflets (Roy, 2004). Further disadvantages include potential tissue inflammation due to 
the foreign body reaction and slow or incomplete polymer degradation. Moreover, while the 
scaffold degrades, the free space formed is progressively filled by cells and ECM, which may 
cause fibrosis (scar tissue) leading to excessive contraction and distortion during maturation. 
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In addition, polymeric valvular scaffolds lack the elaborate histoarchitecture and biochemical 
cues of the native valvular ECM.  However, their main disadvantage is their poor mechanical 
properties, which make them unlikely candidates for direct implantation (without cells and in 
vitro conditioning) to the demanding valvular environment in the body (Rabkin and Schoen, 
2002).  
1.2.10.3 Tissue decellularisation techniques 
Decellularised xenogeneic or allogeneic biological scaffolds are an attractive approach in 
valvular TE since they possess natural histoarchitectures and biochemical cues, which favour 
cell adhesion, migration and proliferation. Decellularisation involves the removal of cells and 
their immunogenic components, including lipid membranes, membrane-associated antigens 
and soluble proteins, whilst retaining the integrity and architecture of the ECM proteins 
(GAGs, elastin and collagen; Korossis et al., 2002). Over the years, there have been a 
number of treatments developed for tissue decellularisation, employing physical treatments or 
chemical agents. Among the latter, non-ionic detergents, ionic detergents, zwitterionic 
detergents (which combine the properties of both ionic and non-ionic), biologic agents (such 
as enzymes), or a combination of these have been used (Dohmen and Konertz, 2009). 
Among the physical treatments, freeze-thawing, direct pressure, sonication and agitation, 
have been reported in the literature (Dohmen and Konertz, 2009). These physical treatments 
have been successful in achieving cells lysis, but cellular debris remains unless removed by 
subsequent processing with chemicals.  
Decellularisation treatments with non-ionic detergents aim at disrupting the lipid-lipid and lipid-
protein interactions of the cells, without interfering with structural protein-protein interaction of 
the ECM (Seddon et al., 2004). The most common non-ionic detergent used is Triton X-100, 
which removes almost all nuclear material, but not all cellular debris (Grauss et al., 2005). 
Moreover, it causes an almost complete loss of GAGs, affecting the histoarchitecture and 
mechanical properties of the tissue. Ionic detergents have been shown to be effective in 
removing cytoplasmic and nuclear material. The most commonly used ionic detergents 
include sodium dodecyl sulphate (SDS) and sodium-deoxycholate. Booth et al. (2002), 
reported on a number of different methods used to decellularise porcine aortic valve leaflets. 
The study used different detergents, including Triton X-100, SDS, and sodium deoxycholate at 
different concentrations. They reported that only the protocols that utilised SDS or sodium 
deoxycholate could achieve decellularisation, whilst maintaining the major ECM proteins. 
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However, sodium deoxycholate was effective only when used in high concentrations, raising 
concerns about the cytotoxicity of the produced scaffolds. On the other hand, SDS achieved 
complete decellularisation using much lower concentrations, which enabled the effective 
removal of the detergent, as confirmed by cytotoxicity studies (Wilcox et al., 2005). The same 
group also investigated the effects of different concentrations of SDS in hypotonic or isotonic 
buffer on the mechanical integrity of aortic valve leaflets, and reported increased extensibility 
of the decellularised leaflets due to the hypotonic buffer. Nevertheless, the strength of the 
decellularised tissue was comparable to the native aortic valve (Korossis et al., 2002).  
Zwitterionic detergents combine the properties of ionic and non-ionic detergents. These 
detergents have a greater capability to denature proteins than non-ionic detergents. Two 
different zwitterionic detergents have been used in decellularisation treatments, including 3-
[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS; blood vessels) (Dahl et 
al., 2003), and sulfobetaine-10 (SB-10) and -16 (SB-16) (nerves) (Hudson et al., 2004a; 
2004b). CHAPS-treated arteries showed histological properties similar to the native control, 
but significantly decreased burst pressure and maximum stress. Nevertheless the decrease 
was similar to the decrease obtained using Triton X – 100 and hypotonic/hypertonic solutions 
(Dahl et al., 2003). CHAPS has been shown to be most effective for cell removal from thinner 
tissues (Petersen et al., 2010) and less effective for thicker tissues (Du et al., 2011). 
Another method used in tissue decellularisation involves enzymatic digestion with proteases 
and nucleases (Ruoslahti and Pierschbacher, 1987). Nucleases, such as endonucleases and 
exonucleases, degrade ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) (Tarone et 
al., 1982). The most commonly used proteolytic enzyme is trypsin. Although enzymatic 
digestion with trypsin has been used as a means of decellularisation, it has been shown to be 
ineffective in producing acellular tissues (Korossis et al., 2002).  Grauss et al. (2005) reported 
that the use of trypsin to decellularise porcine aortic valves caused distortion of elastic fibres, 
changes in collagen distribution, and washout of GAGs, chondroitin sulphate, laminin and 
fibronectin.  
Hypertonic and hypotonic solutions have been used in decellularisation treatments due to 
their capabilities of dissociating DNA from proteins and causing cell lysis through osmotic 
effects with minimal changes in the ECM architecture (Cox and Emili, 2006; Xu et al., 2007). 
Mirsadraee et al. (2006) used a decellularisation protocol incorporating an ionic detergent 
(SDS), in combinations with hypotonic and hypertonic solutions, and enzymatic digestion. 
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They reported successful decellularisation of human pericardium, which retained its 
histoarchitecture and was void of cells and cell debris. The mechanical strength of the 
decellularised tissue was not significantly different compared to the native tissue. 
1.2.10.4 Mechanotransduction in tissue engineering 
Once implanted in the body, engineered constructs will be subjected to a complex 
biomechanical environment, potentially consisting of time varying changes in stresses, strains, 
fluid pressure, fluid flow, and cellular deformation (Guilak et al., 1995). These physical factors 
influence the synthetic capabilities of the cells in the engineered tissues when implanted, 
determining the success or failure of the engineered grafts. Indeed, the cells convert 
mechanical stimuli into biochemical responses, which eventually lead to ECM protein 
production and cell differentiation, through a process called mechanotransduction (Ingber et 
al., 2006). Therefore, elucidating and understanding the mechanisms of mechanotransduction 
(Williams et al., 1999) is of paramount importance in FTE. Many studies have suggested that 
physical factors may improve and accelerate tissue regeneration and repair in vitro. 
Mechanical stretch has been shown to increase cellular alignment, proliferation and protein 
synthesis in many different cell types (Buckley et al., 1988). Mechanically interactive 
bioreactors have been used to increase matrix deposition in tissue engineered cartilage by 
using cyclic compression (Buschmann et al., 1995). Other studies have shown improved 
success of tissue engineered constructs such as blood vessels by preconditioning grafts with 
pulsatile fluid flow and pressure (Niklason, 1999). It has been observed that forces transmitted 
bi-directionally between the cytoskeleton and the extracellular matrix (ECM) can switch 
hepatocytes between growth and differentiation (Mooney et al., 1992), and mechanically 
stressed dermal fibroblasts differentiate into myofibroblasts (Grinnell, 1994). Moreover, fluid-
induced shear stress has a well-known impact on vascular cell morphology, proliferation, and 
orientation. The long term application of cyclic strain has been shown to increase organisation 
of engineered smooth muscle tissue in vitro (Kim et al., 1999), whereas exposing cartilage 
constructs to dynamic compression at physiological frequencies has been shown to enhance 
ECM synthesis rates in chondrocytes (Eschenhagen et al., 1997).  
The elements involved in the mechano-chemical transduction include ECM, cell-ECM, and 
cell-cell adhesions, membrane components, specialized surface processes, cytoskeletal 
ﬁlaments, and nuclear structures. The ECM reacts when the whole tissue or organ is 
stressed, changing its original stress distribution. The cells in the tissue sense the distortion or 
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the change in the stress of the ECM through transmembrane adhesion receptors, such as 
integrins, which are connected to the cytoskeletal network of the ECM (Wang et al., 1993; 
Choquet et al., 1997; Ingber, 1997). Integrins are connected to the cytoskeleton through focal 
adhesion proteins; when they transfer the forces from the ECM to the cells, the cytoskeleton 
rearranges its interlinked actin microﬁlaments, microtubules and intermediate ﬁlaments, as 
well as associated organelles (e.g., mitochondria), to strengthen the whole cell against 
mechanical distortion (Wang et al., 1993; Ralph et al., 2002). The mechanical force 
transferred inside the cell can guide its differentiation. Cells need to attach to the ECM to 
divide; when the ECM rigidity increases, the cytoskeletal tension increases causing cell 
flattening, whereas, when the ECM rigidity decreases the force is transferred to internal 
microtubules causing cell rounding which can switch off cell division, turning on differentiation 
or even apoptosis. Depending on the level of the forces exerted on the cells, the stresses can 
be concentrated on specific molecules within the cells, affecting the change of specific 
biochemical activities (Ingber, 2006).  
The complex mechanisms underlying mechanotransduction need to be fully determined, 
however, the basis of this process is beginning to be unravelled. The majority of research has 
been carried out in simple two-dimensional culture systems in which the cells are subjected to 
fluid flow and/or stretch. Most cell types in vivo exist in 3D and there are as yet, few studies of 
mechanotransduction in 3D systems. Moreover, the type and appropriate amount of 
mechanical stimuli needed to improve tissue formation remains unknown. The development of 
functional simulation systems for the study of tissues in response to physiological mechanical 
stimulation will provide important model systems for the enhancement of understanding into 
mechanotransduction, and the relationship between physical conditions, cellular function, 
matrix remodelling and tissue properties. 
1.2.10.5 Cells in valvular tissue engineering 
One of the main issues in the application of TE heart valves is appropriate cell sourcing since 
the patient’s cells that are required to create autologous TE constructs are associated with a 
number of limitations. The most important of these include: the long time required for cell 
expansion to sufficient numbers, which may affect patient survival, and the decreased 
proliferative ability of cells from older patients. In general, two main cell type have been used 
in valvular TE, including differentiated stromal cells (such as ECs and/or SMCs), and stem 
cells (Mendelson and Schoen, 2006). Stem cells, which can be generally divided into two 
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main types, including adult and embryonic stem cells, have unique properties such as 
multipotency (adult), pluripotencey (embryonic), and capacity of self-renewal. Adult stem cells 
include hematopoietic stem cells (forming blood cells), endothelial progenitor cells (EPCs), 
and mesenchymal stem cells (MSCs). Adult stem cells are an attractive cell source since they 
can be easily isolated from bone marrow biopsies of the patients, and have extensive 
proliferation capacity in vitro (Vesely, 2005). 
Endothelial progenitor cells (EPCs) are capable of differentiating into ECs. Since EPCs also 
circulate in the blood, they can be attracted by scaffolds coated with appropriate cell-signalling 
molecules, with a view to encouraging EPC adhesion and differentiation (Schoen, 2008). 
Cultured MSCs show spindle shape morphology, characteristic of myofibroblasts, and express 
cell markers characteristics of VICs. Studies have shown that MSCs injected in a mouse after 
infarction, have been able to differentiate into cardiac myocytes, ECs and vascular SMCs 
(Orlic et al., 2001). Other studies have reported that human MSC-derived cells showed a 
myofibroblastic phenotype expressing α-smooth muscle actin (α-SMA) and vimentin. Kadner 
et al. (2002) investigated the feasibility of using human bone-marrow-derived MSCs in the TE 
of heart valves. These cells were shown to express α-SMA and vimentin, and to produce 
collagen type I and III. 
Embryonic stem cells generated a great interest in the tissue engineering field due to their 
high differentiation potential into all the three germ layers. However, there are ethical 
concerns associated with their harvesting which is embryo-destructive; in addition to this, 
embryonic stem cells derived cells may be rejected by the patient and undifferentiated 
embryonic stem cells may be tumorogenic (Forsberg and Hovatta, 2012).  
Takahashi and Yamanaka (2006) successfully investigated the reprogramming of terminally 
differentiated cells in order to provide them with the capacities of pluripotent stem cells, 
including the capability of differentiating to any tissue of the body. These reprogrammed cells 
were called induced pluripotent stem cells (iPCs), and these cells, in contrast to embryonic 
stem cells, do not raise ethical concerns and may overcome the issue of immunological 
rejection. To date, no studies about heart valve engineering using iPCs have been reported in 
the literature. A few studies have, however, investigated the use of this cell type for vascular 
tissue engineering (Samuel et al., 2013; Hibino et al. 2012). 
With regards to stromal cells, Shinoka et al. (1995) used a mixed population of SMCs and 
fibroblasts isolated from ovine femoral arteries and subsequently seeded onto PGLA and PGA 
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scaffolds. Unfortunately, femoral artery does not represent the ideal cell source due to the 
medical complications related to cells transplant. Schnell et al. (2001) cultured myofibroblasts, 
derived from human saphenous vein, on polyurethane scaffolds. This source represents a 
more clinically realistic cell source, since saphenous veins are already being used as 
heterotopic grafts in coronary artery bypass surgery, thus they can be harvested with 
minimally invasive surgery. Although promising results have been obtained using the 
aforementioned cell types, the ideal cell type for heart valve TE would be VICs and VECs, 
even though it would be very difficult to obtain them without damaging the valve of the patient 
(Flanagan and Pandit, 2003). Masoumi et al. (2013a) cultured porcine aortic and pulmonary 
VICs on anisotropic, micro-moulded poly(glycerol sebacate) scaffolds, and reported retention 
of the mechanical properties of the scaffolds and high collagen deposition after 14 and 28 day 
cultures. 
1.2.10.6 Bioreactors for heart valve tissue engineering  
Different types of bioreactors have been developed for the mechanical stimulation and 
conditioning/maturation of tissue-engineered cardiovascular constructs, including vascular 
grafts (Niklason et al., 1999; Seliktar et al., 2000), myocardial patches (Sodian et al., 2001), 
and heart valves (Zeltinger et al., 2001). The optimum TE bioreactor should provide simple 
modes of mechanical/hydrodynamic stimulation, accommodate multiple samples, and provide 
sterile and physiological temperature, oxygen and pH environment to the conditioning 
samples. In addition, the bioreactor should be able to replicate the 
biomechanical/hydrodynamic environment experienced by the native heart valves in vivo. 
Native heart valves in vivo are subjected to cyclic circumferential stretch, shear stress, and 
flexure during valve opening and closing (Berry et al., 2010).  
In the field of valvular TE, the most commonly used bioreactors are pulse duplicators 
(Hoerstrup et al., 2000a, 2000b; Dumont et al., 2002; Hildebrand et al., 2004), even though 
simple bioreactors exerting uniaxial tensile strain have been used for engineering mitral valve 
chordae (Shi and Vesely, 2004). Hoerstrup et al. (2000b) created one of the first heart valve 
bioreactors to culture/condition PGA valvular scaffolds seeded with carotid ECs and carotid 
myofibroblasts under gradually increased medium flow and pressure conditions. The cultured 
tricuspid valve leaflets were subsequently implanted into lambs and showed poor 
hemodynamic performance (Hoerstrup et al., 2000a). Lichtenberg et al. (2006) developed a 
pulsatile flow bioreactor, which featured flow rate, pressure and temperature monitoring, and 
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this was used to condition decellularised human pulmonary valves seeded with human 
autologous EPCs for up to 21 days. The conditioned valves were then implanted at the 
pulmonary position of two paediatric patients. The 3.5 years follow-up showed normal patient 
growth and normal valve growth (Cebotari et al., 2006). 
Flanagan et al. (2007) used a pulsatile flow bioreactor to condition fibrin-based tissue-
engineered valves seeded with ovine carotid artery-derived cells for up to 12 days. The 
dynamically-conditioned valves showed enhanced deposition of ECM proteins, lower 
shrinkage and higher cell attachment and alignment, compared to control valves cultured in a 
beaker with stirring. Lee et al. (2009) also used a pulsatile bioreactor for the endothelialisation 
of decellularised pulmonary valves seeded with epithelial progenitor cells. The seeded valves 
demonstrated complete endothelialisation after 7 days of dynamic conditioning. Dohmen et al. 
(2011) reported on the clinical application of decellularised pulmonary allografts, seeded with 
autologous vascular ECs in a bioreactor system prior to implantation. Ten years 
postoperatively, the implanted valves showed no calcification and excellent haemodynamics. 
Accumulating evidence suggests that bioreactors are important for the culture/conditioning/ 
maturation of tissue-engineered heart valves. However, even though the duplication of the 
physiological conditions experienced by native valves in vivo for the conditioning of the 
valvular TE constructs represents a plausible starting point, there is still a significant need for 
further research in optimising the conditioning/maturatrion of TE valves in terms of magnitude 
and frequency of the mechanical/haemodynamic stimulus. Along these lines, it would be 
beneficial to decouple the complex synergistic mechanical/haemodynamic stimuli experienced 
by heart valves, especially those with the more complex geometries (such as the AV valves), 
with a view to understanding the specific effect of different forces on cell function and 
construct remodelling and maturation.  
1.2.10.7 Computational modelling for tissue engineering  
Information on the mechanical/hydrodynamic environment of tissues is crucial in FTE. Many 
of the tissues and organs that require replacement, such as the heart valves, have an 
important biomechanical function. Thus, in vivo stress-strain mechanical histories need to be 
measured in order to provide the appropriate mechanical properties to the constructs. For 
tissues such as heart valves, there is a lack of experimental information on the in vivo 
mechanical environment due to the inability or limitations of physically measuring it. For such 
cases, in vivo strain can only or more easily be estimated by analytical and computational 
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methods. The information provided through computational modelling can then be used for the 
maturation/conditioning of TE constructs in vitro. Computational modelling has also been used 
to estimate the dynamic strain magnitude after in vitro conditioning (Mol et al., 2005), to 
optimise tissue growth in bioreactor culture (Wick and Farooque, 2009) and to investigate the 
impact of fluidic forces and stresses on cells and tissue engineered constructs during growth 
in vitro (Hutmacher and Singh, 2008).  
The bioreactor used in this study was a cyclic strain simulator, which was designed to subject 
the pericardial samples to biaxial stretching, similar to the circumferential and radial stretching 
experienced by the MV leaflets in vivo. The deformation of the scaffolds in the bioreactor 
stations used in this study was designed to duplicate the deformation of the MV leaflets in 
vivo, characterised by inflation during systole and deflation during diastole. Dynamic flexure 
induced by cyclic inflation/deflation has been reported as being the major mode of 
deformation of heart valve leaflets (Vesely and Boughner, 1989). A strain value of 10% was 
chosen to be applied on the pericardial scaffold, representing the maximum physiological 
strain experienced by the MV anterior leaflets during the cardiac cycle, obtained through 
computational modelling of the MV apparatus performed by Roberts (2012). Roberts (2012) 
investigated the deformations experienced by the MV leaflets using mathematical models. He 
studied the geometry and a constitutive model to describe the mechanical properties and 
behaviour of the MV leaflets, and then he brought them together to finally create the finite 
element model. Roberts then modelled the annular deformation using different annular 
configurations (fixed annulus and elastic boundary method to obtain 15% and 25% saddle 
height ratios (SVR)). The model showed highly regional characteristics of the strains.  
Little work has been focused on the modelling of the MV compared to the aortic valve. The 
reason for this is related to the fact that the MV is non-symmetrical and anatomically more 
complex than the aortic valve. Finite element model analysis of the MV leaflets was performed 
by a few groups (Kunzelman et al., 1993b; Einstein et al., 2005; Dal Pan et al. 2005; Lim et al. 
2005; Votta et al. 2008). A number of published in vitro experimental studies into anterior 
leaflet deformation at physiological pressures can be found in the literature (Sacks et al., 
2002; Chen et al., 2004a; He et al., 2005; Jimenez et al., 2007). In particular, Sacks et al. 
(2002) placed three- dimensional spatial positions of markers in the central region of the MV 
anterior leaflet in a left ventricle-simulating flow loop to investigate the strains in the leaflet; 
they reported mean peak strain values ranging from 2.5 to 3.3% in the circumferential 
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direction and between 16 to 22% for the radial direction. Jimenez et al. (2007) used a similar 
experimental approach; the values of the peak strain in the radial direction ranged between 
13.52 and 29.72% depending on the annular configuration, whereas the peak strain for the 
circumferential direction was 11% and was not affected by the change in annular 
configuration. Several approaches have been taken to attempt to quantify MV dynamics 
through in vivo experiments; in a study by Sacks and Yoganathan (2007), sonomicrometry 
was used for the quantification of the strains of the anterior leaflets. Their finding showed 
areal strain values (deﬁned as the changes in the area) ranging from 15 to 20% throughout 
the cardiac cycle. Nevertheless, the highly dynamic motions, large anisotropic deformations, 
complex surface geometries of the MV represent an obstacle for currently available imaging 
technologies; thus, the quantification of the magnitudes of strains on the valve have proven 
difficult to measure.   
 
1.3 Aims and objectives  
Aims: 
The aim of this study was to investigate the tissue engineering of MV leaflets for MV leaflets 
reconstruction. The experimental approach involved the use of decellularised porcine 
pericardium seeded with porcine MSCs and mechanically conditioned in a biaxial strain 
bioreactor. 
The underpinning hypothesis was that a MV leaflet-relevant biomechanical and biochemical 
environment in vitro could selectively guide recellularisation of decellularised pericardial 
scaffolds in order to produce MV leaflet equivalents.  
The biomechanical and biological properties of porcine MV leaflets and decellularised and 
native porcine pericardium were studied for comparative purposes. The cell type, seeding 
density and time for seeding decellularised pericardial samples were assessed. Finally, the 
decellularised constructs seeded with MSCs were cultured in a bioreactor, under dynamic 
conditioning for up to 1 day to investigate the effects of biaxial strain on cell viability and 
alignment of the cell-seeded constructs.  
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Objectives: 
 To compare the biological, biochemical and biomechanical properties of porcine MV 
leaflets and pericardium. 
 To assess the effects of decellularisation of porcine pericardium on the 
histoarchitecture, the total amount of DNA, the presence of specific matrix proteins 
and on the mechanical properties of the tissue by comparison with fresh pericardium. 
 To determine the in vitro biocompatibility of the decellularised porcine pericardium. 
 To investigate the seeding density and time for culturing different cells types (porcine 
dermal fibroblasts, SMCs, MSCs) on the decellularised porcine pericardium under 
static conditions prior to loading on the bioreactor. 
 To calibrate the bioreactor, in terms of the frequency and strain level to apply during 
mechanical conditioning of the decellularised porcine pericardial samples seeded with 
pMSCs. 
 To investigate the function of the bioreactor under static conditions in terms of sterility 
maintenance and cell culture medium circulation using fresh porcine pericardial 
samples. 
 To investigate the static culture of the cell-seeded pericardial scaffolds in the biaxial 
bioreactor under sterile conditions. 
 To investigate the effects of the dynamic conditioning on the viability and spatial 
arrangement of cells as well as on the histoarchitecture of the cell-seeded scaffolds 
cultured in the bioreactor. 
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Chapter 2 
General Materials and Methods  
This chapter describes the general materials and methods used to investigate the histological, 
immunohistochemical, biochemical and biomechanical properties of fresh and decellularised 
porcine pericardium and fresh mitral valve (MV) leaflets, both anterior and posterior. In 
addition, it describes cell culture techniques and cell viability assays used throughout this 
study. 
2.1. Equipment  
The laboratory equipment used in order to carry out the experiments in this project is listed in 
Table 2.1. 
Equipment Model Supplier 
Actuator Superpump Vivitro system 
Actuator controller Smart step microstepping 
smartdrive PCW-5008 
Industrial Devices Corporation 
Autoclavable bag - Westfield limited 
Automatic Pipettes Gilson P2-P1000 Anachem Ltd 
Automatic Pipettes Finnipipette® P2-P1000 Thermo Fisher Scientific Inc 
Balances (Accuracy: 
0.01g/0.0001g) 
GR200/GX2000 Jencons PLC 
Bench top centrifuge   5415R Eppendorf 
Blood tissue spinner  SB3 Stuart 
Cell counter  - ENM 
Cell medium aspirator  Vacusafe comfort Integra Biosciences 
Centrifuge tube - Fisher Scientific 
Chemostat Bioconsole ADI 1025 Applikon biotechnology 
Chemostat controller Biocontroller ADI 1010 Applikon biotechnology 
Class II safety cabinet  Herasafe Heraeus 
Class II safety cabinet 11518/85 Heraeus 
CO2 Incubator MCO-20AIC SANYO Biomedical Europe BV 
 45 
 
Culture tubs (500 ml) - Nalgene 
Freezer (-20°C)  Electrolux 3000 Jencons Plc 
Fridge  Electrolux ER8817C Jencons Plc 
Fume cupboard/fume hood - Whiteley 
Heater controller - Electrical Engineering, 
University of Leeds 
Flexible silicone rubber 
heaters 
020100C2 100 (Watts) Watlow 
Histology cassettes CMB-160-030R Thermol Fisher Scientific Ltd 
Histology water bath  MH8515 Barnstead Electrothermal 
Hot forceps  Speci-leps BIOS EUROPE 
Hot plate  E18.1 hotplate Raymond A Lamb 
Hot wax dispenser  E66 wax dispenser Raymond A Lamb 
Light box KL003 Kermo limited 
Luer (stainless steel) (Various) Cole parmer 
Magnetic stirrer Stuart SB161 Scientific Laboratory Systems 
Ltd 
Micro plate 
spectrophotometer 
Multiskan spectrum Thermo Scientific 
 
Microscope (upright) 
 
Olympus BX51 
Microscopes, medical 
Diagnostic Systems and 
Olympus Patient systems Ltd 
 
Microscope (inverted phase 
contrast) 
 
Olympus CK40 
Microscopes, medical 
Diagnostic Systems and 
Olympus Patient systems Ltd 
 
Microscope (inverted phase 
contrast) 
 
Olympus IX71 
Microscopes, medical 
Diagnostic Systems and 
Olympus Patient systems Ltd 
Microtome  RM2125 RTR Leica Microsystems 
Microwave KM19W, 800w 
PROLINE 
KM19W, 800w PROLINE 
Monitor for the actuator B8961 Industrial Devices Corporation 
Nanodrop 
Spectrophotometer 
ND-1000 Labtech Int 
Orbital shaker POS300 Grant-bio 
 46 
 
Orbital shaker  IKA KS130 basic Jencons Plc 
Oven (hot air) OMT225 SANYO Biomedical Europe BV 
Peristaltic pump Easy load II77200-50 Cole parmer 
Peristaltic pump Multichannel pump 7536-04 Cole parmer 
pH meter  Jenway 3010 VWR International 
Plastic histology cassettes 
Ltd 
CMB-160-030R Thermo Fisher Scientific 
Plate reader  Multiskan Spectrum 1500 Thermo Fisher Scientific 
Plate shaker  IKA KS130 basic Jencons Plc 
Pipette boy  Acu Intergra Biosciences 
Quick connectors (Various) Cole parmer 
Silicone o rings (Various) Thomson Bros. Limited 
Silicone tubes  - Masterflex 
Slide holder  E102 Raymond A Lamb 
Sterile filter Midisart 2000 Sartorius stedium biotech 
Sterile gloves  - Kimberly-Clark 
Stopcock Luer fittings, nickel-plated brass 
three-way stopcocks 
Cole parmer 
Temperature probe - RS 
Tensile testing machine  3365 Instron® tensile tester 
Thickness gauge  - Mitutoyo 
Tissue processor  TP11020 Leica Microsystems 
Vortexer 2  MS2 minishaker IKA 
Water bath  Grant Jencons Plc 
Wax oven Windsor E18/31 Scientific Laboratory Supplies 
Table 2.1: Equipment used throughout the study. 
 
2.2 Chemicals 
The chemicals used during this project are listed in Table 2.2. 
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Chemical/Reagent Supplier 
Acetic acid  Thermo Fisher Scientific Ltd 
Acetone  European Bios 
Alcian blue  Raymond A Lamb 
Alpha-SMA Sigma  
Amphotericin B Lonza 
Antifoam Sigma 
Aniline blue (Masson trichrome staining) Bios Europe 
Aprotinin 10 KIU.ml-1   Nordic pharma 
Biebrich scarlet acid fuchsin (Masson trichrome staining)  Bios Europe 
Bovine serum albumin  Sigma-Aldrich 
Calcium chloride  VWR International 
Chloramine T  Sigma-Aldrich 
Citric acid  VWR International 
Collagenase Sigma 
Collagen I 
 
Millipore  
MAB3391 
Collagen III Abcam, ab7778 
Collagen IV Dako M0785 
Chondroitin sulphate Sigma 
Chondroitin sulphate B  Sigma-Aldrich 
DABCO  Sigma-Aldrich 
p-dimethylaminobenzaldehyde  Sigma-Aldrich 
1,9 dimethylene blue Sigma-Aldrich 
Dimethyl sulfoxide (DMSO)  Sigma-Aldrich 
DNeasy blood & tissue kit  QIAgen 
DNAse  Sigma-Aldrich 
DPX mountant  Thermo Fisher Scientific Ltd 
Dulbecco’s PBS tablets  Oxoid Microbiology Products, 
Thermo Scientific 
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Eosin Biostain 
Ethanol  Thermo Fisher Scientific Ltd 
Ethylenediaminetetraactic acid (EDTA)  Fisher Scientific 
Fibronectin Dako A0245 
Foetal calf serum  Biosera 
Formaldehyde  Biostain 
Formic acid  Sigma-Aldrich 
Gentamicin  Biochrom 
Giemsa solution  VWR International 
Glacial acetic acid 
 
VWR International 
Glycerol  Sigma-Aldrich 
Hank’s balanced salt solution (HBSS) Lonza 
Haematoxylin (for H&E) Lamb 
Haematoxylin solution, Gill No. 3 (for Alcian blue-PAS) Sigma-Aldrich 
HEPES buffer (1M) Lonza 
Hydrochloric acid (12M)  VWR International 
Hydrogen peroxide (30%, v/v)  Sigma-Aldrich 
Isotype control DAKO 
Isotype control GeneTex 
Laminin Sigma L8271 
L-glutamine  Invitrogen 
Live/Dead assay kit  Invitrogen 
Magnesium chloride  Thermo Fisher Scientific Ltd 
Methanol  Vichers Laboratories 
Miller’s elastin  Raymond A Lamb 
MTT reagent  Sigma-Aldrich 
Neutral buffered formalin  Biostain Ready Reagents 
Nuclease free water  Fermentas 
Nutrient agar  University of Leeds 
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Oxalic acid  VWR International 
Paraffin wax  Thermo Fisher Scientific Ltd 
PBS with Ca and Mg Lonza 
PBS without Ca and Mg Lonza 
Penicillin  Invitrogen Ltd 
Peracetic acid  Sigma-Aldrich 
Perchloric acid (60%)  BDH  
Percoll Sigma-Aldrich 
Picric acid  Sigma-Aldrich 
Picro sirius red  VWR International 
pH standards (4,7,10)  Scientific Laboratory Supplies Ltd 
Polymyxin B  Fluka analytical 
Potassium permanganate 5% (w/v)  Bios Europe 
Propan-1-ol  VWR International  
RNAse  Sigma-Aldrich 
SAB agar  University of Leeds 
Schiffs reagent (Alcian blue-PAS) Sigma-Aldrich 
Sodium acetate  Thermo Fisher Scientific Ltd. 
Sodium azide  Sigma-Aldrich 
Sodium chloride  Thermo Fisher Scientific Ltd 
Sodium di-hydrogen orthophosphate   VWR International 
Sodium dodecyl sulphate (SDS)  Sigma Life Science 
Sodium formate  VWR International 
Sodium hydroxide  VWR International 
Streptomycin  Invitrogen 
Trans-4-hydroxy-L-proline  Sigma-Aldrich 
Trigene Scientific  Laboratory Supplies Ltd 
Tripsin  Sigma-Aldrich 
Trizma base  Sigma-Aldrich 
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Trypan blue Sigma 
Trypsin (0.25% w/v)/EDTA Lonza 
Tyrode’s balanced salt solution  Sigma-Aldrich  
Tween 20  Sigma-Aldrich 
Vancomycin hydrochloride  Aldrich chemistry 
Vimentin Leica 
Virkon  Scientific Laboratory Supplies Ltd 
Von Willebrand Dako A0082 
Weigert’s iron hematoxylin (Masson trichrome staining) Bios Europe 
Xylene  Genta medical 
Table 2.2: Chemicals and reagents used throughout the study. 
 
2.3 Consumables 
The consumables and plasticware used during this project are listed in Table 2.3 and Table 
2.4, respectively. 
Item  Model/Size Supplier 
Glass coverslips Scientific MIC3228 Laboratory Supplies 
Filter paper  Whatman® Grades 1-5 Whatman 
International Ltd 
ImmEdge Hydrophobic Barrier 
Pen 
H-000 Vector Laboratories 
Microtome blades  SD3050835 Fisher Scientific 
Parafilm M  -  Sigma-Aldrich Ltd 
Scalpel blade  Size 22 Fisher Scientific 
Superfrost Microscope Slide MIC3040 Scientific Laboratory 
Supplies 
Superfrost Plus Microscope Slide MIC3022 Scientific Laboratory 
Supplies 
Syringe needles - Thermo Fisher 
Scientific Ltd 
Table 2.3: General consumables used throughout the study. 
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Item  Model/Size Supplier 
Bijous 5 ml Scientific Laboratory 
Supplies Ltd 
Cell culture flasks 75 cm2 Thermo Fisher 
Scientific Ltd 
Disposable plastic syringes 1ml, 2ml, 5ml, 10ml, 20ml, 50ml Scientific Laboratory 
Supplies 
Eppendorf  1.5ml Sigma-Aldrich 
Pipette tips (non-filtered) 10μl, 20μl, 200μl, 1000μl, 5000μl Star Labs 
OptiplateTM  96-well  PerkinElmerTM 
Universals 25ml Scientific Laboratory 
Supplies 
Well plates, Nunc® (flat and 
round bottomed) 
6-well, 12-well, 96-well plates Thermo Fisher 
Scientific Ltd 
Table 2.4: Plasticware used throughout the study. 
 
2.4 Cells 
Porcine skin fibroblasts, porcine mesenchymal stem cells (pMSCs) and porcine smooth 
muscle cells (pSMCs) were used in this study. The cells had been previously isolated, 
cryopreserved and stored in the in-house cell bank. Specifically, dermal fibroblasts were 
isolated from porcine skin by collagenase digestion by Dr. Iraklis Papageorgiou; pSMCs were 
isolated by Dr. Helen Wilcox from porcine aorta according to the explant method described by 
Wilcox et al. (2005) and pMSCs were isolated from porcine bone marrow by Dr. Rick Knight 
and Dr. Daniel Thomas using the Percoll gradient method described by Knight (2003). Cells 
were resurrected from frozen. Dermal fibroblasts and pSMCs were cultured for phenotyping 
by immunofluorescence. pMSCs were phenotyped using flow cytometry by Dr Daniel Thomas. 
 
2.5 General stock solutions 
2.5.1 Phosphate buffered saline (PBS) 
PBS was prepared by dissolving 1 tablet of Oxoid Dulbecco PBS in 100 ml of distilled water 
using a magnetic stirrer and stirrer bar. The pH was adjusted to 7.2 – 7.4 by adding 6 M 
 52 
 
hydrochloric acid or 6 M sodium hydroxide while stirring. The solution was autoclaved at 
121°C and 15 lb sq. in. for 20 min and stored for up to 1 month at room temperature. 
2.5.2 Tris buffered saline (TBS) 
Tris solution (2 M) was prepared by dissolving 242 g of trizma base into 500 ml of distilled 
water. The pH was adjusted to 7.6 by adding 6 M hydrochloric acid or 6 M sodium hydroxide. 
The volume was made up to 1 L with distilled water. A volume of 25 ml of the Tris solution 
was mixed with 50 ml of 3 M sodium chloride solution. The volume was made up to 1 L with 
distilled water and the pH was adjusted to 7.6. Finally, the solution was autoclaved at 121°C 
and 15 lb. sq. in. for 20 min and stored for up to 1 month at room temperature. 
2.5.3 TBS containing 0.05% (w/v) Tween 20 
Tween 20 (500 µl) was added to 1 L of TBS. The pH was adjusted to 7.6 and the solution was 
stored at room temperature for up to 3 months. 
2.5.4 Complete cell culture medium 
Dulbecco’s modified Eagle’s medium (DMEM) was supplemented with 10% (v/v) foetal bovine 
serum (FBS), 100 U∙ml-1 penicillin, 100 U∙ml-1 streptomycin, and 2 mM L-glutamine. This was 
stored for up to two weeks at 4°C. 
 
2.6 Preparation, cleaning, and sterilisation of glassware  
Reusable glassware, such as bottles and measuring cylinders, were washed with detergent, 
rinsed and whenever necessary, sterilised. Immediately after use, the glassware was washed 
manually using Decon in tap water with brushes.  
2.6.1 Dry heat sterilisation  
All glassware and metal surgical instruments that could be sterilised by dry heat were covered 
with aluminium foil and placed in an oven and kept at 190°C for 4 hours. 
2.6.2 Moist heat sterilisation (autoclaving)  
Solutions and plasticware, not suitable for dry heat sterilisation, were sterilised by autoclaving 
at 121°C and 15 lb. sq. in. for 20 minutes. 
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2.6.3 Filter sterilisation  
Solutions not suitable for autoclaving were sterilised using single use 0.2 μm filters (Scientific 
Lab Supplies, UK) and a disposable syringe. 
 
2.7 Measurement of pH  
A Jenway 3010 pH meter was used to measure the pH of the solutions. The pH meter was 
calibrated using pH standard solutions at pH 4, 7 and 10. The solutions were gently stirred 
during measurements using a magnetic stirrer. The values were taken when the reading 
reached a steady state. To adjust the pH of the solution, 1-6 M hydrochloric acid or 1-6 M 
sodium hydroxide was added drop-wise while stirring. 
 
2.8 Dissection of porcine pericardium and mitral valve leaflets 
Porcine hearts were obtained from 24-26 weeks old pigs from a local abattoir and dissected 
within 3-4 hours of slaughter. The dissected tissues were either frozen, or used immediately 
for the biomechanical and biological testing. Loose pericardium (parietal layer) was separated 
from the heart and gently stripped of the adherent layer of fatty tissue (Figure 2.1). Excess 
tissue (fat and connective tissue) was carefully trimmed from the pericardium using scissors.  
 
Figure 2.1: Dissection of porcine pericardium. Separation of the parietal layer from the heart. 
 
Following isolation of the pericardium, the heart was exposed and the MV leaflets were 
dissected (Figure 2.2). During MV leaflet dissection, the heart was separated in two parts by 
cutting along the inter-ventricular septum, in order to isolate the left side of the heart. The left 
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atrium was then removed, and the left ventricle was opened in order to access the MV 
leaflets. The leaflets were separated from the chordae tendineae and the annulus fibrosus, 
leaving a small bar (around 0.5 - 1 cm) of the annulus fibrosus attached to the leaflets (Figure 
2.2c).  
 
Figure 2.2: Dissection of porcine mitral valve leaflets. (a) Open view of the left ventricle, after 
removal of the left atrium. (b) The mitral valve apparatus consisting of the leaflets, chordae tendineae 
and papillary muscles. (c) Anterior and posterior leaflets with a small bar (around 0.5-1 cm) of annulus 
fibrosus. MV: mitral valve. 
 
2.9 General experimental approach  
Six pericardia were isolated from six different hearts and were decellularised according to the 
in-house decellularisation protocol. Fresh pericardia were also used for the biomechanical and 
biological testing (6 in each case). Decellularised and fresh pericardial samples, measuring 5 
mm width by 10 mm length, were cut across and along the collagen fibre alignment, (Fig. 
2.3a, b) and tested biomechanically, histologically and immunohistochemically. Fibre 
alignment was visualized using a light box and two polarized light filters. Fresh and 
decellularised samples with no particular fibre orientation were used for biochemical analysis. 
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Anterior and posterior MV leaflet strips measuring 5 mm width by 10 mm length were cut 
along the circumferential and radial direction (Fig. 2.3c) and tested biomechanically, 
histologically and immunohistochemically. Due to the small size of the leaflets, it was only 
possible to isolate one sample per leaflet per heart. Anterior and posterior leaflet samples with 
no particular fibre orientation were used for biochemical analysis. The test groups used for 
biomechanical and histological analysis, together with their abbreviations are summarised in 
Table 2.5. 
 
Figure 2.3: Orientation of pericardial and MV leaflet samples used in the biomechanical and 
histological testing: Fresh pericardial samples were isolated parallel (a) and orthogonally (b) to the 
collagen fibre alignment. Leaflet samples were isolated along the circumferential and radial directions 
of the leaflets (c). 
 
Abbreviation Description 
PO Pericardium orthogonal to the collagen fibred alignment 
PP Pericardium parallel to the collagen fibres alignment 
DPO Decellularised pericardium orthogonal to the collagen fibres alignment 
DPP Decellularised pericardium parallel to the collagen fibres alignment 
LAR Leaflet anterior along the radial direction 
LAC Leaflet anterior along the circumferential direction 
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LPR Leaflet posterior along the radial direction 
LPC Leaflet posterior along the circumferential direction 
Table 2.5: Abbreviations of the test groups used throughout the project. 
 
2.10 Sample preparation for histology & immunohistochemistry  
2.10.1 Tissue fixation 
Tissue samples were placed into individual histological cassettes. The tissues were fixed in 
10% (v/v) neutral buffered formalin (NBF), for 1 to 2 hours prior to tissue processing.  
2.10.2 Tissue processor and paraffin embedding 
Dehydration, clearing and infiltration were performed using an automated tissue processor. 
The cassettes containing the tissue blocks were sequentially immersed in 10% (w/v) neutral 
buffered formalin, 70% (v/v) ethanol, 90% (v/v) ethanol, 100% ethanol, 100% ethanol, 100% 
ethanol, three pots of xylene, and three final steps of paraffin waxing. The samples were 
immersed in each solution for 1 hour under vacuum at room temperature except the waxing 
which was carried out at 50°C. Subsequently, the histology cassettes were removed and 
transferred to fresh molten wax. The tissues were removed from the cassettes and correctly 
oriented in wax block moulds containing molten wax. The samples were positioned so that 
they were cut along the thickness of the tissue; in this way the different layers of the leaflets 
and the pericardium could be clearly observed by microscopy following histological staining 
and immunohistochemistry. The samples were left to cool and harden at room temperature. 
The wax blocks were removed from the mould, with the block left attached to the cassette 
base, and the excess wax was trimmed. 
2.10.3 Sectioning and slide preparation 
The paraffin embedded tissue samples were sectioned using a microtome at a thickness of 6 
m. The isolated sections were carefully transferred to a 45 - 50°C water bath before they 
were transferred onto Superfrost microscope slides for histological staining or Superfrost Plus 
slides for immunohistochemistry labelling. The tissue sections were then dried using a 60°C 
hotplate.  
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2.10.4 Tissue section dewaxing and rehydration 
The slides were immersed into 2 pots of xylene for 10 min each, inside a fume hood, before 
they were sequentially immersed in three pots of 100% ethanol for 3, 2 and 2 min, 
respectively, in a pot of 70 % (v/v) ethanol for 2 min and finally into running tap water for 3 
minutes. 
2.10.5 Dehydration and mounting 
Following staining, all sections were immersed into 70 % (v/v) ethanol for 5 sec, followed by 
immersion in 3 different pots of 100 % ethanol for 1, 2, 3 min, respectively. Finally, the 
sections were immersed sequentially into 2 different pots of clean xylene (clearing solvent) for 
10 min each inside a fume hood. The sections were then mounted using DPX mountant and 
were left to air dry for a minimum of 4 hours inside a fume hood. 
 
2.11 Histological Staining 
2.11.1 Haematoxylin & eosin 
Rehydrated sections were placed in Mayer’s hematoxylin solution for 1 min. Subsequently, 
the slides were rinsed until clear under running tap water, and then immersed in eosin solution 
for 3 min. The stained sections were then dehydrated and mounted as described in Section 
2.10.5.   
2.11.2 Alcian blue- periodic acid and Schiffs reagent (PAS) 
Rehydrated sections were immersed in Alcian blue solution for 15 min and rinsed in running 
tap water for 1 min. The sections were then treated in periodic acid and Schiffs reagent (PAS) 
for 5 and 15 min, respectively. Subsequently, the sections were rinsed in running tap water for 
5 min and counterstained in hematoxylin for 90 sec to stain the cell nuclei. Finally, the slides 
were dehydrated and mounted as described in Section 2.10.5.   
2.11.3 Sirius red and Millers elastin 
Rehydrated sections were treated for 5 min with potassium permanganate 5 % (w/v), rinsed in 
distilled water and immersed into 1 % (w/v) oxalic acid for 2 min. The slides were then rinsed 
well using distilled water and then immersed in 70 % (v/v) and 95 % (v/v) ethanol. Following 
this, the slides were stained using Miller’s stain for 1 h. The slides were then rinsed in 70 % 
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(v/v) and 95 % (v/v) ethanol and tap water. The sections were counterstained with Weigerts 
hematoxylin for 10 min, and then rinsed in tap water and distilled water. Finally, the slides 
were stained using picro Sirius red for 1 h and rinsed in distilled water before blotting dry. The 
slides were dehydrated and mounted as described in Section 2.10.5.   
2.11.4 Masson’s trichrome 
Rehydrated sections were fixed by immersion in Bouin’s solution overnight. This type of 
fixation enhanced trichrome intensity and brilliance. Following this, the slides were rinsed 
sequentially in running tap water and distilled water in order to wash out the Bouin fixative. 
The slides were immersed for 7 min in Weigert’s iron hematoxylin solution to stain the cell 
nuclei. The sections were then stained in Biebrich Scarlet acid fuchsin for 7 min (cell 
cytoplasm and muscle staining), rinsed in distilled water and placed in phosphotungstic acid 
solution for 10 min to allow for a better staining of the collagen fibres during the subsequent 
immersion in aniline blue solution for 7 min. The sections were rinsed briefly and dehydrated 
and mounted as described in Section 2.10.5.     
 
2.12 Immunohistochemistry 
2.12.1 Antigen retrieval methods 
Antigen retrieval is useful in order to unmask the antigens that can be masked due to the 
tissue fixation procedure. Antigen retrieval reagents were used to pretreat the tissue sections 
in order to break the protein cross-links formed by formalin fixation and thereby uncover 
hidden antigenic sites.  
 
Citric acid microwave treatment 
Reagents 
 Citric acid buffer solution (10mM) was adjusted to pH 6.0 using NaOH (6 M).  
Method 
The slides were laid out on a pyrex dish so that they did not overlap, and with the tissue 
sections facing upwards. Citric acid was added in the pyrex dish in order to cover the tissue 
 59 
 
sections. The pyrex dish was then covered with cling film and microwaved on full power for 10 
min. After the dish was cooled, the slides were removed.       
Proteinase k 
Reagents 
 Proteinase k (Dako) was used for the proteolytic digestion of the tissue sections.  
Method 
The sections were treated with one drop of proteinase k for 7 min before they were rinsed in 
running tap water for 5 min. 
Trypsin retrieval method 1 (0.1 % w/v trypsin) 
Reagents 
 Trypsin solution was prepared by dissolving 0.1 g trypsin and 0.1 g calcium chloride in 100 
ml TBS (pH 7.6). The trypsin solution was then warmed to 37°C, and the pH was adjusted 
to 7.8 by adding drops of 1 M sodium hydroxide. 
Method 
The sections were incubated at 37°C for 10 min in prewarmed distilled water before they were 
digested in trypsin at 37°C for 30 min. The sections were then rinsed in running tap water for 
5 min. 
Trypsin retrieval method 2 (0.5 % w/v trypsin) 
This method was the same as the trypsin retrieval method 1, but in this case the trypsin 
solution was prepared by dissolving 0.5 g trypsin instead of 0.1 g. 
 
2.12.2 Antibodies 
The primary antibodies, isotypes and antigen retrieval methods are illustrated in Table 2.6. 
The protein concentration used for the isotype control was the same as the specific primary 
antibody. 
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Antigen Suppli-
er 
Clone Isotype Antigen 
retrieval 
method 
Diluted 
concentra
tion 
Antibo-
dy 
dilutio
n 
Isotype 
dilution 
 
Alpha-SMA 
 
Sigma 
A2547 
 
1A4 
Mouse 
IgG2a (Dako 
X0943) 
Trypsin  
(Method 1) 
 
15.25 
mg·L-1 
 
1:400 
 
1:6 
 
Collagen I 
 
Millipor
e 
MAB33
91 
 
5D8-G9 
Mouse IgG1 
(Dako 
X0931) 
Trypsin 
(Method 1) 
 
10 mg·L-1 
 
1:50 
 
1:5 
 
Collagen III 
 
Abcam, 
ab7778 
 
- 
Rabbit IgG 
(GeneTex, 
GTX35035) 
 
Proteinase 
k 
 
20 mg·L-1 
 
1:50 
 
1:750 
 
Collagen IV 
 
 
Dako 
M0785 
 
CIV 22 
Mouse IgG1  
(Dako 
X0931) 
 
Proteinase 
k 
 
1.6 mg·L-1 
 
1:50 
 
1:3 
 
 
Fibronectin 
 
 
 
Dako 
A0245 
 
 
- 
DAKO rabbit 
immunoglo- 
bulin 
Fraction, 
code X0936 
 
 
Trypsin 
(Method 2) 
 
 
49 mg·L-1 
 
 
1:100 
 
 
1:300 
 
Laminin 
 
 
Sigma 
L8271 
 
LAM-89 
Mouse IgG1  
(Dako 
X0931) 
 
Proteinase 
k 
 
9 mg·L-1 
 
1:800 
 
1:10 
 
Chondroitin 
sulphate 
 
Sigma 
 
CS-56 
Mouse  
IgM (Dako 
X0942) 
 
Proteinase 
k 
 
3 mg·L-1 
 
1:200 
 
1:33 
 
Vimentin 
 
Leica 
NCL-L-
VIM-V9 
Mouse IgG1  
(Dako 
X0931) 
 
Citric acid 
microwave  
 
78 mg·L-1 
 
1:50 
 
2:3 
 
 
Von 
Willebrand 
 
 
Dako 
A0082 
 
 
- 
DAKO rabbit 
immunoglo- 
bulin 
Fraction, 
code X0936 
 
 
Proteinase 
k 
 
 
15.5 
mg·L-1 
 
 
1:200 
 
 
1:1000 
Table 2.6: Primary antibodies, isotypes and antigen retrieval methods used. 
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2.12.3 Immunohistochemistry protocol 
Reagents 
The reagents used for the immunohistochemistry were: 
 TBS pH 7.6; 
 TBS containing 0.05 % (v/v) Tween 20, pH 7.6; 
 Antibody diluent: 100 ml TBS (pH 7.6) supplemented with 0.01 % (w/v) sodium azide and 
0.01 % (w/v) bovine serum albumin (BSA). The pH was adjusted to pH 7.6 and the solution 
was stored at 4 °C and used within 1 month; 
 PBS pH 7.2 - 7.4; 
 3 % (v/v) hydrogen peroxide (H2O2), prepared by diluting 30 % (v/v) H2O2 10× using PBS 
at pH 7.6; 
 Ultravision Detection kit (only with mouse and rabbit primary antibodies). 
 Substrate chromagen: 20 µl of liquid DAB + chromagen was added to 1 ml of substrate 
buffer and mixed thoroughly.  
Method 
Paraffin embedded tissue sections were dewaxed and rehydrated as described in Section 
2.10.4. Antigen retrieval was carried out according to the manufacturer’s instructions. The 
sections were incubated in 3 % (v/v) H2O2 to block endogenous peroxidase activity present in 
the tissue. The sections were then washed in running tap water for 3 min and the tissue 
samples on each slide were circled using a hydrophobic marker. The sections were washed 
using TBS and 1 drop of dual endogenous enzyme block was added to each section (10 min 
of incubation). The sections were then washed twice for 10 min using TBS. The primary 
monoclonal antibody was applied at a suitable dilution (according to manufacturer’s 
instructions) and incubated in a moist atmosphere (humid chamber) at room temperature for 
60 min (overnight at 37°C for collagen I).  
Two negative controls were used; the primary antibody was replaced by the isotype control (at 
a suitable concentration) in one section and by no antibody in another section. Following the 
application of the primary antibody or the isotype control, the sections were washed twice for 
10 min using TBS containing 0.05 % (w/v) Tween, followed by another 2 washes in TBS of 10 
min each. Subsequently, 20 µl of labelled polymer-HRP was applied onto each section and 
incubated for 30 min at room temperature in the dark. The Polymer-HRP had the same 
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function as a secondary antibody, thus, it attached to the primary antibody and to the 
substrate chromagen in order to allow the final coloured reaction. The sections were then 
washed twice for 10 min using TBS containing 0.05 % (w/v) Tween 20, followed by another 2 
washes in TBS of 10 min each. Excess buffer was tapped off. Finally, 15 µl of substrate 
chromagen was added from the Envision kit to each section, in order to visualise the labelling 
of the sections, and incubated for 10 min at room temperature. After 4 washes in distilled 
water, the sections were counterstained through immersion into hematoxylin for 10 s. The 
sections were then rinsed using tap water until the water ran clear. Finally, the sections were 
dehydrated and mounted as described in Section 2.10.5.   
Data analysis 
Images of the tissue sections treated for histology and immunohistochemistry were captured 
using an Olympus BX51 microscope. 
 
2.13 Electron Microscopy  
Tissue for scanning electron microscopy (SEM) was fixed overnight with 2.5 % (w/v) 
glutaraldehyde and post-fixed overnight with 1 % (w/v) osmium tetroxide and then dehydrated 
using an ascending alcohol gradient. Following dehydration, critical point drying was carried 
out using a Polaron E3000. The tissue samples were then coated with gold and mounted on 
13 mm diameter stubs. Fresh specimens prepared for environmental scanning electron 
microscopy (ESEM) analysis were imaged immediately after mounting on pin stubs. The 
samples were imaged for both SEM and ESEM analysis in an FEI Quanta 200F FEG ESEM.  
 
2.14 Biochemical Assays  
2.14.1 Freeze-drying  
Tissue samples were frozen overnight at -20°C for subsequent biochemical assays. The wet 
weights for the different tissues used in the biochemical assays are reported in Table 2.7. The 
samples were lyophilised at -40°C for up to 3 days. The tissue samples were weighed after 24 
hours, 48 hours and 52 hours to ensure a constant weight in order to have complete 
dehydration.  
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Tissue and abbreviations Hydroxyproline 
(mg) 
Hydroxyproline  
denatured (mg) 
Glycosaminoglycans  
(mg) 
Anterior leaflet (LA) 
Posterior leaflet (LP) 
60 - 60 
Fresh pericardium (FP) 60 60 60 
Decellularised pericardium 
(DP) 
60 90 90 
Table 2.7: Wet weights used in the biochemical assays. The values are expressed as mg of wet 
weights. 
 
2.14.2 Hydroxyproline assay 
Reagents  
The following reagents were used for the hydroxyproline assay: 
 Hydroxyproline buffer: 13.3 g citric acid, 32 g sodium acetate (3H2O), 9.1 g sodium 
hydroxide in 3.2 ml glacial acetic acid and  80 ml propan-1-ol (n-propanol). The volume 
was made up to 300 ml using distilled water. The pH was adjusted to between 6.0 – 6.5 by 
adding drops of 6 M hydrochloric acid while stirring. The final volume was adjusted to 400 
ml using distilled water. The solution was kept for up to 2 months in a dark bottle at 4°C. 
 Ehrlich’s reagent: 7.5 g p-dimethylaminiobenzaldehyde in 30 ml propan-1-ol and 13 ml 62 
% (v/v) perchloric acid, with the final addition of 7 ml of distilled water. The solution was 
stirred until fully dissolved and then used within 1 h. 
 Oxidizing solution prepared by dissolving 1.41 g chloramine T in 100 ml distilled water. The 
solution was used immediately.  
Method  
The method used was based on the method reported by Edwards and O’ Brien (1980). Prior 
to running the final biochemical analysis, the tissue sample was freeze dried, as described in 
Section 2.14.1, and then acid hydrolysed. 
Acid hydrolysis 
Freeze dried tissue was weighed, macerated and placed in 15 cm glass test tubes. 
Hydrochloric acid (6 M, 4 ml for each individual sample) was added to the test tubes and the 
tissues were autoclaved at 121°C for 2, 4, 5 and 6 h. After cooling and prior to biochemical 
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analysis, 6 M sodium hydroxide was added to the tissue to adjust the pH to 7. The final 
volume in each test tube was recorded. 
Biochemical analysis 
Trans-4-hydroxy-L-proline was diluted in hydroxyproline buffer at the concentrations of 2, 4, 6, 
8, 10, 15, 20, 25 and 30 µg·ml-1, in order to produce working calibrator solutions. 
Hydroxyproline buffer was used as the blank control for the assay. Triplicates of test and 
standard solutions were added in a volume of 50 µl to a flat-bottomed 96 well plate. 
Chloramine T (100 µl) was added to each well and the plate was gently shaken for 5 min. 
Ehrlich’s reagent (100 µl) was then added to each well and the plate was incubated for 45 min 
in a water bath at 60°C. The optical densities were measured using a micro plate reader 
spectrophotometer at 570 nm. The concentration of hydroxyproline in the acid-hydrolysed 
tissue samples was calculated by interpolation from the standard absorbance curve (Figure 
2.4).  
 
Figure 2.4: Standard curve for hydroxyproline. Data expressed as means (n=6) ± 95% confidence 
limits. 
 
2.14.3 Collagen denaturation assay 
Only the fresh and decellularised pericardial groups were used for this assay. 
Reagents 
The following reagents were used for the collagen denaturation assay: 
 Digest buffer: 1.21 g trizma base and 0.15 g calcium chloride in 100 ml distilled water. The 
pH was adjusted to 7.8 by adding 6 M hydrochloric acid or 6 M sodium hydroxide. The 
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solution was autoclaved at 121°C for 20 min and stored at room temperature for up to 1 
month. 
 α-chymotrypsin: α-chymotrypsin from bovine pancreas was dissolved in digestion buffer at 
5 mg·ml-1. The solution was used immediately.  
Method 
Following freeze drying (Section 2.14.1), the samples were incubated in 5 ml of α-
chymotrypsin solution at 30°C for 24 h, and then centrifuged for 10 min (α-chymotrypsin only 
reacts with denatured collagen when the protein is not in its native folded conformation). The 
supernatants were then transferred to 15 cm glass test tubes with HCl (6 M, 4 ml per sample) 
to be acid hydrolised. Neutralisation and biochemical analysis of the samples was followed as 
described in Section 2.14.2.  
2.14.4 Glycosaminoglycan (GAG) assay (sulphated proteoglycans)  
This method was used to quantify the sulphated sugar content of the tissues.  
Reagents 
The following reagents were used for the GAG assay: 
 Digestion buffer: 0.788 g L-cysteine and 1.8612 g sodium ethylenediaminetetraacetic acid 
in 1 L of PBS. The pH was adjusted to 6.0 ± 0.1 by adding 6 M hydrochloric acid or 6 M 
sodium hydroxide drops. The solution was stored at room temperature for up to 6 months. 
 Papain digestion solution: 1250 Units of papain were dissolved in 25 ml of digestion buffer. 
The solution was used immediately. 
 Tris solution (0.2 M) was prepared by dissolving 24.22 g of trizma base in 500 ml distilled 
water. The pH was adjusted to 8.0 ± 0.1 by adding 6 M hydrochloric acid. The volume was 
made up to 1 L using distilled water. The solution was autoclaved for up to one month at 
room temperature. 
 Sodium di-hydrogen orthophosphate (0.1 M) prepared by dissolving 3.45 g sodium di-
hydrogen orthophosphate in 250 ml distilled water. The solution was stored at room 
temperature for up to 3 months. 
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 Di-sodium hydrogen orthophosphate (0.1 M) prepared by dissolving 3.55 g di-sodium 
hydrogen orthophosphate in 250 ml distilled water. The solution was stored at room 
temperature for up to 3 months. 
 Assay buffer was prepared by mixing 137 ml of 0.1 M sodium di-hydrogen orthophosphate 
with 63 ml 0.1 M di-sodium hydrogen orthophosphate. The pH was adjusted to 6.8 using 6 
M hydrochloric acid or 6 M sodium hydroxide. The solution was stored at room 
temperature for up to 3 months. 
 1, 9 dimethylene blue (DMB) dye solution prepared by adding 2 g of sodium formate and 
16 mg of 1,9 DMB into 5 ml of ethanol and 2 ml of formic acid using a magnetic stirrer. The 
volume was made up to 1 L using distilled water. The pH was adjusted to 3.0 using formic 
acid. The dye was stored at room temperature for up to 3 months. 
Method 
Papain digestion 
Freeze dried tissue samples were weighed, macerated and placed in sterile universal tubes 
with 5 ml papain digestion solution. The samples were incubated for 36 hours with gentle 
agitation at 60°C.  
Biochemical analysis 
Standard calibrator solutions of chondroitin sulphate were prepared at 0, 3.125, 6.25, 12.5, 
25, 50 and 100 µg·ml-1. Assay buffer was used as the blank control for the assay. Triplicates 
of test and standard solutions were added in a volume of 40 µl to a flat-bottomed 96 well 
plate. DMB dye solution (250 µl) was added to each well and the plate was gently shaken for 
2 min. The optical densities were measured using a micro plate reader spectrophotometer at 
525 nm. The concentration of sulphated sugars in each acid hydrolysed tissue sample was 
calculated by interpolation from the standard absorbance curve (Figure 2.5).  
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Figure 2.5: Standard curve for GAGs. Data expressed as means (n=6) ± 95% confidence limits. 
 
2.15 MTT assay 
This method was used to assess the viability of both fresh and decellularised seeded 
pericardial samples.  
Reagents 
The following reagents were used for the MTT assay: 
 MTT (3-(4, 5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) solution: 5 mg·ml-1 
MTT was made in PBS pH 7.6. This solution was stored in a foil wrapped container at -
20 °C, and thawed to room temperature before use. 
 Dimethyl sulfoxide (DMSO). 
 PBS with Ca and Mg. 
Method 
Tissue samples of specific weighs were macerated with a scalpel blade, placed in 1.5 ml 
autoclaved eppendorf tube of known weighs and then weighed aseptically. MTT solution (200 
μl) and PBS with Ca and Mg (400 μl) were added to each microtube aseptically. The tubes 
were incubated on a blood rotator at 30 rpm for 4 h at 37°C. Following incubation, the tubes 
were centrifuged in a micro centrifuge at 14,000 g for 5 min, the supernatant was removed 
and 1 ml of DMSO was added into each tube aseptically. The tubes were further incubated on 
the blood rotator at 30 rpm for 17 h at 37 °C, and then centrifuged at 14,000 g for 5 min in a 
micro centrifuge prior to transferring aliquots of 200 μl supernatant from the micro tubes to a 
clear flat-bottomed 96-well plate. The absorbance was read at 570 nm with a reference filter 
at 630 nm. The DMSO was used as a blank.  
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2.15.1 MTT assay validation  
The optimum amount of tissue to be used during MTT assay was validated. Three replicates 
out of each one of three fresh porcine pericardia were processed straight after dissection 
through MTT assay, at different weighs: 20, 50, 100, 150 and 200 mg. The final values of 
optical densities for each weigh were plotted on GraphPad Prism to get the standard 
absorbance curve. The optimum value of weigh of tissue to be used for future experiments 
was chosen to be in the linear region of the plotted standard curve. The same optimum value 
of weigh of fresh tissue was used for decellularised samples.  
 
2.16 Live/dead staining of fresh and recellularised pericardial scaffolds 
Fresh and decellularised seeded pericardial scaffolds were harvested for live/dead staining at 
different time points in order to assess the viability of the cells.  
Reagents 
 Live/dead staining solution was prepared using PBS at pH 7.6, supplemented with 1 μM 
calcein AM and 1 μM ethidium homodimer-1 (1.2 μl calcein and 5 μl of ethidium 
homodimer-1 in 5ml of PBS pH 7.6). 
 DABCO/glycerol: 10 ml of 2.5% (w/v) DABCO into 90 ml of glycerol. Solution was stored 
for up to 3 months at 4°C in a foil wrapped bottle. 
Method 
A rectangular piece (approximately 5×6 mm2) was cut from the central area of each sample, 
and placed into individual wells of a 6-well tissue culture plate, keeping the cell seeded or 
mesothelial surface uppermost. The samples were kept moist with complete cell culture 
medium during dissection. Live/dead stain solution was added into each well to completely 
cover the tissue. The plate was fitted with its lid and incubated at room temperature in the 
dark for 45 min. The samples were washed 3 times in TBS pH 7.6 for 10 min each on a plate 
rocker, and they were then wet mounted with DABCO/glycerol onto a microscope slide and 
covered with a glass coverslip. The samples were viewed using an Olympus BX51 
microscope. Live cells were stained green and dead cells were stained red. The acquired 
pictures were then processed through Image J for live/dead cell counting. 
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2.16.1 Live/dead cell counting  
The percentage of live and dead cells was counted using Image J. Firstly, both live and dead 
cells visible on the top surface of the samples were counted, followed by counting only the live 
cells. The percentage of live cells was then calculated. The same procedure was followed for 
the dead cells. 
 
2.17 Cell culture techniques 
2.17.1 Cell culture  
The cells used in this study were all cultured in complete cell culture medium, (Section 2.5.4). 
Cell culture operations and medium changes were performed aseptically in a Class II cabinet. 
All culture media and reagents were allowed to equilibrate to 37°C before use. The cells were 
cultured at 37°C in 5 % CO2 (v/v) in air (standard conditions). 
2.17.2 Cell resurrection 
The cells were removed from liquid nitrogen storage and rapidly defrosted in a 37°C water 
bath. The cells (1 ml) were then added to a 25 cm2 flask with 14 ml of complete cell culture 
medium, (Section 2.5.4), and were cultured under standard conditions.  
2.17.3 Cell passaging  
Once the cells achieved confluence, the culture medium was aspirated from the culture flasks, 
and the cell layer was washed in PBS without calcium or magnesium for 2 min. Trypsin/EDTA 
(1.5 ml; Lonza) was added to the T25 culture flasks, which were then incubated under 
standard conditions for 5 to 10 min. Progress of cellular detachment was regularly monitored 
using an inverted light microscope. Gentle physical tapping of the flasks was used to help the 
detachment process. Culture medium (8.5 ml) was added to each flask to stop the action of 
the trypsin/EDTA, and the cell suspension was transferred into a universal tube and 
centrifuged for 10 min at 180 g. Following centrifugation, the supernatant was carefully 
removed and the cell pellet was re-suspended in a specific volume of complete cell culture 
medium, depending on the amount of cells needed for the subsequent experiments. The 
culture medium was changed every 2 to 3 days until the cells became confluent and ready to 
be passaged again.  
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2.17.4 Cell counting 
After detachment and centrifugation (Section 2.17.3), the cell pellet was re-suspended in 1 to 
2 ml of complete cell culture medium. An improved Neubauer haemacytometer (Fisher 
Scientific) was used to count the live cells under an inverted microscope. For this purpose, 
trypan blue dye (20 µl; 0.4 % w/v; Sigma) was added to 20 µl of the cell suspension, and 10 
µl of the solution was added to the chamber. Non-viable cells took up the dye and appeared 
blue, whereas live cells appeared colourless and bright due to the fact that their cell 
membrane was intact, prohibiting dye intake. Viable cells were counted in 4 out of the 9 grids 
of the haemocytometer. The total number of viable cells per ml in the cell suspension was 
calculated as follows: 
Number of cell·ml   (
number of viable cells
4
)   104  2 
 Where 4 was the number of grids counted and 2 was the dilution factor required due to the 
dilution of the cell suspension with trypan blue. 
2.17.5 Cell cryopreservation 
Reagents 
 Cryopreservation medium: Standard culture medium (Dulbecco’s modified Eagle’s 
medium; DMEM) supplemented with 10 % (v/v) filter-sterilised dimethyl sulfoxide (DMSO). 
DMSO prevented the formation of ice crystals during freezing. However, DMSO is highly 
toxic and, therefore, the cells were frozen immediately after aliquoting. 
Method 
After cell counting (Section 2.17.4), the cell suspension was diluted to 106 cells per ml with 
cryopreservation medium. The cell suspension was then aliquotted to 1 ml into cryovials and 
placed into a cryo-freezing pot which contained isopropanol. The pot was kept at -80 °C 
overnight and, subsequently, the cryovials were transferred to liquid nitrogen for long-term 
storage.  
2.17.6 Cell characterization 
Dermal fibroblasts and pSMCs were cultured for phenotyping by immunofluorescence. The 
markers that were used to confirm cell phenotype are summarised in Table 2.8. 
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Cell type α-SMA Calponin Desmin Vimentin 
Fibroblast - Not done - + 
SMCs + + + Not done  
Table 2.8: Characterisation of SMCs and fibroblasts. Positive (+) indicates expression of the 
marker by the cells; negative (-) indicates that the cells did not express the marker.   
 
2.17.6.1 Immunofluorescence labelling 
The antibodies and isotype controls used in the immunofluorescence labelling are listed in 
Table 2.9. The protein concentration used for the isotype control was the same as used for 
the specific primary antibody. The secondary antibody (Alexa fluor 488, goat anti-mouse IgG) 
was used at a concentration of 10 mg·L-1. SMCs were used as positive control when labelling 
-SMA and desmin for fibroblasts.  
Antigen Supplier Clone Isotype 
Diluted 
concentration 
Antibody 
dilution 
Isotype 
dilution 
 
α-SMA 
 
 
Sigma A2547 
 
1A4 
 
Mouse IgG2a 
(Dako X0943) 
 
15.25 mg·L-1 
 
1:400 
 
1:6 
 
Calponin 
Novocastra 
26A11, NCL-
CALPONIN-B 
 
26A11 
 
Mouse IgG2b 
 
24 mg·L-1 
 
1:50 
 
1:50 
Desmin Vector VP-
D502 
DE-R-11 Mouse IgG1 
(Dako X0931) 
54 mg·L-1 1:50 1:2 
Vimentin Leica NCL-L-
VIM-V9 
Mouse IgG1 
(Dako X0931) 
78 mg·L-1 1:50 2:3 
Table 2.9: Primary antibodies, isotypes and dilutions used in immunofluorescence labelling. 
 
Reagents 
 TBS pH 7.6. 
 TBS containing 0.05 % (v/v) Tween 20, pH 7.6. 
 Antibody diluent: 100 ml TBS (pH 7.6) with 0.01 % (w/v) sodium azide and 0.01 % (w/v) 
bovine serum albumin (BSA). The pH was adjusted to 7.6, and the solution was stored at 
4 °C and used within 1 month. 
 PBS pH 7.2 - 7.4. 
 72 
 
 Dye buffer: 1.211 g of trizma base, 0.3724 g of EDTA, 5.8 mg of sodium chloride in 1 L of 
distilled water. The solution was autoclaved at 121°C for 20 min. 
 DAPI dye solution: 10 mg of DAPI in 10 ml of nuclease free water (1 mg·ml-1). The solution 
was stored at -25°C for up to 6 months. 
 Working dye solution: 2.5 µl of DAPI dye solution in 25 ml of dye buffer (0.1 mg·ml-1) in a 
dark bottle. The pH was adjusted to 7.4 by adding 6 M hydrocholoric acid or 6 M sodium 
hydroxide. The solution was used immediately after preparation. 
Method   
Fibroblasts at passage 4 and SMCs at passage 6 were cultured on multi-spot slides for 17 
hours under standard conditions. To each spot, 50 µl of cell suspension at a cell density of 
2×103 per ml was added. Following culture, the slides were washed with 5 ml of PBS for 2 
min, fixed in mixture of acetone and methanol (1:1) for 1 min, and air dried for 5 min. The 
slides were then rinsed in running tap water for 10 min, followed by washing in TBS for 5 min 
and addition of 20 µl of the appropriate primary antibody (diluted using the antibody diluent). 
The slides were then incubated in a moist environment for 1 hour at room temperature prior to 
being washed twice in TBS containing 0.05 % (w/v) Tween 20 for 10 min each, followed by 10 
min wash in TBS. Subsequently, fluorochrome-labelled secondary antibody (20 μl) was added 
for 30 min at room temperature in the dark. The slides were then washed twice for 10 min 
each with TBS containing 0.05 % (w/v) Tween 20, and then rinsed once for 10 min in TBS 
prior to incubation in working solution for 10 min in the dark. The slides were finally rinsed in 
PBS three times for 10 min each in the dark before being mounted with DABCO/glycerol 
solution (Section 2.16).  
 
2.18 Biomechanical testing 
The biomechanical properties of the leaflets and pericardium were investigated using low 
strain-rate uniaxial tensile loading to failure tests according to the protocol described by 
Korossis et al. (2002). Eight groups of tissue were used for this test including PO, PP, DPP, 
DPO, LAC, LAR, LPC and LPR, (Table 2.5). Six samples were tested for each group.  
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2.18.1 Tissue sample preparation 
Fresh and decellularised pericardial samples, measuring 10 mm in length by 5 mm in width, 
were isolated orthogonally (PO, DPO) and parallel (PP, DPP) to the direction of the collagen 
fibres (Fig. 2.3a, b).  Fresh posterior and anterior leaflet samples, measuring 10 mm in length 
by 5 mm in width, were also isolated along the circumferential (LAC, LPC) and radial (LAR, 
LPR) directions of the mitral valve leaflets (Fig. 2.3c). The specimens were dissected using 
parallel razor blades fitted onto a cutting block (Figure 2.6). Prior to testing, the thickness of 
the sample was measured using a Mitutoyo thickness gauge (Figure 2.7) at 3 different points 
along its length and averaged. Subsequently, the test sample was clamped onto a titanium 
holder (Figure 2.8) with the aid of sandpaper and a small amount of superglue to prevent 
slippage. 
 
Figure 2.6: Cutting block used for the dissection of the tissue samples. 
 
 
Figure 2.7: Thickness gauge used to measure the thickness of the samples. 
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Figure 2.8: Tissue sample holder used in the tensile testing. 
 
The holder was fitted with a removable securing bracket, which ensured that no loading was 
imposed to the specimen until the start of the test. The bracket was also used to set the 
gauge length of the specimens to 10 mm. 
Once the test sample was secured to the holder, the inferior part of the holder was secured to 
the base of an Instron® tensile tester (model 3365) fitted with a 500 N load cell, and the 
crosshead was lowered at a slow speed until it locked to the superior part of the holder. Once 
the superior holder part was secured to the cross-head, the bracket was removed and the 
bath was risen up in order to accommodate testing in PBS. The solution was kept at 37°C. 
The experimental set up used is illustrated in Figure 2.9. 
 
Figure 2.9: Experimental set-up used for the uniaxial tensile loading to failure in the Instron 
tensile tester. 
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2.18.2 Test procedure  
Prior to testing the samples were preconditioned under cyclic loading using a double-ramp 
wave function at a rate of 10 mm·min-1 and then they were sequentially loaded to failure at the 
same rate. During testing, load data from the load cell and the displacement of the crosshead 
was recorded. Prior to the actual testing, preliminary testing was conducted in order to 
estimate the average transition strain (εt) of the different groups, which was used as the limit 
for the preconditioning regime. In particular, 3 additional samples from each of the 8 test 
groups (PP, PO, DPP, DPO, LAC, LAR, LPC, LPR), were subjected to simple uniaxial tensile 
loading to failure (with no preconditioning) at a rate of 10 mm·min-1 and their force-extension 
response was recorded. Subsequently, the force-extension data was converted to stress-
strain (as described below) and the average (εt) was calculated. During the actual testing the 
samples of each test group were preconditioned for 50 cycles from 0% strain up to the 
average εt for the particular group, before the samples were loaded to failure. The tensile 
machine was set to produce a specimen preloading of 0.01 N before the operating program 
started to acquire any data. Thus, zero extension was recorded at the point at which a 0.01 N 
load was detected. The preloading allowed generation of consistent results by overcoming the 
problem related to the “noise” (unloaded oscillating signal) of the load cell. The preloading 
value was chosen in order to be just over the value of the noise of the load cell. Moreover, the 
tissue samples were slack when clamped into the tissue holder in order to avoid loading of the 
specimens during clamping and before the actual testing. Therefore, the preloading limit 
allowed straightening of the tissue and initiation of data recording after a load of 0.01 N was 
detected by the load cell. Failure was taken to occur when the first decrease in load was 
detected during specimen extension. The mode of failure observed was middle section 
necking and rupture for all of the specimens tested. During testing, load data from the load 
cell and specimen extension data from the stroke of the cross-head of the tensile testing 
machine was recorded.  
2.18.3 Data processing 
The recorded force-extension histories of the samples were converted to stress-strain in 
Microsoft Excel XP. The engineering stress (σ) was calculated from the recorded force (F) 
according to: 
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where F was the acquired force in N,  σ the stress in Pa, and A
 
the original cross-sectional 
area (CSA) of the un-deformed specimen in mm2. The CSA was calculated as  
 
      , 
where w was the width of the sample (5 mm) and t its average thickness. The changes in 
thickness and width during preloading were considered negligible and were not taken into 
account. The strain (ε) was calculated from the extension data according to the formula:  
  
  
      
 
where Δl was the extension of the specimen (displacement of the cross head), l i the initial 
gauge length of the specimen, set by the holder bracket, and Δl i the extension produced by 
the preloading. Subsequently, the stress-strain behaviour of the specimens was plotted and 
used to obtain the elastin phase slope (El-E), collagen-phase slope (Coll-E), transition stress 
(σt) and strain (εt), ultimate tensile strength (σuts) and failure strain (εuts).  
A typical stress-strain curve for heart valve leaflet tissue is illustrated in Figure 2.10, indicating 
the six parameters used in the study. 
 
Figure 2.10: Typical stress-strain behaviour of valve leaflet tissue. UTS: ultimate tensile strength. 
Adapted from Fung (1984). 
 
The files that were obtained during testing were exported from the operating program of the 
tensile testing machine and imported to Microsoft Excel XP as spreadsheets for further 
processing. In Excel, the load and extension data were manually converted to stress and 
strain, respectively, as described above. All the 6 mechanical parameters were determined on 
the basis of the stress-strain curve obtained, as illustrated in Figure 2.10. The elastin and 
collagen phase slope were calculated by selecting the region of the curve which better 
 77 
 
represented the specific phase slope, and then by processing the same interval on Origin Pro 
8 to calculate the slope by using the function Fit-Linear. The analysis of the results was 
carried out per treatment group (at least 6 replicates from 6 different pigs per group). The six 
parameters for each specimen were finally averaged over the number of specimens in the 
group, and analysed statistically.  
 
2.19 Data analysis 
Statistical analyses were carried out in Microsoft Excel (2003 or 2007) or GraphPad Prism 5, 
and all numerical values are presented as means ± 95 % confidence intervals (C.I.). The 
Student’s t-test was used for comparison of groups of two means, and one-way ANOVA was 
applied for the comparison of data from more than two groups, followed by calculation of the 
minimum significant difference (MSD) by the T-method for equal sample sizes (Sokal and 
Rohlf, 1981). The MSD was calculated according to: 
         
The Q-value was obtained from the table of the critical values of the studentized range with α 
= 0.05, whereas the standard error of the mean (SE) was calculated as: 
   √
  
 
 
where MS is the mean square (average of the variances) within groups and n the number of 
replicates. The MSD was compared to the differences between the means of the paired 
groups. Significance was accepted when the difference of the means was greater than the 
MSD (p < 0.05).  
Arcsine transformation was applied to data expressed as percentages in order to fulfil the 
assumption of normally distributed data, required by the one-way ANOVA. The values of 
percentages were arcsine transformed as follows: 
  
    
 
       √
 
   
 
where x is the data expressed as a percentage and y is the data arcsine transformed. The 
arcsine transformed values were then averaged and the 95 % C.I.`s were calculated. The 
upper and lower limits were then calculated as follows: 
 78 
 
                           
                          
The mean, upper and lower limits values were then back transformed to report the data as 
percentages: 
      (
 
    
 
     
   
) 
Finally, the upper and lower error bars were calculated as follows: 
                                 
                                 
The mechanical analysis of the fresh pericardial groups (parallel and orthogonal to the 
collagen fibers) was performed twice, providing two different data sets for the statistical 
analysis presented in Chapter 3 and Chapter 4. The reason for repeating the mechanical 
analysis was that the use of the same data set for two different statistical analysis would 
increase the Type I error (which occurs when the null hypothesis is true, but is rejected).  
 79 
 
Chapter 3  
Properties of porcine pericardium and mitral 
valve leaflets 
3.1 Introduction 
In order to develop tissue-engineered substitutes for mitral valve (MV) leaflet reconstruction, it 
is necessary to investigate the inherent characteristics of the native MV leaflets. A deep 
understanding of the characteristics of the natural MV leaflets is necessary in order to develop 
appropriate replacement constructs with similar characteristics, structure and functional 
capability to the native leaflets. The work presented in this PhD thesis utilised decellularised 
porcine pericardium for the development of cell seeded and unseeded MV leaflet 
replacements. Autologous, allogeneic and chemically-treated xenogeneic (porcine) 
pericardium has been routinely used in the clinical setting for MV repair (Maranto and Schoen, 
1988; Duran and Gometza, 1993). As such the use of decellularised porcine pericardium in 
MV leaflet repair represents a plausible option. Moreover, previous studies have 
demonstrated that the human and porcine mitral valve apparatuses share similar anatomical 
structure and histoarchitecture (Kunzelman et al., 1994). Therefore, porcine MV leaflets were 
used in this study for comparative purposes due to the limited availability of human tissue.  
This chapter presents the biomechanical and biological properties of fresh porcine 
pericardium and MV leaflets. Fresh pericardium and leaflets were investigated in order to 
generate a benchmark and investigate (in subsequent chapters) both the effects of 
decellularisation on porcine pericardium and the suitability of cell-seeded and unseeded 
decellularised pericardium as MV leaflet replacements. The biomechanical properties were 
studied through low strain rate uniaxial tensile loading to failure and the biological properties 
were studied in terms of histoarchitecture, protein and glycosaminoglycan (GAG) content. A 
comparison between biomechanics and biological results was made in order to understand 
the relationship between structure and biomechanical properties of the tissue. 
The spatial cell distribution and the distribution and organisation of the extracellular matrix 
(ECM) components (GAGs, collagen, and elastin) in the tissues were investigated by 
histological staining. GAGs are one of the main components of the ECM in heart valve leaflets 
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providing resistance to compression (Baeurle et al., 2009). Chondroitin sulphate represents 
one of the main acidic GAGs of the human heart valves, together with hyaluronic acid 
(Murata, 1981). In addition to histological staining, chondroitin sulphate distribution was 
investigated using immunohistochemical staining, and the amount of sulphated GAG in the 
tissues was quantified using the GAG biochemical assay. 
Another important component of the ECM of the valve leaflets is elastin, which provides the 
recoiling mechanism for the large deformation of the leaflets during the cardiac cycle (Cleary 
and Gibson, 1996). Collagen represents the major load-bearing component of the ECM of the 
leaflets and its preservation following tissue decellularisation is of paramount importance for 
the structural integrity of the decellularised scaffold. Collagen I and III are the most abundant 
types in MV leaflets (Kunzelman et al., 1993a), whereas collagen IV forms a two dimensional 
reticulum and is usually found in the basement membrane of the leaflets. The chemical 
composition of collagen consists of three amino acids, which include glycine, proline, and 
hydroxyproline (HXP), with the latter being the major component of collagen. As such, the 
total collagen in the tissues investigated in this study was quantified by the HXP biochemical 
assay. In addition, immunohistochemical staining was used to investigate collagen I, III and IV 
localisation and distribution in the tissues. 
Immunohistochemical staining was further used to detect additional ECM proteins, including 
fibronectin and laminins. Fibronectin is a glycoprotein which aids cell attachment to the ECM. 
It has a high affinity to collagen and GAGs and a good capability of binding to cell surfaces, 
forming a bridge between the cell and the ECM (Ruoshlati et al., 1981). Laminins are major 
glycoproteins in the basal lamina, which is one of the layers of the basement membrane 
(Timpl et al., 1979). Laminins influence cell differentiation, migration, and adhesion, as well as 
phenotype and survival and they are different from fibronectin in the amino acid composition 
and immunological reactivity. Apart from detection of ECM proteins, immunohistochemical 
staining was also used to detect cytoskeletal components, namely -smoth muscle actin (-
SMA), vimentin and Von Willebrand factor, which are indicative of particular cell types. This 
was necessary in order to determine the cell types and distribution present in the fresh 
porcine MV leaflets, with a view to guiding the selection of cells in the reseeding of the 
decellularised pericardial scaffolds. -SMA is a protein typical of smooth muscle cells (SMCs) 
and is present in high amounts in vascular SMCs (Skalli et al., 1989). Vimentin is an 
intermediate filament protein that is expressed in mesenchymal cells (Fraga et al., 1998) and 
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it was used to stain fibroblasts in the MV leaflets. The Von Willebrand factor is a glycoprotein 
required to maintain normal haemostasis and it was used to detect endothelial cells (Sadler, 
1998). 
 
3.1.1 Aims and objectives 
Aims: 
The aim of the work presented in this chapter was to investigate the biological and 
biomechanical properties of fresh porcine pericardium and MV leaflets, with a view to 
generating a benchmark for assessing the effects of decellularisation on porcine pericardium 
and the suitability of cell-seeded and unseeded decellularised pericardium as MV leaflet 
replacements.  
Objectives: 
Specifically, the objectives of this chapter were to characterise: 
 the presence, spatial arrangement and amount of the ECM proteins in fresh porcine 
pericardium and MV leaflets  
 the cell types present in the MV leaflets, and  
 the biomechanical properties of fresh porcine pericardium and MV leaflets. 
 
3.2 Material and methods 
The general materials and methods used for the histological, immunohistochemical, 
biochemical and biomechanical evaluation of the fresh porcine pericardium and MV leaflets, 
have been described in Chapter 2, Section 2.11, 2.12, 2.14 and 2.18, respectively. Fresh 
pericardial samples were dissected orthogonally (PO) and parallel (PP) to the direction of the 
collagen fibres, and MV leaflet samples were isolated along the circumferential (anterior: LAC; 
posterior: LPC) and radial (anterior: LAR; posterior: LPR) directions, for histological, 
immunohistochemical and biomechanical analysis, as described in Chapter 2, Section 2.9. 
Biochemical characterisation of fresh porcine pericardium (FP) and anterior (LA) and posterior 
(LP) MV leaflets with no particular fibre orientation was performed in order to quantify the 
amount of ECM collagen (HXP) and GAGs. A number of samples equal to 6 was used to 
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calculate the HXP and GAGs content; only during the validation of hydrolysis technique, a 
number of samples equal to 3 was used. 
Various staining were used for the histological analysis of samples; haematoxylin & eosin 
(H&E) staining was used to investigate the general distribution of cell nuclei. Alcian blue-PAS 
was used to determine GAG distribution, whereas Sirius red and Miller’s elastin staining was 
used to examine the collagen and elastin distributions in the tissues, respectively. In addition, 
Masson’s trichrome stain was used to stain collagen, muscle, fibrin, cytoplasm and nuclei.  
Immunohistochemical staining of fresh porcine pericardium and MV leaflets was performed in 
order to study the presence, distribution and spatial arrangement of their ECM proteins. For 
this purpose, tissue sections were stained with monoclonal antibodies against collagen I, III 
and IV, chondroitin sulphate, fibronectin and laminin. Moreover, and in order to identify the 
type and distribution of cells in the native MV leaflet cells, tissue sections were stained with 
antibodies against α-SMA, vimentin and Von Willebrand factor. All negative control sections 
(including isotype and omission of HRP controls) showed absence of staining. 
The biomechanical behaviour of the native porcine pericardium and MV leaflets was 
investigated under uniaxial tensile loading to failure in order to study the directional anisotropy 
of the pericardium and the directional and regional (posterior vs. anterior) anisotropy of the 
MV leaflets (n = 6). The biomechanical parameters investigated included the overall stress-
strain behaviour, elastin phase slope (El-E), collagen phase slope (Coll-E), transition stress 
(σt) and strain (εt), ultimate tensile strength (UTS) and failure strain (εUTS).   
 
3.3 Results 
3.3.1 Histological characterisation of porcine pericardium and mitral valve 
leaflets  
3.3.1.1 Porcine Pericardium 
Fresh pericardium showed a three-layered structure (Figure 3.1b, d, f), comprising an outer 
layer of cells (mesothelium), the fibrosa consisting of collagen and well organized elastin 
fibres, and the epipericardial layer consisting of collagen fibres and sparsely arranged elastin 
fibres (Figure 3.1b, d). GAGs were observed (blue; Alcian blue-PAS stain) mainly in the 
mesothelial layer (Fig. 3.1f, h).  
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Figure 3.1: H&E, Sirius red/Miller’s elastin, Masson’s trichrome and Alcian blue - PAS staining 
of fresh pericardial samples isolated parallel (PP; a, b, e and f) and orthogonally (PO; c, d, g and h) 
to the direction of the collagen fibres. Sections were stained with H&E (a, c), Sirius red/Miller’s elastin 
(b, d), Masson’s trichrome (e, g) and Alcian blue - PAS (f, h). Brackets indicate the various layers. E: 
epipericardial layer/side; F: fibrosa; M: mesothelial layer/side. Scale bars indicate 100 µm. 
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H&E staining clearly demonstrated the spatial cell distribution in the pericardium (Fig. 3.1a, c), 
with the cell nuclei stained blue/black by haematoxylin and the cells appeared to be spread 
throughout the fibrosa and the epipericardial layer. Cells were also observed covering the 
mesothelial surface of the pericardial sections. Cell cytoplasm and most ECM fibres, such as 
collagen, were stained by eosin in varying shades and intensities of pink. Samples stained 
with Sirius red and Miller’s elastin demonstrated red-stained collagen and black/purple-stained 
elastin fibres in the fibrosa and in the epipericardium (Fig. 3.1b, d). 
Samples stained with Masson’s trichrome demonstrated blue-stained collagen fibres, 
blue/black-stained cell nuclei, red-stained cytoplasm and deep-red-stained muscle (Fig. 3.1e, 
g). These samples clearly demonstrated the wavy structure of the collagen fibres. Samples 
stained with Alcian blue-PAS (Fig. 3.1f, h) demonstrated blue-stained GAGs, magenta-stained 
neutral mucins and deep-blue-stained cell nuclei. GAGs appeared to be located mainly in the 
mesothelial layer. 
3.3.1.2 Mitral valve leaflets 
The histological analysis of the MV leaflets demonstrated a characteristic quadrilaminar 
structure comprising the atrialis, mainly consisting of elastin fibres (Fig. 3.2b, d, f, h), the 
spongiosa with a high concentration of GAGs (Fig. 3.3b, d, f, h), the fibrosa consisting of 
collagen fibres (Fig. 3.3a, c, e, g), and the ventricularis consisting of elastin fibres (Fig. 3.2b, 
d, f, h).  Samples stained with H&E (Fig. 3.3a, c, e, g) showed blue/black-stained cell nuclei, 
which were spread throughout the four layers, as well as on the surface of the leaflets forming 
an endothelial cell layer. Blood vessels were mainly located in the atrialis and upper fibrosa. 
Samples stained with Sirius red/Miller’s elastin demonstrated black/purple-stained elastin 
fibres in both the atrialis and ventricularis, but in a higher alignment in the atrialis (Figure 3.2b, 
d, f, h). The quadrilaminar structure of the leaflets was particularly obvious under Masson’s 
trichrome staining (Fig. 3.3a, c, e g). In particular, it was possible to observe the spongiosa 
layer consisting mainly of GAGs and pale-blue-stained loosely organised collagen fibres, and 
the fibrosa layer consisting of dense bands of intense-blue-stained wavy collagen. Under 
Masson’s trichrome staining, cytoplasm and nuclei were stained red and blue/black 
respectively, whereas blood vessels were stained red. GAGs were visualised under Alcian 
blue-PAS staining, and were coloured blue when alone and blue/purple when mixed with 
neutral mucins (Figure 3.3b, d, f, h). No significant morphological differences in the histology 
between the anterior and posterior leaflets were observed. 
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Figure 3.2: H&E and Sirius red/Miller’s elastin staining of MV leaflets circumferential (LAC; a, b) 
and radial (LAR; c, d) anterior, circumferential (LPC; e, f) and radial (LPR; g, h) posterior. Sections 
were stained with H&E (a, c, e and g), Sirius red/Miller’s elastin (b, d, f and h). The black arrows 
indicate the elastin fibres. A: atrialis layer/side; F: fibrosa; S: spongiosa; V: ventricularis layer/side. 
Scale indicates 500µm. 
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Figure 3.3: Masson’s trichrome and Alcian blue – PAS staining of MV leaflets circumferential 
(LAC; a, b) and radial (LAR; c, d) anterior, circumferential (LPC; e, f) and radial (LPR; g, h) posterior. 
Sections were stained with Masson’s trichrome (a, c, e and g), Alcian blue - PAS (b, d, f and h). 
Brackets indicate the various layers. The red arrows and circles indicate the blood vessels. A: atrialis 
layer; F: fibrosa; S: spongiosa; V: ventricularis layer. Scale bars indicate 500 µm. 
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3.3.2 Collagen and glycosaminoglycan content of porcine pericardium and mitral 
valve leaflets 
Biochemical characterisation of fresh porcine pericardium (FP) and anterior (LA) and posterior 
(LP) MV leaflets was performed in order to quantify the amount of ECM collagen (HXP) and 
GAGs. Collagen content was assessed following acid hydrolysis and GAGs following papain 
digestion of a known weight of tissue. These methods have been described in Chapter 2, 
Section 2.14.  
3.3.2.1 Collagen content  
Validation of hydrolysis technique  
In order to determine whether the acid hydrolysis of the tissues resulted in complete 
hydrolysis of the collagen it was necessary to determine the concentrations of HXP after 
various durations of hydrolysis. The amount of HXP (μg·mg-1
 
dry weight) determined after 2, 
4, 5 and 6 h of acid hydrolysis of the pericardial and MV leaflet tissues are illustrated in Figure 
3.4. The data for each tissue type was analysed by one way ANOVA. No significant difference 
was found in the concentration of HXP after 2, 4, 5 or 6 hours hydrolysis of the FP and LP 
tissues (p = 0.148 and p = 0.120, respectively). In contrast, significant differences were found 
in the amount of HXP released from the LA tissue between 2 h and 6 h and between the 4 h 
and 6 h, with the amount of HXP being higher after 6 h (p < 0.05; MSD = 29.013; Fig. 3.4b). 
There was no significant difference in the HXP released after 5 and 6 hours hydrolysis. Thus, 
it was decided to use the 6 h time point for the acid hydrolysis of all tissue analysed in this 
study.  
Hydroxyproline content of tissues  
The amount of HXP per mg dry weight of FP, LA and LP after 6 h of acid hydrolysis was 
83.252 (±9.704) µg·mg-1, 99.302 (± 13.987) µg·mg-1 and 80.054 (± 20.433) µg·mg-1, 
respectively (Figure 3.5). The LA and LP groups were statistically compared and no significant 
difference was observed (p = 0.074). The final percentage of collagen content was 58.276% 
for FP, 69.511% for LA and 56.038% for LP. The final percentage of collagen was calculated 
as the HXP amount converted in mg·mg-1 and multiplied by 7 (as 1/7 of 1mg of collagen is 
HXP). 
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Figure 3.4: HXP content per dry weight of fresh pericardium (a), anterior (b) and posterior (c) 
leaflets after 2, 4, 5 and 6 h time points of acid hydrolysis. Data is presented as the mean (n=3) 
±95% C.I. Asterisk and connectors indicate significant difference between originator and end-arrow 
column (determined by ANOVA and calculation of MSD p < 0.05). Significant differences were found 
between 2 and 6 h and between 4 and 6 h acid hydrolysis within the LA group (p < 0.05; MSD = 
29.013). HXP: hydroxyproline. 
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Figure 3.5: HXP content per dry weight of anterior (LA) and posterior (LP) leaflets after 6 h of 
acid hydrolysis. Data is presented as the mean (n=6) ± 95% C.I. Data was analysed by unpaired 
student`s t-test that showed no significant difference between groups (p =0.074). HXP: hydroxyproline. 
 
3.3.2.2 GAG content of porcine pericardium and mitral valve leaflets  
The amount of GAGs per dry weight of FP, LA and LP was 8.425 (±3.367) µg·mg-1, 23.898 (± 
8.653) µg·mg-1 and 24.590 (± 5.787) µg·mg-1, respectively. The LA and LP groups were 
statistically compared and no significant difference was observed (p = 0.868; Figure 3.6).  
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Figure 3.6: GAG content per dry weight of fresh pericardium (FP), anterior (LA) and posterior 
(LP) leaflets. Data is presented as the mean (n=6) ± 95%C.I. Data was analysed by unpaired 
student`s t-test that showed no significant difference between groups (p =0.868). GAGs: 
glycosaminoglycans. 
 
3.3.3 Distribution of ECM and cellular proteins in porcine pericardium and mitral 
valve leaflets  
3.3.3.1 Chondroitin sulphate 
Images of porcine MV leaflet and pericardial sections labelled with antibody against 
chondroitin sulphate are shown in Figure 3.7 and 3.8, respectively. Both the anterior and 
posterior leaflet sections (LAR, LAC, LPR, LPC) were stained positive, indicated by a deep 
brown coloration, in the spongiosa layer (Fig. 3.7a - d). Positive staining was also observed in 
the ventricularis of the LAR section (Fig. 3.7b). Positive staining was also demonstrated in the 
pericardial sections, along the mesothelial layer (Fig.3.8a, b). No brown coloured staining was 
observed in the tissue sections stained with the isotype control (Fig. 3.7e, Fig. 3.8c).  
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Figure 3.7: Localisation of chondroitin sulphate in MV leaflets circumferential (LAC; a) and radial 
(LAR; b, e) anterior, circumferential (LPC; c) and radial (LPR; d) posterior.  Sections were stained with 
chondroitin sulphate (a - d) and isotype control (e). Portions of tissue positive for chondroitin sulphate 
were brown stained. No brown coloured staining was observed in the tissue section stained with the 
isotype control (e). Brackets indicate the various layers. A: atrialis layer/side; F: fibrosa; S: spongiosa; 
V: ventricularis layer/side. Scale bars indicate 500µm. 
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Figure 3.8: Localisation of chondroitin sulphate in fresh pericardial samples isolated parallel 
(PP; a, c) and orthogonally (PO; b) to the direction of the collagen fibres. Sections were stained with 
chondroitin sulphate (a, b) and isotype control (c). Portions of tissue positive for chondroitin sulphate 
were brown stained. No brown coloured staining was observed in the tissue section stained with the 
isotype control (c). The red arrows indicate the mesothelial layer stained brown. E: epipericardial 
layer/side; M: mesothelial layer/side. Scale bars indicate 100 µm. 
 
3.3.3.2 Collagen I 
The porcine MV leaflet and pericardial sections labelled with antibody against collagen I are 
shown in Figure 3.9 and 3.10, respectively. Positive staining, indicated by a deep brown 
coloration, was observed in both the anterior (LAR) and posterior (LPR) radial leaflet sections, 
with particular prevalence in the fibrosa. Positive staining was also observed throughout the 
whole thickness of the circumferential leaflet sections (Fig. 3.9a, c). In the case of the 
pericardial samples, collagen I was detected throughout the fibrosa and epipericardial layers 
of the parallel (PP) and orthogonal (PO) sections (Fig.3.10a, b). No brown staining was 
observed in the tissue sections stained with the isotype control (Fig. 3.9e, Fig. 3.10c).  
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Figure 3.9: Localisation of collagen I in MV leaflets circumferential (LAC; a) and radial (LAR; b) 
anterior, circumferential (LPC; c) and radial (LPR; d, e) posterior. Sections were stained with collagen I 
(a - d) and isotype control (e). Portions of tissue positive for collagen I were stained brown. No brown 
staining was observed in the section stained with the isotype control (e). A: atrialis layer/side; F: 
fibrosa; S: spongiosa; V: ventricularis layer/side. Scale bars indicate 500 µm. 
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Figure 3.10: Localisation of collagen I in fresh pericardial samples isolated parallel (PP; a, c) and 
orthogonally (PO; b) to collagen fibre direction. Sections were stained with collagen I (a, b) and isotype 
control (c). Regions positive for collagen I were stained brown. No brown staining was observed in the 
isotype control (c). E: epipericardial layer; F: fibrosa; M: mesothelial layer. Scale bars indicate 100 µm. 
 
3.3.3.3 Collagen III 
Images of porcine MV leaflet and pericardial sections labelled with antibody against collagen 
III are shown in Figure 3.11 and 3.12, respectively. Positive staining (deep brown) was 
observed in the fibrosa of the circumferential anterior leaflet (LAC), and the circumferential 
(LPC) and radial (LPR) posterior leaflet sections (Fig. 3.11a, c, d). The radial anterior leaflet 
(LAR) section demonstrated positive staining throughout its whole thickness (Fig. 3.11b). 
Collagen III was also detected in the pericardial sections (PO, PP), with positive staining 
present throughout the fibrosa and epipericardial layers (Fig.3.12a, b). No staining was 
observed in the tissue sections stained with the isotype control (Fig. 3.11e, Fig. 3.12c).  
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Figure 3.11: Localisation of collagen III in MV leaflets circumferential (LAC; a) and radial (LAR; b, 
e) anterior, circumferential (LPC; c) and radial (LPR; d) posterior. Sections were stained with collagen 
III (a – d) and isotype control (e). Portions of tissue positive for collagen III were brown stained. No 
brown coloured staining was observed in the tissue section stained with the isotype control (e). 
Brackets indicate the various layers. A: atrialis layer/side; F: fibrosa; S: spongiosa; V: ventricularis 
layer/side. Scale bars indicate 500 µm. 
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Figure 3.12: Localisation of collagen III in fresh pericardial samples isolated parallel (PP; a, c) 
and orthogonally (PO; b) to the direction of the collagen fibres. Sections were stained with collagen III 
(a, b) and isotype control (c). Portions of tissue positive for collagen III were brown stained. No brown 
coloured staining was observed in the tissue section stained with the isotype control (c). Brackets 
indicate the various layers. E: epipericardial layer; F: fibrosa; M: mesothelial layer. Scale bars indicate 
100 µm. 
 
3.3.3.4 Collagen IV 
Images of porcine leaflet and pericardial sections labelled with antibody against collagen IV 
are shown in Figure 3.13 and 3.14, respectively. Both the anterior (LAR, LAC) and posterior 
(LPR, LPC) leaflet sections demonstrated positive staining (deep brown) in the sub-
endothelial regions of the capillaries found within the leaflets, and the sub-endothelial regions 
of the atrial and ventricular surfaces of the leaflets (Fig. 3.13a - d). Positive staining for 
collagen IV was also observed in the mesothelial and epipericardial layers of the pericardial 
sections (Fig.3.14a, b). No positive staining was observed in the sections stained with the 
isotype control (Fig. 3.13e, Fig. 3.14c). 
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Figure 3.13: Localisation of collagen IV in MV leaflets circumferential (LAC; a) and radial (LAR; b, 
e) anterior, and circumferential (LPC; c) and radial (LPR; d) posterior. Sections were stained with 
collagen IV (a - d) and isotype control (e). Collagen IV was stained brown. No staining was observed in 
the isotype control (e). The red arrows indicate blood vessel stained brown. A: atrialis side; V: 
ventricularis side. Scale bars indicate 500 µm. 
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Figure 3.14: Localisation of collagen IV in fresh pericardial samples isolated parallel (PP; a, c) 
and orthogonally (PO; b) to the direction of the collagen fibres. Sections were stained with collagen IV 
(a, b) and isotype control (c). Collagen IV was stained brown. No staining was observed in isotype 
control (c). The red arrows indicate vessels, and the mesothelial/epipericardial layers stained brown. 
E: epipericardial layer; M: mesothelial layer. Scale bars indicate 100 µm. 
 
3.3.3.5 Fibronectin 
Images of porcine MV leaflet and pericardial sections labelled with antibody against 
fibronectin are shown in Figure 3.15 and 3.16, respectively. Positive staining (deep brown) 
was observed throughout the thickness of the MV leaflet sections (Fig. 3.15a - d). Fibronectin 
was also detected in the pericardial sections, in the region close to the mesothelium 
(Fig.3.16a, b). No staining was observed in the MV leaflets tissue section stained with the 
isotype control (Fig. 3.15e), whereas weak staining was observed in the fresh pericardial 
section (Fig. 3.16c).  
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Figure 3.15: Localisation of fibronectin in MV leaflets circumferential (LAC; a) and radial (LAR; b, 
e) anterior, circumferential (LPC; c) and radial (LPR; d) posterior. Sections were stained with 
fibronectin (a – d) and isotype control (e). Portions of tissue positive for fibronectin were brown stained. 
No staining was observed in isotype control (e). A: atrialis side; V: ventricularis side. Scale bars 
indicate 500 µm. 
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Figure 3.16: Localisation of fibronectin in fresh pericardial samples isolated parallel (PP; a, c) 
and orthogonally (PO; b) to the collagen fibre direction. Sections were stained with fibronectin (a, b) 
and isotype control (c). Regions positive for fibronectin were stained brown. Weak staining was 
observed in isotype control (c). E: epipericardial layer/side; M: mesothelial layer/side. Scale bars 
indicate 100 µm. 
 
3.3.3.6 Laminin 
Images of porcine MV leaflet and pericardial sections labelled with antibody against laminin 
are shown in Figure 3.17 and 3.18, respectively. Positive staining (deep-brown) was observed 
throughout the thickness of both the anterior and posterior leaflet sections, with particular 
prevalence in the sub-endothelium regions of the capillaries and the sub-endothelium regions  
of the atrial and ventricular surfaces of the leaflets (Fig. 3.17a - d). Positive staining was also 
observed throughout the thickness of the pericardial sections, with increased occurrence in 
the mesothelial and epipericardial layers (Fig.3.18a, b). Weak staining was observed in the 
MV leaflets tissue section stained with the isotype control (Fig. 3.17e), whereas no staining 
was observed in the fresh pericardial section (Fig. 3.18c).  
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Figure 3.17: Localisation of laminin in MV leaflets circumferential (LAC; a) and radial (LAR; b, e) 
anterior, circumferential (LPC; c) and radial (LPR; d) posterior. Sections were stained with laminin (a – 
d) and isotype control (e). Regions positive for laminin were stained brown. Weak staining was 
observed in isotype control (e). The red arrows indicate blood vessels. A: atrialis side; V: ventricularis 
side. Scale bars indicate 500 µm. 
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Figure 3.18: Localisation of laminin in fresh pericardial samples isolated parallel (PP; a, c) and 
orthogonally (PO; b) to the direction of the collagen fibres. Sections were stained with laminin (a, b) 
and isotype control (c). Regions positive for laminin were stained brown. No staining was observed in 
isotype control (c). E: epipericardial layer/side; M: mesothelial layer/side. Scale bars indicate 100 µm. 
 
3.3.3.7 Alpha-SMA 
Immunohistochemical staining of MV leaflet sections against -SMA was performed in order 
to detect the presence and spatial distribution of SMCs and myofibroblasts (Figure 3.19). 
Positive staining (deep brown) was observed in the sub-endothelial regions of the capillaries 
and the atrial surface of the leaflets (Fig. 3.19a - d). Apart from these regions, positive staining 
was also expressed by a portion of cells throughout the leaflets, whereas the ECM was also 
stained with a light brown colour (Fig. 3.19a, b). No staining was observed in the tissue 
sections stained with the isotype control (Fig. 3.19e).  
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Figure 3.19: Localisation of  - SMA in MV leaflets circumferential (LAC; a) and radial (LAR; b, e) 
anterior, circumferential (LPC; c) and radial (LPR; d) posterior. Sections were stained with alpha – 
SMA (a – d) and isotype control (e). Portions of tissue positive for  - SMA were brown stained. No 
brown coloured staining was observed in the tissue section stained with the isotype control. The red 
arrows indicate the blood vessels which have been positively stained. A: atrialis side; V: ventricularis 
side. Scale bars indicate 500 µm. 
 
3.3.3.8 Vimentin 
Immunohistochemical staining of MV leaflets against vimentin was performed in order to 
detect the presence and spatial distribution of fibroblasts (Figure 3.20). Positive staining 
(deep-brown) was observed throughout the thickness, and around the capillaries, of both the 
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anterior and posterior leaflet sections (Fig. 3.20a - d). No staining was observed in the 
sections stained with the isotype control (Fig. 3.20e). 
 
Figure 3.20: Localisation of vimentin in MV leaflets circumferential (LAC; a) and radial (LAR; b, e) 
anterior, circumferential (LPC; c) and radial (LPR; d) posterior. Sections were stained with vimentin (a 
– d) and isotype control (e). Regions positive for vimentin were stained brown. No staining was 
observed in isotype control (e). Red arrows indicate blood vessels. A: atrialis side; V: ventricularis side. 
Scale bars indicate 500 µm. 
 
3.3.3.9 Von Willebrand factor  
Porcine MV leaflet sections were labelled with antibody against the Von Willebrand factor in 
order to detect the presence and spatial distribution of endothelial cells (Figure 3.21). Positive 
staining (deep brown) was observed around the capillaries and on the atrial and ventricular 
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faces of both the anterior and posterior leaflets (Fig. 3.21a - d). No brown staining was 
observed in the tissue sections stained with the isotype control (Fig. 3.21e).  
 
Figure 3.21: Localisation of Von Willebrand factor in MV leaflets circumferential (LAC; a) and 
radial (LAR; b, e) anterior, circumferential (LPC; c) and radial (LPR; d) posterior. Sections were stained 
with Von Willebrand factor (a – d) and isotype control (e). Regions positive for Von Willebrand factor 
were stained brown. No staining was observed in isotype control (e). Red arrows indicate blood 
vessels. A: atrialis side; V: ventricularis side. Scale bars indicate 500 µm. 
 
3.3.4 Biomechanical properties of porcine pericardium and mitral valve leaflets  
3.3.4.1 Porcine pericardium 
The calculated biomechanical parameters for the fresh pericardial samples are illustrated in 
Figures 3.22 through to 3.28. In general, no statistically significant differences were found in 
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any of the biomechanical parameters studied between the two pericardial directions, 
indicating that pericardium is a rather isotropic tissue. 
 
Figure 3.22: Average elastin phase slope for fresh pericardium tested along (PP) and across 
(PO) the collagen fibres. Data is presented as the mean (n=6) ± 95% C.I. Data was analysed by 
unpaired student`s t-test that showed no significant difference between groups (p =0.260). 
 
 
Figure 3.23: Average collagen phase slope for fresh pericardium tested along (PP) and across 
(PO) the collagen fibres. Data is presented as the mean (n=6) ± 95% C.I. Data was analysed by 
unpaired student`s t-test that showed no significant difference between groups (p =0.126). 
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Figure 3.24: Average transition stress for fresh pericardium tested along (PP) and across (PO) 
the collagen fibres. Data is presented as the mean (n=6) ± 95% C.I. Data was analysed by unpaired 
student`s t-test that showed no significant difference between groups (p =0.093). 
 
 
Figure 3.25: Average transition strain for fresh pericardium tested along (PP) and across (PO) 
the collagen fibres. Data is presented as the mean (n=6) ± 95% C.I. Data was analysed by unpaired 
student`s t-test that showed no significant difference between groups (p =0.240). 
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Figure 3.26: Average ultimate tensile strength for fresh pericardium tested along (PP) and 
across (PO) the collagen fibres. Data is presented as the mean (n=6) ± 95% C.I. Data was analysed 
by unpaired student`s t-test that showed no significant difference between groups (p =0.307). 
 
 
Figure 3.27: Average failure strain for fresh pericardium tested along (PP) and across (PO) the 
collagen fibres. Data is presented as the mean (n=6) ± 95% C.I. Data was analysed by unpaired 
student`s t-test that showed no significant difference between groups (p =0.192). 
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Figure 3.28: Average thickness for fresh pericardium tested along (PP) and across (PO) the 
collagen fibres. Data is presented as the mean (n=6) ± 95% C.I. Data was analysed by unpaired 
student`s t-test that showed no significant difference between groups (p =0.580). 
 
3.3.4.2 Mitral valve leaflets 
The averaged biomechanical parameters for the MV leaflet samples are illustrated in Figures 
3.29 through to 3.35. The results indicated that there was no statistically significant difference 
between the circumferential and radial direction of the leaflets, or between the anterior and 
posterior leaflet groups, in the case of the transition strain (t), failure strain (UTS), and 
thickness (p = 0.319, p = 0.180 and p = 0.080, respectively; Fig. 3.32, 3.34, 3.35). However, 
significant differences were found in the elastin (El-E) and collagen (Coll-E) phase slopes, 
transition stress (t), and ultimate tensile strength (UTS) between the anterior and posterior 
leaflets, and between the radial and circumferential directions. Specifically, the radial anterior 
leaflet (LAR) group demonstrated significantly increased El-E compared to the two posterior 
leaflet (LPR, LPC) groups (p < 0.05; MSD = 0.036, Fig. 3.29), representing a lower 
extensibility for the anterior leaflet along the radial direction. The anterior leaflet also 
demonstrated a significantly increased Coll-E along the circumferential direction (LAC) 
compared to both its radial direction (LAR) and the posterior leaflet (LPC, LPR) groups (p < 
0.05; MSD = 5.444, Fig. 3.30). This indicated that at higher pressures (higher stress), the 
anterior leaflet extended less along its circumferential direction, in order to withstand the 
increased pressure, but at the same time it extended more along its radial direction in order to 
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close the orifice of the valve. With regards to the σt, the circumferential anterior leaflet (LAC) 
group demonstrated higher values compared to the radial posterior leaflet (LPR) group (p < 
0.05; MSD = 0.114, Fig. 3.31). The circumferential anterior leaflet (LAC) group also showed a 
significantly higher UTS compared to both the radial anterior leaflet (LAR) group and the 
posterior leaflet (LPC, LPR) groups (p < 0.05; MSD = 37.245, Fig. 3.33). In general, the 
anterior leaflet demonstrated a significant degree of anisotropy between its radial and 
circumferential directions, with significant differences in the Coll-E and UTS between the two 
directions. On the other hand, the posterior leaflet did not demonstrate any directional 
anisotropy since there were no significant differences in the biomechanical parameters 
studied between the radial and circumferential directions of this leaflet. 
 
 
Figure 3.29: Average elastin phase slope for the anterior leaflets tested circumferentially (LAC) 
and radially (LAR); the posterior leaflets tested circumferentially (LPC) and radially (LPR).  Data 
is presented as the mean (n=6) ± 95% C.I. Asterisk and connectors indicate significant difference 
between originator column and end arrow column, as determined by ANOVA and calculation of the 
MSD (p < 0.05; MSD = 0.036). LAC: anterior leaflet circumferential; LAR: anterior leaflet radial; LPC: 
posterior leaflet circumferential; LPR: posterior leaflet radial. 
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Figure 3.30: Average collagen phase slope for the anterior leaflets tested circumferentially 
(LAC) and radially (LAR); the posterior leaflets tested circumferentially (LPC) and radially 
(LPR). Data is presented as the mean (n=6) ± 95% C.I. Asterisk and connectors indicate significant 
difference between originator column and end arrow column, as determined by ANOVA and 
calculation of the MSD (p < 0.05; MSD = 5.444). LAC: anterior leaflet circumferential; LAR: anterior 
leaflet radial; LPC: posterior leaflet circumferential; LPR: posterior leaflet radial. 
 
Figure 3.31: Average transition stress for the anterior leaflets tested circumferentially (LAC) 
and radially (LAR); the posterior leaflets tested circumferentially (LPC) and radially (LPR). Data 
is presented as the mean (n=6) ± 95% C.I. Asterisk and connectors indicate significant difference 
between originator column and end arrow column, as determined by ANOVA and calculation of the 
MSD (p < 0.05; MSD = 0.114). LAC: anterior leaflet circumferential; LAR: anterior leaflet radial; LPC: 
posterior leaflet circumferential; LPR: posterior leaflet radial. 
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Figure 3.32: Average transition strain for the anterior leaflets tested circumferentially (LAC) and 
radially (LAR); the posterior leaflets tested circumferentially (LPC) and radially (LPR). Data is 
presented as the mean (n=6) ± 95% C.I. The data was analysed using ANOVA and calculation of the 
MSD which showed no significant difference between groups (p = 0.319). LAC: anterior leaflet 
circumferential; LAR: anterior leaflet radial; LPC: posterior leaflet circumferential; LPR: posterior leaflet 
radial. 
 
Figure 3.33: Average ultimate tensile strength for the anterior leaflets tested circumferentially 
(LAC) and radially (LAR); the posterior leaflets tested circumferentially (LPC) and radially 
(LPR). Data is presented as the mean (n=6) ± 95% C.I. Asterisk and connectors indicate significant 
difference between originator column and end arrow column, as determined by ANOVA and 
calculation of the MSD (p < 0.05; MSD = 37.245). LAC: anterior leaflet circumferential; LAR: anterior 
leaflet radial; LPC: posterior leaflet circumferential; LPR: posterior leaflet radial. 
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Figure 3.34: Average failure strain for the anterior leaflets tested circumferentially (LAC) and 
radially (LAR); the posterior leaflets tested circumferentially (LPC) and radially (LPR). Data is 
presented as the mean (n=6) ± 95% C.I. The data was analysed using ANOVA and calculation of the 
MSD which showed no significant difference between groups (p = 0.180). LAC: anterior leaflet 
circumferential; LAR: anterior leaflet radial; LPC: posterior leaflet circumferential; LPR: posterior leaflet 
radial. 
 
Figure 3.35: Average thickness for the anterior leaflets tested circumferentially (LAC) and 
radially (LAR); the posterior leaflets tested circumferentially (LPC) and radially (LPR). Data is 
presented as the mean (n=6) ± 95% C.I. The data was analysed using ANOVA and calculation of the 
MSD which showed no significant difference between groups (p = 0.080). LAC: anterior leaflet 
circumferential; LAR: anterior leaflet radial; LPC: posterior leaflet circumferential; LPR: posterior leaflet 
radial. 
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3.4 Discussion 
This chapter presented an analysis of the biomechanical and biological properties of the 
native pericardium and MV leaflets. Histological examination of fresh pericardium revealed a 
trilaminar structure comprising the mesothelial, fibrosa and epipericardial layers, as has 
previously been reported in the literature (Ishihara et al., 1980, Bucciante, 1975). Collagen 
fibres appeared to be concentrated mainly in the fibrosa and epipericardial layers, as 
demonstrated by Masson’s trichrome and Sirius red/Miller’s elastin staining. Elastin was 
spread throughout the pericardial layers, with some fibre alignment in the fibrosa layer. 
Mucins and GAGs were observed through Alcian blue-PAS staining, which demonstrated 
neutral mucins throughout the thickness of pericardial samples, and GAGs mainly in the 
mesothelial layer.  The biomechanical characterisation results for the pericardial specimens 
demonstrated an isotropic behaviour for the pericardial tissue. Similar findings have been 
reported for human pericardium by Lee et al. (1987). The values of the biomechanical 
parameters found in this study were comparable to those reported by Mirsadraee (2005). In 
particular, the values reported by Mirsadraee for the average Coll-E along and across the 
collagen fibre direction were 50 MPa and 35 MPa, respectively (47 MPa and 21 MPa in this 
study, respectively), whereas the values reported for the UTS along and across the collagen 
fibre direction were 9 MPa and 6 MPa, respectively (7 MPa and 4 MPa in this study, 
respectively). This represents a good agreement between the present and previously reported 
work, especially considering the fact that since the pericardium has many attachments to 
adjoining structures, such as the diaphragm and sternum, opening the chest could cause 
deformation and damage of the pericardium, modifying its biomechanical properties (Watkins 
and Lewinter, 1993). Braga/Vilela et al. (2008) have reported a collagen directionality in the 
pericardial sac with higher number of fibres obliquely oriented from the lower central region 
toward the upper left lateral region of the porcine pericardium. However, in the present study it 
was not possible to observe a dominant collagen directionality in the pericardial samples 
tested, which was also depicted on the isotropic biomechanical behaviour of the tissue. This 
was due to the limited size and localisation of the samples that it was possible to isolate, 
which were always too small to allow for a complete investigation of the whole pericardial sac.  
The histological examination of the porcine MV leaflets revealed the characteristic 
quadrilaminar structure previously reported in the literature for both porcine and human MV 
leaflets (Gross and Kugel, 1931; Kunzelman et al., 1993a; Flanagan et al., 2003), comprising 
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the atrialis, spongiosa, fibrosa and ventricularis layers. Collagen was observed mainly in the 
fibrosa layer, whereas GAGs were spread particularly in the spongiosa and ventricularis. 
Previous studies have reported that the proteoglycan content was higher in the posterior 
leaflet and in the free edge of the anterior (Grande-Allen et al., 2004). This particular 
organisation was related to the stress state of the closed valve, where the chordae and the flat 
region of the anterior leaflet were in tension, whereas the free edge of the anterior leaflet and 
most of the posterior leaflet were in appositional compression. The areas under compression 
require a tissue organisation able to withstand compressive forces and, therefore, the GAG 
content was higher in these regions since GAGs, through their hydrophilicity, are capable of 
withstanding compression. Elastic fibres were observed mainly in the atrialis and ventricularis. 
The leaflet histoarchitecture was comparable to the observed structure of the pericardium. 
The pericardial fibrous layer was quite comparable to the fibrosa of the leaflets, rich in densely 
packed collagen fibres and with sparse elastic fibres. However, the collagen fibre orientation 
in the pericardium was more multidirectional compared to the fibrosa of the leaflets, which 
was mainly aligned along the circumferential direction. 
The biomechanical analysis of the porcine MV leaflets showed an anisotropic behaviour for 
the anterior leaflet and a rather isotropic behaviour for the posterior one. The average 
collagen phase slope and ultimate tensile strength of the circumferential anterior leaflet group 
was significantly greater than the radial anterior leaflet group and the posterior leaflet groups. 
Moreover, the transition stress of the circumferential anterior leaflet group was significantly 
higher than the radial posterior leaflet group, whereas the elastin phase slope of the radial 
anterior leaflet group was higher than the posterior leaflet groups. In general, the 
circumferential anterior leaflets group was less extensible than the other groups. The 
decreased extensibility of the anterior leaflet compared to the posterior one has been 
extensively reported in the literature. Kunzelman et al. (1993a) and Jensen et al. (2006) 
reported that the higher stiffness of the anterior leaflet was related to the highest stress levels 
during cardiac cycles. The directional anisotropy of the anterior leaflet has also been reported 
in the literature. May-Newman and Yin (1995) reported that the anterior leaflet was more 
extensible along the radial direction than along the circumferential one. Kunzelman and 
Cochran (1992) and Roberts (2012) observed the same directional anisotropy in the anterior 
leaflet. 
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The results reported by Roberts (2012) were similar to those reported in the present study. 
Specifically, the average ultimate tensile strength and failure strain values for the 
circumferential and radial anterior leaflet groups found in the present study were 3 MPa and 
45%, and 1 MPa and 74%, respectively. These values compare well to the corresponding 
values of 10MPa and 50%, and 1 MPa and 60%, reported by Roberts. Similar agreement was 
found in the case of the ultimate tensile strength and failure strain for the posterior leaflet, with 
the corresponding values for the circumferential and radial groups found in the present study 
being 0.9 MPa and 71%, and 0.7 MPa and 73%, respectively, and the corresponding values 
reported by Roberts being 0.98 MPa and 77%, and 1 MPa and 40%, respectively. Several 
studies (Jensen, 2006; Kunzelman et al., 1993a; May-Newman and Yin, 1995; Roberts, 2012) 
agree that the anisotropic behaviour of the anterior leaflet relates to the orientation of the 
collagen fibres, which are highly oriented along the circumferential direction of both MV 
leaflets. The histological results presented in this chapter verified this. Another reason for the 
biomechanical anisotropy between the radial and circumferential direction of the anterior 
leaflet could be related to the different thickness of the fibrosa at different regions of the 
anterior leaflet. Indeed, previous studies (Bucciante, 1975; Jensen et al., 2006) have reported 
that the fibrosa (layer richest in collagen) was the thickest layer near the MV annulus, 
whereas the atrialis and spongiosa layers (loose connective tissue and elastin) were the 
thickest layer towards the free edge of the leaflets. In contrast, the histology of the posterior 
leaflet presented a more isotropic histoarchitecture compared to the anterior leaflet. This was 
also depicted in the biomechanical parameters of the posterior leaflet, which did not 
demonstrate any significant differences between the circumferential and radial directions. The 
biomechanical isotropy of the posterior leaflet found in the present study was in agreement 
with the results reported by Roberts (2012) and May-Newman and Yin, (1995).  
In terms of the biochemical content of the tissues, no difference in the GAG and HXP content 
of the anterior and posterior leaflet was found. The HXP (70% for LA and 56 % for LP) and 
GAG (23.9 µg·mg-1 for LA and 24.6 µg·mg-1 for LP) contents of the leaflets found in the 
present study were similar to those reported previously for porcine and human MV leaflets 
(Cole et al., 1984; Lis et al., 1987; Grande-Allen et al., 2004) (60% and 67% collagen for 
porcine and human, respectively; 18.9 µg∙mg-1 GAGs). Similarly, the HXP (83.3%) and GAG 
(8.4 µg·mg-1) contents of the pericardium found in the present study were similar to those 
reported by Mirsadraee et al. (2006) for fresh human pericardium (104 µg·mg-1 collagen and 
11 µg·mg-1 GAGs).  
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Immunohistochemical labelling was used to detect specific ECM proteins in the MV leaflets 
and pericardium. Positive staining for collagen I and III was shown in both the anterior and 
posterior leaflets, and pericardium, with particular prevalence in the fibrosa layer of the leaflets 
and the epipericardial layer of the pericardium. This was in agreement with previous studies, 
which have reported collagen III is usually co-localised with collagen I (Kuhn, 1987; Liu et al., 
1997). The presence of the basement membrane was detected by using collagen IV and 
laminin staining. The basement membrane supports and facilitates the growth of epithelial 
cells (Brown et al., 2006). In this study, sections of anterior and posterior MV leaflets and 
pericardium showed specific staining for laminin and collagen IV in the atrialis and 
ventricularis of the leaflets, and underneath the mesothelium and in the epipericardial layer of 
the pericardium. Moreover, positive staining for fibronectin was observed throughout the 
thickness of the MV leaflet and pericardial sections, with particular prevalence in the regions 
close to the mesothelial layer in the pericardial samples. Chondroitin sulphate was observed 
in the spongiosa of both the anterior and posterior leaflets, and in the ventricularis of the radial 
anterior leaflet sample. Pericardial sections were stained positive for chondroitin sulphate 
along their mesothelial layer. Previous studies have shown the presence of chondroitin 
sulphate in the free edge and central region of the anterior MV leaflet providing mechanical 
support in these areas subjected to compression and tension (Grande-Allen et al., 2004). 
Immunohistochemical labelling was also used to detect the type of cells and their distribution 
in the MV leaflets. A portion of the cells throughout the thickness of the leaflets was stained 
positive for -SMA, indicating the presence of myofibroblasts or SMCs. -SMA was also 
observed in the subendothelial region of the capillaries and of the atrial surface of both the 
anterior and posterior leaflets. The presence of SMCs in blood vessels has been previously 
reported in the literature (Etchevers et al., 2001), whereas the presence of -SMA in the 
atrialis might be related to the fact that the mechanical activity of the SMCs may offer a higher 
plasticity correlated to possible regulation of contraction against shear stress (Bairati and 
DeBiasi, 1982). Both the anterior and posterior leaflets were stained positive for vimentin 
throughout their thickness and around their capillaries, indicating the presence of 
mesenchymal cells. Positive staining for the Von Willebrand factor, which is indicative of 
endothelial cells (Ruggieri and Ware, 1993), was observed in both the anterior and posterior 
leaflets, localised in the endothelium of the capillaries and of the atrial and ventricular surfaces 
of the leaflets.  
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3.5 Conclusions 
In this Chapter a detailed histological, immunohistochemical, biochemical and mechanical 
characterisation of porcine MV leaflets and porcine pericardium was presented. Histological 
examination showed the typical tri- and quadrilaminar structure of fresh pericardium and MV 
leaflets, respectively. The composition of the fibrosa layer was comparable between the two 
tissues. Immunohistochemical labelling allowed the localisation of specific proteins in the 
porcine MV leaflets and pericardium. Biochemical analysis showed that the MV leaflets and 
the fresh pericardium had HXP and GAG contents similar to those reported in the literature. 
Fresh pericardium demonstrated rather isotropic behaviours along the two directions studied; 
whereas anterior leaflet samples were more anisotropic. In particular, anterior leaflet 
specimens cut circumferentially were stiffer than those cut radially and the posterior leaflets.  
After the characterisation of fresh pericardial tissue, decellularisation procedure was 
performed and assessed for effectiveness of decellularisation and maintenance of the 
biological and mechanical properties of tissue.  
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Chapter 4  
Decellularisation of porcine pericardium 
4.1 Introduction 
This chapter describes the procedure followed for the production of the acellular porcine 
pericardial scaffolds, as well as their quality assessment. Decellularised porcine pericardium 
was used in this project for research into the development of cell-seeded and unseeded mitral 
valve (MV) leaflet replacements. Tissue decellularisation should not impair the integrity of the 
ECM proteins of the tissue and should not leave any cells or cell fragments in the scaffold that 
could compromise its biocompatibility. Cells and cell remnants that may still be present after 
decellularisation are immunologically active and might potentially carry diseases (Dohmen 
and Konertz, 2009). However, it has been reported that DNA remnants of less than 300 bp 
are acceptable since they would most likely be degraded via enzymatic breakdown after 
implantation (Bennett et al., 1985; McCoy et al., 2004; Gilbert et al., 2007; Gilbert et al., 2009). 
Xenogeneic scaffolds carry a risk of causing an immunogenic reaction, and xenogeneic 
disease transmission, such as the porcine endogeneous retrovirus (PERV) (Weiss, 1998; 
Wilson et al., 1998). However, previous studies have shown that with a maximum 2% residual 
DNA still present in the scaffold there was no risk of PERV transmission to another species 
(Leyh et al., 2003). In addition, xenogeneic scaffolds are readily available and this makes 
them more attractive than allogeneic scaffolds.  
In humans, the immunogenic reaction upon implantation of xenogeneic tissues is initiated by 
the galalpha1-3Galbeta1-(3)4GlcNAc-R (gal) epitope. gal has been reported to cause a 
hyper-acute immune reaction, which is mediated by pre-formed anti-gal antibodies. The 
pericardial scaffolds researched in the present study were decellularised according to an in-
house patented protocol. This protocol has been used to develop a vascular patch, which is 
now marketed in Europe (Tissue Regenix Group plc). As such, the particular protocol has 
previously undergone extensive assessment, and it has been shown to effectively remove the 
-gal epitope from porcine tissues (Stapleton et al., 2008), as well as retaining ECM proteins 
which play an important role in cell attachment, such as fibronectin and laminins, despite 
causing a loss of collagen IV (Mirsadraee et al., 2007). Hence, -gal detection as well as 
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immunohistochemical staining of ECM proteins was not repeated in the present study for the 
assessment of the pericardial scaffolds. Another important issue with decellularised scaffolds 
is their potential cytotoxicity, which can be caused by residuals of the reagents used in the 
decellularisation, and can generate adverse effects after implantation. 
The decellularisation protocol used in the present study for the decellularisation of pericardium 
utilised sodium-dodecyl-sulphate (SDS) at a concentration of 0.1 % w/v in the presence of 
proteinase inhibitors. SDS is an ionic detergent, which has been shown to effectively remove 
the cellular components from human pericardium, porcine heart valves, human amniotic 
membrane and tendons (Booth et al., 2002; Grauss et al., 2005; Wilcox et al., 2005; 
Mirsadraee et al.,  2006; Wilshaw et al., 2006). However, it has also been associated with loss 
of GAGs and growth factors (Courtman et al., 1994; Kasimir et al., 2003; Reing et al., 2010), 
as well as with protein denaturation, by disrupting protein-protein interactions, when used at 
high concentrations (Gilbert et al., 2006). The protocol also employed nucleases (RNAse, 
DNAse). Endonucleases catalyse the hydrolysis of the interior bonds of the ribonucleotide and 
deoxyribonucleotide chains, whereas exonucleases catalyse the hydrolysis of the terminal 
bonds of deoxyribonucleotide and ribonucleotide chains, leading to the degradation of RNA or 
DNA (Freyman, 2005). EDTA was included in the initial wash buffers. EDTA is a chelating  
agent, which can bind the bivalent cations Ca2+ and Mg2+, necessary for cell attachment, and 
as such it facilitates in the removal of the cellular material from the tissue (Klebe, 1974; Klebe, 
1975; Gailit and Ruoslahti, 1988; Moore et al., 1994). It is also an inhibitor of 
metalloproteinases.   
Cell lysis in the decellularisation protocol used in the present study, was facilitated through 
treatment with a hypotonic solution, which lysed the cells through osmotic shock (Martins-
Green and Bissell, 1995; Vyavahare et al., 1997; Goissis et al., 2000; Dahl et al., 2003; 
Woods and Gratzer, 2005). However, the hypotonic solution alone was not sufficient to 
remove the cellular debris, this was facilitated by additional nuclease and chemical treatments 
(Dahl et al., 2003). During cell lysis, various proteases are released from the disrupted cells, 
which have the potential to cause ECM damage. This can be avoided by protease inhibitors, 
such as aprotinin or leupeptin. In addition, many proteases can be inhibited by controlling the 
temperature and pH of, and the exposure time of the tissues to the solutions used during 
decellularisation. The decellularisation protocol used in this study, utilised aprotinin and EDTA 
at pH 7-8 in order to avoid the proteolysis of the ECM proteins (Gilbert et al., 2006). Moreover, 
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the present study utilised peracetic acid (PAA) to sterilise the pericardial scaffolds.  Previous 
studies have reported the use of peracetic acid (PAA) to both remove cellular fragments and 
provide sterilisation and disinfection. It has also been reported that following treatment with 
PAA, several types of collagen (I, III, IV, V, VI, and VII) were still identified within porcine 
tissue, such as small intestinal submucosa and urinary bladder (Badylak et al., 1995; Brown et 
al., 2006). In addition, many of the ECM GAGs (hyaluronic acid, heparin, heparin sulphate, 
chondroitin sulphate A, dermatan sulphate), as well as laminin and fibronectin were also 
retained following PAA treatment (Hodde et al., 1996, 2002; Brown et al., 2006). PAA has also 
been shown not to have any adverse effect on the mechanical behaviour of decellularised 
scaffolds (Freytes et al., 2004).  
 
4.1.1 Aims and objectives 
Aims: 
The aim of the work present in this chapter was to adapt the in-house protocol to effectively 
decellularise porcine pericardium, and to assess the decellularised scaffolds.  
Objectives: 
 
 To produce batches of decellularised porcine pericardium using an established 
method 
 To determine the extent of decellularisation using histology and DNA assays  
 To determine the effects of the decellularisation on: 
o Histoarchitecture of the scaffold  
o Biocompatibility of the scaffold  
o Total collagen and glycosaminoglycan content  
o Biomechanical properties  
 
 
4.2 Materials and methods 
4.2.1 Decellularisation 
This method was developed by Fisher et al. (2008).  
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4.2.1.1 Solutions used in the decellularisation protocol  
Wash buffer I with EDTA (2.7 mM; 0.1%) and aprotinin (10 KIU·ml-1) 
EDTA (1 g) was added to 1 L of PBS. The pH was adjusted to 7.2-7.4 by adding 6 M 
hydrochloric acid or 6 M sodium hydroxide while stirring. The solution was autoclaved at 
121°C for 20 min and stored at room temperature for up to one month. Aprotinin (1 ml, 10,000 
KIU·ml-1) was added aseptically to the solution just before use. The solution with added 
aprotinin was then stored at 4-5°C for up to 1 week. 
Wash buffer II with aprotinin (10 KIU·ml-1)  
Aprotinin (1 ml, 10,000 KIU·ml-1) was added aseptically to 1 L of PBS just before use; solution 
with added aprotinin was stored at 4 - 5°C for up to 1 week. 
Disinfection solution 
Disinfection solution was made up by supplementing 100 ml of PBS with 0.5 mg·ml-1 of 
gentamicin, 0.2 mg·ml-1 of polymyxin B and 0.5 mg·ml-1 of vancomycin hydrochloride. The pH 
was adjusted to 7.2 - 7.4, and the solution was sterilised by filtration using a 0.2 µm pore size 
filter into a sterile container. The volume was finally made up to 500 ml with sterile PBS. 
Hypotonic buffer plus EDTA (2.7 mM) and aprotinin (10 KIU·ml-1)  
Trizma base (1.21 g) and EDTA (1 g) were dissolved in 900 ml of distilled water. The pH was 
adjusted to 8.0 – 8.2 and the volume made up to 1 L. The solution was autoclaved at 121°C 
for 20 min and stored at room temperature for up to one month. Aprotinin (1 ml, 10,000 
KIU·ml-1) was added aseptically just before use. 
SDS (0.1% w/v) in hypotonic buffer 
SDS (0.1% w/v) stock solution was prepared by adding 10 g of SDS to 100 ml distilled water. 
The solution was sterilised by filtration and stored for up to one month at room temperature. 
SDS stock solution (5 ml) was then added aseptically to 495 ml of autoclaved hypotonic 
buffer. The solution was stored for up to one week at 4 - 5°C. 
Nuclease solution with DNAse (50 U∙ml-1) and RNAse (1 U∙ml-1) 
Deoxyribonuclease I (DNAse) was rehydrated to a final concentration of 10,000 U·ml-1 
(according to the manufacturer’s instructions) using DNAse reconstitution buffer. 
Ribonuclease I (RNAse) was rehydrated to a final concentration of 100 U·ml-1 (according to 
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the manufacturer’s instructions) using distilled water. Both the DNAse and RNAse solutions 
were filter sterilised. Aliquots (5 ml) were made in bijous and stored at -20°C for up to three 
months. 
Trizma base (6.1 g) and magnesium chloride (2.0 g) were dissolved in 80 ml of distilled water. 
The pH was adjusted to 7.5 - 7.7 and the volume was made up to 990 ml with distilled water. 
The solution was autoclaved at 121°C for 20 min and stored at room temperature for up to 
one month. On the day of use, 10 ml of RNAse stock and 5 ml of DNAse stock were added to 
the solution, which was then used within 10 min. 
Hypertonic buffer with Tris (50 mM) and sodium chloride (1.5 M) 
Sodium chloride (87.66 g) and Tris (6.06 g) were added to 900 ml of distilled water. The pH 
was adjusted to 7.5 - 7.7. The volume was then made up to 1000 ml with distilled water. The 
solution was autoclaved at 121°C for 20 min and stored at room temperature for up to one 
month. 
Peracetic acid solution (0.1 % v/v) 
Peracetic acid (1.57 ml) was added to a 500 ml of autoclaved PBS. The pH was adjusted to 
7.3 and the solution was used within one hour of preparation. 
4.2.1.2 Procedure 
Fresh porcine pericardia were dissected, as described in Chapter 2, Section 2.8, and a 
sample measuring 9 cm × 6 cm was isolated from each pericardium. The sample size was 
sufficient to carry out all necessary post-decellularisation assessment. Each sample was cut 
crosswise at one of the edges, as shown in Figure 4.1, to identify the mesothelial and 
epipericardial surfaces. Following isolation, the samples were stored in moist filter paper at -
20C° for subsequent use. 
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Figure 4.1: Size and shape of the decellularised pericardial sample showing the mesothelial 
surface. 
 
Prior to decellularisation, the frozen pericardial samples were placed in a pot, with enough 
wash buffer II to cover the whole surface of the sample, and thawed for 15 to 30 min at 37°C 
in an incubator. The samples were then cleaned with forceps to remove as much of the fat as 
possible. After cleaning, the samples were incubated in disinfection solution (1 ml·cm-2) with 
agitation at 100 rpm (Grant bio shaker) for 30 min at 37°C. They were then washed in wash 
buffer I (4 ml∙cm-2) for 3 periods of 30 min each with agitation at 100 rpm on a plate shaker, at 
room temperature. Subsequently, the samples were incubated overnight at 4 - 5°C in 
hypotonic buffer (2 ml∙cm-2) with agitation at 100 rpm, before they were incubated in SDS in 
hypotonic buffer (2 ml∙cm-2) at room temperature for 24 h with agitation at 100 rpm. The 
samples were then washed in wash buffer II (4 ml∙cm-2) for 3 periods of 30 min each with 
agitation at 100 rpm on a plate shaker and at room temperature. The samples were then 
incubated in nuclease solution (2 ml∙cm-2) for 3 h at 37°C with agitation at 50 rpm. Following 
this, the samples were washed in wash buffer I (4ml∙cm-2) for 3 periods of 30 min each with 
agitation at 100 rpm on a plate shaker, and at room temperature. They were then incubated in 
hypertonic buffer (2 ml∙cm-2) overnight at 37°C with agitation at 100 rpm. The samples were 
then washed in wash buffer II (4 ml∙cm-2) for 3 periods of 30 min each with agitation at 100 
rpm on a plate shaker, and at room temperature. Tissues were then incubated in peracetic 
acid solution (2 ml∙cm-2) for 3 h at room temperature with agitation at 150 rpm. Finally, the 
samples were washed in wash buffer II (4 ml∙cm-2) for 3 periods of 30 min each with agitation 
at 100rpm on a plate shaker, and at room temperature prior of being stored in wash buffer II 
(2 ml∙cm-2) at 4°C for up to 3 months. The process is summarised in Figure 4.2. 
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Figure 4.2: Process flow diagram of decellularisation method. 
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4.2.2 Characterisation of decellularised pericardium  
The materials and methods used for the histological, biochemical, microscopical (SEM and 
ESEM) and biomechanical evaluation of the decellularised pericardia have been described in 
Chapter 2. The biocompatibility of the scaffolds was evaluated through contact and extract 
cytotoxicity assays, and their sterility using both nutrient broths and agar plates. The 
effectiveness of decellularisation was determined in terms of DNA removal through DNA 
assay. A sample size of n= 6 was used for the biochemical, biomechanical, cytotoxicity and 
assessment of the DNA content of the scaffolds.  
4.2.2.1 Contact cytotoxicity assay 
Decellularised pericardial samples (n = 6) of a 5 mm2 area were attached to a 6-well culture 
plate using 10 µl collagen solution prepared from rat tails by Dr Andrew Aldridge, neutralised 
and gelled with 5 µl sodium hydroxide (0.1 M) in a 2:1 ratio. Collagen solution (20 µl), 
neutralised and gelled with 10 µl of sodium hydroxide, was placed into one of the wells as a 
negative control, whereas a drop of cyanoacrylate contact adhesive was placed into the 
centre of a second well as a positive control. Prior to cell seeding, all wells were washed three 
times with PBS for 10 min each. Cell suspension (2 ml) of porcine dermal fibroblasts at 
passage 5 (P5, cultured as described in Chapter 2, Section 2.17), was added into each well at 
a concentration of 3×105 cells∙ml-1 of complete cell culture medium (Chapter 2, Section 2.5.4). 
The seeded samples were cultured for 48 hours at 37 °C in 5 % (v/v) CO2 in air and then 
observed and photographed under phase contrast light microscopy. The medium was then 
aspirated and the wells were washed gently using PBS containing Ca+2 and Mg+2. The cells 
were then fixed using 10 % (w/v) NBF for 10 min. Subsequently, the NBF was aspirated and 
the cells were stained using Giemsa solution for 5 min. The wells were rinsed with tap water 
until the water run clear and the plate was allowed to air dry. Finally, the samples were 
photographed again under light microscopy. The assay was repeated with pMSCs at P5 
(cultured as described in Chapter 2, Section 2.17).  
4.2.2.2 Extract cytotoxicity assay 
Reagents 
Culture medium containing double strength FBS: DMEM supplemented with 20% (v/v) FBS, 
200 U∙ml-1 penicillin, 200 U∙ml-1 streptomycin, and 4 mM L-glutamine. The medium was stored 
for up to 2 weeks at 4°C.  
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Method 
Soluble extracts were prepared using decellularised pericardial samples (n = 6). DMEM with 
80% (v/v) DMSO was used as positive (cytotoxic) control and cell culture medium (Section 
2.5.4) was used as negative control. The samples were finely minced with a scalpel and 
incubated in DMEM (1 ml per 100 mg tissue weight) for 72 h at 37°C with agitation. The 
samples were then centrifuged at 19,000 g for 15 min and the supernatants were collected, 
checked for sterility by plating 100 µl onto agar plates (nutrient agar, fresh blood agar and 
Sabouraud), and stored at -20°C for up to one month until required. Porcine dermal 
fibroblasts at P6 (cultured as described in Chapter 2, Section 2.17) were seeded at a density 
of 1×104 cells per well of a 96 wells plate and cultured for 24 h at 37 °C in 5 % (v/v) CO2 in air 
in order to achieve 80 % confluence after 48 hours. The previously produced extracts were 
thawed at 37°C and centrifuged at 19,000 g for 15 min. The culture medium was then 
aspirated and replaced with 100 µl of culture medium containing double strength FBS. The 
tissue extracts, and the positive and negative controls, were added in replicates of 6 to wells 
of the 96-well plate with the fibroblasts, and the cells were cultured for a further 48 h under 
standard conditions. Subsequently, the adenosine triphosphate (ATP) content of the cells was 
determined using the ATPLite-M assay (Perkin Elmer) following the manufacturer’s 
instructions. Prior to carrying out the ATPLite-M assay, the reagents were equilibrated to room 
temperature after incubation and the vial of lyophilised substrate solution was reconstituted by 
adding 25 ml of substrate buffer. The original cell culture medium was then aspirated from 
each well and 50 µl of culture medium was added. Mammalian cell lysis solution (50 µl) was 
added to each well and shaken at 500 rpm for 5 min. Following this, 50 µl of substrate 
solution was added to each well and shaken at 500 rpm for 5 min. The luminescence was 
measured using a Top Count NXT; data were recorded in counts per second and plotted 
using Microsoft Excel or GraphPad Prism. 
4.2.2.3 DNA quantification 
The DNA content of fresh (n = 6) and decellularised (n = 6) pericardial samples (25 mg and 
250 mg of wet tissue, respectively) was isolated using the DNeasy kit (Qiagen, DNeasy Blood 
& Tissue Kit), according to the manufacturer’s instructions. Each sample was macerated using 
a scalpel blade and placed in a sterile 1.5 ml microcentrifuge tube. Buffer ATL (180 μl for fresh 
and 360 μl for decellularised pericardium) and proteinase K (20 μl for fresh and 40 μl for 
decellularised pericardium) was added to the macerated tissue, mixed by vortexing, and 
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incubated at 56°C for 3 h or until the tissue was completely digested. During the 3 h 
incubation, the samples were vortexed every 30 min to enhance dispersion. Following this, 
each sample was vortexed again for 15 s. Buffer AL (200 μl for fresh and 400 μl for 
decellularised pericardium) was added to each sample, and mixed thoroughly by vortexing; 
then ethanol (100 %, v/v) was added (200 μl for fresh and 400 μl for decellularised  
pericardium), and mixed thoroughly by vortexing. 
Each sample was then transferred to a separate DNeasy Mini spin column in a 2 ml collection 
tube, and centrifuged at 6,000 g for 1 min. The flow-through was discarded together with the 
collection tube. The DNeasy Mini spin column was placed in a new 2 ml collection tube and 
500 μl Buffer AW1 was added, and centrifuged for 1 min at 16,000 g. The flow-through was 
discarded together with the collection tube. The DNeasy Mini spin column was placed in a 
new 2 ml collection tube. Buffer AW2 was added (500 μl) and centrifuged for 3 min at 20,000 
g to dry the DNeasy membrane. Drying the membrane of the DNeasy Mini spin column was 
important, since residual ethanol might interfere with subsequent reactions. The flow-through 
was discarded again together with the collection tube. The DNeasy Mini spin column was then 
placed in a clean 1.5 ml or 2 ml microcentrifuge tube, and 200 μl Buffer AE was pipetted 
directly onto the DNeasy membrane. The samples were then incubated at room temperature 
for 1 min, and then centrifuged for 1 min at 6000 g to elute the DNA. The elution process was 
repeated twice for maximum DNA yield. The extracted DNA was either subjected to 
quantification immediately, or stored at –20 °C until required. The final concentration of DNA 
was quantified using a Nanodrop spectrophotometer (ND-1000 V3.71). Buffer AE (2 μl) was 
used as a blank. The extracted DNA sample (2 μl) was loaded onto the Nanodrop and the 
absorbance was determined at 260 nm. Three readings were taken for each sample, and the 
mean was considered as the sample absorbance. The DNA concentration (ng·μl-1) in the 
sample was used to calculate the DNA weight/tissue weight (μg∙mg-1) according to: 
                                  
          
 
 
where DNAc  represented the DNA concentration in the Buffer AE (ng·μl-1) and w the total 
weight of the sample. The volume of the Buffer AE containing extracted DNA was 400 μl 
(twice elution). The total weight for each sample was 25 mg for fresh and 250 mg for 
decellularised pericardium. The mean ± 95 % C.I. of the DNA weight/tissue weight (ng·mg-1) 
for each of the fresh and decellularised groups was calculated. 
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4.2.2.4 Sterility assessment 
Reagents 
The reagents used in the sterility assessment included:  
 Nutrient broth, which was used to detect aerobic bacterial contamination. 
 Thioglycolate broth: 29 g of thioglycolate broth was dissolved in 1 L of distilled water, 
which was then aliquotted in glass universals (10 ml each). The solution was autoclaved at 
121°C for 20 min prior to use. The thioglycolate broth is an enriched isolation mediuim 
used primarily to differentiate various organisms in terms of oxygen requirements. The 
oxygen level throughout the broth was reduced via reaction with sodium thioglycolate. This 
broth was used for the detection of anaerobic bacterial contamination. 
 Agar plates, inlcuding nutrient agar (NA), fresh blood agar (FBA) and Sabouraud agar 
(SAB). These were used for the detection of aerobic bacterial contamination. 
Method 
A 5 mm2 sample was dissected from each one of the 6 decellularised pericardial patches. The 
samples were minced and put separately in nutrient broths and kept at 37°C for up to 21 days 
to assess aerobic bacteria growth. The nutrient broth was used for the cultivation of less 
fastidious microorganisms. The sterility was checked after 2, 7 and 21 days.  
A sample from each one of the 6 decellularised pericardial patches was minced and put 
separately in thioglycolate broth, and kept at 37°C for 72 h. After incubation, the solution of 
each sample was spread aseptically onto an individual fresh blood agar plate and left in an 
anaerobic incubator (AnaeroGenTM, OXOID, 3.5 l) at 37°C for up to 15 days. 
The sterility of the liquid in which the tissues were stored was also tested using different agar 
plates. A volume of 100 μl was plated on the agar plates. Specifically, NA was used for the 
detection of non-fastidious micro-organisms, FBA was used for the detection of fastidious 
micro-organisms, and SAB was used for the detection of fungal growth, since it has had a low 
pH that inhibited the growth of most bacteria. The plates were kept for up to 21 days at 37°C, 
with the exception of the SAB plates, which were kept at 30°C. Sterility was checked after 2, 7 
and 21 days. 
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4.3 Results 
4.3.1 Histioarchitecture of decellularised pericardium  
Following decellularisation, pericardial scaffold sections were cut parallel and orthogonally to 
the collagen fibre alignment, and stained with H & E, Sirius red/Miller’s elastin, Masson 
trichrome and Alcian blue-PAS. Histological analysis of the sample sections did not reveal any 
remaining cells (Fig. 4.3a, c, e - h). Following decellularisation, the pericardium appeared 
swollen and there were gaps in the ECM at the locations where cells used to reside; this was 
obvious in all the images. The histoarchitecture of the collagen and elastin fibres was 
preserved (Fig. 4.3b, d, e and g), and a weak GAG presence could still be observed in the 
outer layers of the decellularised pericardium, on the mesothelial surface (Fig. 4.3f).  
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Figure 4.3: Histology of decellularised pericardial scaffolds isolated parallel (DPP) and 
orthogonally (DPO). Sections were stained with H&E (a, c), Sirius red/Miller’s elastin (b, d), Masson’s 
trichrome (e, g) and Alcian blue-PAS (f, h). E: epipericardial surface; F: fibrosa layer. Scale bars 
indicate 100 µm. 
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4.3.2 Collagen, denatured collagen and GAG content of native and decellularised 
pericardium  
The results presented in Chapter 3 with regards to the validation of the hydrolysis technique, 
demonstrated that there was a statistically significant difference in the hydroxyproline (HXP) 
amount between 2 h and 6 h and between 4 h and 6 h hydrolysis within the anterior leaflet 
group. Thus, the 6 h time point was used in the present study for the hydrolysis of all tissues.  
The HXP content per dry weight of decellularised pericardium (115.954 ± 18.3 µg·mg-1) was 
significantly higher compared to the HXP content per dry weight of fresh pericardium (83.252 
± 7.4 µg·mg-1) (p = 0.009; Figure 4.4).  The HXP content of denatured collagen per dry weight 
of fresh and decellularised pericardium was 2.845 ± 1.4 µg·mg-1 and 1.531 ± 1.7 µg·mg-1, 
respectively. There was no significant difference in the denatured HXP content between fresh 
and decellularised pericardium (p = 0.262; Figure 4.4). The GAG content per dry weight of 
fresh pericardium (8.425 ± 2.6 µg·mg-1) was significantly higher than that of the decellularised 
pericardium (0.134 ± 0.07 µg·mg-1) (p = 0.000; Figure 4.4).   
 
Figure 4.4: HXP, HXP of denatured collagen (HXP denatured) and GAG content per dry weight 
of fresh (FP) and decellularised (DP) pericardium. Data is presented as the mean (n=6) ± 95% C.I. 
The final percentage of collagen content was 58.3% for FP and 81.3% for DP. The final percentage of 
collagen was calculated as the HXP amount converted in mg∙mg-1 and multiplied by 7 (as 1/7 of 1mg 
of collagen is HXP). Asterisks indicate significant difference, as determined by unpaired student`s t-
test (p = 0.009 for HXP; p = 0.262 for HXP denatured and p = 0.000 for GAGs).  
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4.3.3 Biomechanical properties of native and decellularised pericardium  
The calculated biomechanical parameters for the fresh and decellularised pericardial groups 
are illustrated in Figures 4.5 through to 4.11. In general, no significant differences were found 
in any of the biomechanical parameters studied (p > 0.05), except in the case of the transition 
stress and strain, and thickness (p < 0.05; Fig. 4.5 - 4.11). 
The results demonstrated that decellularisation had an effect on the transition stress (p < 
0.05; MSD = 0.399, Fig. 4.7), with the orthogonal decellularised pericardial group 
demonstrating a significantly higher transition stress compared to the parallel and orthogonal 
fresh pericardial groups. Further significant differences were found in the average transition 
strain, with the orthogonal fresh pericardial group achieving significantly lower values than the 
parallel decellularised group (p < 0.05; MSD = 21.954; Fig. 4.8). The average thickness of the 
orthogonal fresh pericardial group was significantly higher than that of the parallel fresh and 
orthogonal decellularised pericardial groups (p < 0.05; MSD = 0.021; Fig. 4.11). 
 
Figure 4.5: Average elastin phase slope for fresh (FP) and decellularised (DP) pericardium 
tested parallel and orthogonally to the collagen fibre direction (n = 6). Error bars indicate 95% 
C.I. The data was analysed using ANOVA which showed no significant variation in the data (p = 
0.3417). 
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Figure 4.6: Average collagen phase slope for fresh (FP) and decellularised (DP) pericardium 
tested parallel and orthogonally to the collagen fibre direction (n = 6). Error bars indicate 95% 
C.I. The data was analysed using ANOVA, which showed no significant variation in the data  (p = 
0.1725). 
 
Figure 4.7: Average transition stress for fresh (FP) and decellularised (DP) pericardium tested 
parallel and orthogonally to the collagen fibre direction (n = 6). Error bars indicate 95% C.I. 
Asterisk and connectors indicate significant difference between originator and end arrow column, 
determined by ANOVA and MSD. Significant difference was observed between the orthogonal DP and 
both the parallel and orthogonal FP groups (p < 0.05; MSD = 0.399). 
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Figure 4.8: Average transition strain for fresh (FP) and decellularised (DP) pericardium tested 
parallel and orthogonally to the collagen fibre direction (n = 6). Error bars indicate 95% C.I. 
Asterisk and connectors indicate significant difference between originator and end arrow column, 
determined by ANOVA and MSD. Difference was observed between the parallel DP and orthogonal 
FP group (p < 0.05; MSD = 21.954). 
 
Figure 4.9: Average ultimate tensile strength (UTS) for fresh (FP) and decellularised (DP) 
pericardium tested parallel and orthogonally to the collagen fibre direction (n = 6). Error bars 
indicate 95% C.I. Data was analysed using ANOVA which showed no significant variation in the data  
(p = 0.0997). 
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Figure 4.10: Average failure strain (εuts) for fresh (FP) and decellularised (DP) pericardium 
tested parallel and orthogonally to the collagen fibre direction (n = 6). Error bars indicate 95% 
C.I. The data was analysed using ANOVA, which showed no significant variation in the data (p = 
0.1268). 
 
Figure 4.11: Average thickness for fresh (FP) and decellularised (DP) pericardium tested 
parallel and orthogonally to the collagen fibre direction (n = 6). Error bars indicate 95% C.I. 
Asterisk and connectors indicate significant difference between originator and end arrow column, 
determined by ANOVA and MSD. Significant difference was observed between the orthogonal FP and 
both the orthogonal DP and parallel FP groups (p < 0.05; MSD = 0.021). 
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4.3.4 Contact biocompatibility of decellularised pericardium  
Microscopic analysis of the contact cytotoxicity plates showed that both the porcine fibroblasts 
and MSCs attached and grew well into contact with the decellularised pericardium, with no 
evidence of contact inhibition (Fig. 4.12a, d; Fig. 4.13a, d). No changes in cell morphology 
were observed next to the decellularised pericardium or the collagen gel (negative control) 
(Fig. 4.12a, b, d and e; Fig. 4.13a, b, d and e). This provided evidence that the decellularised 
pericardial scaffold was not cytotoxic, whereas the cyanoacrylate glue (positive control) was 
clearly cytotoxic (Fig. 4.12c, f; Fig. 4.13c, f).  
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Figure 4.12: Contact cytotoxicity of decellularised porcine pericardium cultured with porcine 
skin fibroblasts at P5. The figure shows phase contrast (a, b, c) and Giemsa staining (d, e, f) 
pictures. a, d) decellularised pericardium; b, e) collagen gel (negative control); c, f) cyanoacrilate glue 
(positive control). Scale bars indicate 200 (a, b and c) and 500 (d, e and f) µm. 
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Figure 4.13: Contact cytotoxicity of decellularised porcine pericardium cultured with pMSCs at 
P5. The figure shows phase contrast (a, b, c) and Giemsa staining (d, e, f) pictures. a, d) 
decellularised pericardium; b, e) collagen gel (negative control); c, f) cyanoacrilate glue (positive 
control). Scale bars indicate 200 (a, b and c) and 500 (d, e and f) µm. 
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4.3.5 Extract biocompatibility of decellularised pericardium  
The extract cytotoxicity results are illustrated in Figure 4.14. In general, there was no 
significant change in the cellular ATP content (measure of cell viability) of the porcine skin 
fibroblasts incubated with any of the 6 decellularised pericardium extracts compared to the 
DMEM only group (negative control), except in the case of sample 3, which showed a higher 
ATP content compared to the negative control (Fig.4.14). The ATP content in all 6 
decellularised pericardium extracts and the negative control, were significantly higher 
compared to the DMSO group (positive control) (p < 0.05; MSD = 1.9E+6; Fig. 4.14).  
 
Figure 4.14: ATP content of porcine skin fibroblasts incubated with decellularised pericardium 
extracts, DMEM alone (negative control) and 80% (v/v) DMSO (positive control). The results 
represent the means ± 95% C.I. (n = 6). CPS indicates counts per second. Asterisk and connector 
indicate significant difference between originator and end arrow column, determined by ANOVA and 
calculation of the MSD. Significant difference was found between sample 3 and the DMEM only group 
and between all groups and the 80% DMSO group (p < 0.05; MSD = 1868259). 
 
4.3.6 DNA content of fresh and decellularised pericardium 
The DNA amount per wet weight of fresh and decellularised pericardium was 417.69 ± 143.60 
ng·mg-1 and 3.23 ± 0.79 ng·mg-1, respectively (Figure 4.15). This represented approximately 
99% reduction in the DNA content following decellularisation (p < 0.05).  
 141 
 
 
Figure 4.15: DNA content of fresh and decellularised pericardium determined by Nanodrop 
spectrophotometer at 260 nm. The results represent the means ± 95% C.I. (n = 6). The data was 
analysed using unpaired student`s t-test, which showed significant difference between groups (p = 
0.000). The asterisk indicates significant difference.  
 
4.3.7 Ultrastructure of native and decellularised pericardium  
The ultrastructure of fresh and decellularised pericardium was evaluated using SEM and 
ESEM and images are shown in Figure 4.16 and 4.17, respectively. The complex network of 
wavy fibres (collagen and elastin) in the fibrosa layer of the fresh and decellularised 
pericardium is illustrated in Fig. 4.16b and d, respectively. Cell presence was observed on the 
surface of fresh pericardium in contrast to decellularised pericardium (Fig. 4.16a and d). The 
ESEM surface images showed similar histoarchitectures between the fresh and decellularised 
pericardium (Fig. 4.17a and b). 
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Figure 4.16: SEM images of fresh (a, b) and decellularised (c, d) pericardium. a, c) surface; b ,d) 
cross section. The red arrow and circle indicate cell presence.  
 
Figure 4.17: ESEM images of fresh (a) and decellularised (b) pericardium.  
 
4.3.8 Assessment of the sterility of the decellularised pericardium 
No bacterial growth was observed in the nutrient and thioglycolate broths. A few colonies 
were visible on one of the NA and one of the FBA plates, but they were not on the streaks and 
they seemed to be growing within the agar (probably due to batch contamination).  
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4.4 Discussion 
This chapter presented the assessment of the biological and biomechanical properties of 
decellularised porcine pericardial scaffolds, and compared them to the properties of fresh 
porcine pericardium. SEM, ESEM and histological examination revealed that following 
decellularisation the native histoarchitecture of pericardial tissue was well maintained. The 
fibrosa and epipericardial layers were still present after decellularisation, whereas the cell-rich 
mesothelial layer was removed. The fibrosa layer of the fresh and decellularised pericardium 
was comparable to that of the MV leaflets shown in Chapter 3, despite the different alignment 
of the collagen fibres. The histoarchitecture of the collagen and elastin fibres of the 
decellularised pericardium was well preserved, as demonstrated by Sirius red/Miller’s elastin 
and Masson’s trichrome staining. Nevertheless a high loss of GAGs was observed along the 
mesothelial side, which was also confirmed by the biochemical analysis. Specifically, the GAG 
content of the fresh pericardium was significantly higher compared to the GAG content of the 
decellularised pericardium. In addition, both fresh and decellularised pericardium showed an 
average lower GAG content compared to both the anterior and posterior leaflet (Table 4.1). 
The higher GAG content of the MV leaflets can be attributed to the high compressive stresses 
experienced by the MV leaflets during the cardiac cycle, which are counteracted by the GAGs 
acting as shock absorbers.  
Group 
HXP 
(µg·mg-1) 
GAGs 
(µg·mg-1) 
LA  99.30 ± 13.99 23.90 ± 8.65 
LP 80.05 ± 20.43 24.59 ± 5.79 
FP 83.25 ± 7.40 8.43 ± 2.60 
DP 115.95 ± 18.30 0.13 ± 0.07 
Table 4.1: Mean HXP and GAG content for the anterior (LA) and posterior (LP) leaflet group and 
the fresh (FP) and decellularised (DP) pericardial group. Data is presented as the mean (n=6)  ± 
95% C.I. 
 
Moreover, the decellularised pericardium showed significantly higher HXP content compared 
to the fresh. This increase was most likely due to the relative increase in the ratio of these 
molecules to the total dry weight, due to the loss of soluble proteins and cell components 
following decellularisation (Mirsadraee et al., 2006). The HXP contents of the fresh and 
decellularised porcine pericardium were similar to the corresponding contents for human 
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pericardium reported by Mirsadraee et al. (2006) (104 µg·mg-1 for fresh and 118 µg·mg-1 for 
decellularised human pericardium). Moreover, the HXP content of decellularised pericardium 
was higher compared to that of both the anterior and posterior leaflets (Table 4.1). No 
significant difference was observed in the denatured HXP content between fresh and 
decellularised pericardium, indicating that the decellularisation protocol did not cause the 
denaturation of the collagen.  
Decellularisation treatments should not leave any cells or cell fragments in the scaffold, since 
they have been associated with inflammation and calcification, which may impair the longevity 
of the scaffold in vivo (Oswal et al., 2007). The results from the present study indicated a 99% 
reduction in the DNA content of the pericardium following decellularisation. Moreover, the 
contact and extract cytotoxicity assays verified the adequate removal of SDS from the 
pericardial scaffolds, which allowed fibroblasts and pMSCs to grow well in contact with the 
scaffold and with scaffold extracts. One sample of the decellularised scaffold extracts showed 
higher cellular ATP content compared to the negative control. This was probably due to the 
soluble proteins released by the decellularised tissue which might have improved cell growth. 
In addition, the biocompatibility test results showed that disinfection with PAA did not affect 
scaffold biocompatibility. Similar results were obtained by Booth et al. (2002), who reported 
successful decellularisation of porcine aortic valves, without compromising the ECM, using the 
same concentration of SDS in hypotonic buffer. Mirsadraee et al. (2006) reported similar 
biocompatibility results with human pericardium, which was decellularised using the same 
concentration of SDS in hypotonic buffer. 
In terms of the biomechanics, both fresh and decellularised pericardium demonstrated rather 
isotropic behaviours, with similar mechanical properties along and across the collagen fibre 
directions. In addition, most of the biomechanical parameters studied did not demonstrate any 
statistically significant differences between the fresh and decellularised pericardium. However, 
significant differences were observed in the transition stress, transition strain, and thickness 
between fresh and decellularised pericardium. Specifically, the transition stress and strain of 
the decellularised pericardium were higher than that of the fresh tissue. This has also been 
reported by Korossis et al. (2002).  
Compared to the biomechanics of the MV leaflets presented in Chapter 3, both fresh and 
decellularised pericardium demonstrated higher average collagen phase slope, UTS and 
transition stress (Table 4.2). Moreover, the average transition strain of both fresh pericardium 
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groups (orthogonal and parallel), and the orthogonal decellularised pericardium group, were 
lower compared to both the anterior and posterior leaflet groups. The fresh and decellularised 
orthogonal pericardium groups also demonstrated lower average failure strains compared to 
both the anterior and posterior leaflet groups. The lower transition and failure strains 
suggested a reduced extensibility for the fresh and decellularised pericardium compared to 
the MV leaflets. The fresh and decellularised pericardium also demonstrated lower average 
thicknesses compared to the leaflets, but similar to those for human and bovine pericardium, 
commonly used for mitral valve repair (Mirsadraee et al., 2006; Oswal et al., 2007).  
Group 
El-E 
(MPa) 
Coll-E 
(MPa) 
σt 
(MPa) 
εt 
(%) 
UTS 
(MPa) 
εUTS 
(%) 
Thickness 
(mm) 
LAC 
0.05 
± 
0.01 
13.67 
± 
6.25 
0.20 
± 
0.11 
21.25 
+8.90 
-7.70 
2.60 
± 
1.49 
44.77 
+11.39 
-11.11 
0.67 
± 
0.08 
LAR 
0.06 
± 
0.04 
3.52 
± 
2.01 
0.17 
± 
0.06 
33.08 
+23.85 
-19.96 
1.19 
± 
0.66 
74.00 
+18.83 
-25.37 
0.83 
± 
0.27 
LPC 
0.02 
± 
0.01 
2.60 
± 
2.01 
0.17 
± 
0.06 
39.85 
+24.20 
-21.82 
0.90 
± 
0.51 
71.16 
+27.44 
-43.33 
0.74 
± 
0.09 
LPR 
0.02 
± 
0.00 
2.64 
± 
1.67 
0.08 
± 
0.05 
29.63 
+13.63 
-11.99 
0.74 
± 
0.15 
72.76 
+18.78 
-24.53 
0.94 
± 
0.22 
PP 
0.15 
± 
0.13 
22.83 
± 
9.49 
0.39 
± 
0.20 
15.29 
+16.98 
-11.37 
6.66 
± 
3.16 
51.30 
+27.80 
-28.24 
0.21 
± 
0.02 
PO 
0.21 
± 
0.18 
25.01 
± 
8.54 
0.26 
± 
0.14 
8.38 
+6.48 
-4.75 
4.28 
± 
1.33 
29.86 
+10.15 
-9.23 
0.23 
± 
0.01 
DPP 
0.09 
± 
0.06 
35.45 
± 
11.83 
0.64 
± 
0.12 
33.13 
+21.24 
-18.14 
7.89 
± 
2.36 
61.45 
+32.27 
-25.99 
0.22 
± 
0.01 
DPO 
0.13 
± 
0.06 
27.42 
± 
11.54 
0.75 
± 
0.45 
19.94 
+12.07 
-9.78 
6.20 
± 
2.75 
34.94 
+25.73 
-29.82 
0.21 
± 
0.01 
Table 4.2: Mean biomechanical parameters for the anterior leaflet circumferential (LAC) and 
radial (LAR); the posterior leaflet circumferential (LPC) and radial (LPR); the fresh pericardium 
parallel (PP) and orthogonal (PO); the decellularised pericardium parallel (DPP) and orthogonal 
(DPO). Data is presented as the mean (n=6) ± 95% C.I.; El-E: Elastin phase slope; Coll-E: collagen 
phase slope; σt:  transition stess; εt: transition strain; UTS: ultimate tensile strength; εUTS: failure strain.  
 
Despite these differences between decellularised pericardium and MV leaflets highlighted 
above, decellularised pericardial scaffolds could potentially represent a valuable choice for 
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MV leaflet repair both in terms of in vivo and in vitro regeneration. This is especially the case 
when decellularised pericardium is compared to chemically-treated autologous, allogeneic 
and bovine pericardia, which have been reported to have much higher stiffness and lower 
extensibility compared to both decellularised pericardium and MV leaflets (Oswal et al., 2007), 
and not to be able to regenerate and remodel in the patient. 
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Chapter 5  
Cell phenotyping and static cell seeding of 
decellularised pericardium 
5.1 Introduction 
This chapter describes the characterisation of the different cell types that were used in 
experiments to investigate the re-population of decellularised pericardial scaffolds, and the 
investigation of the optimum cell density and time for the cell-seeding of the scaffolds. 
Identification of the optimum seeding density and static seeding time was necessary in order 
for the cells to firmly adhere on the surface of the scaffold prior to dynamic culture in the 
bioreactor. The cells chosen for the repopulation experiments were those that expressed a 
phenotype similar to mitral valve (MV) interstitial cells (VICs). VICs are present throughout the 
MV leaflet tissue and comprise different cell populations concerned with the regulation of ECM 
remodelling and repair (Rabkin-Aikawa et al., 2005). There are three different phenotypes of 
VICs, namely fibroblasts, smooth muscle cells (SMCs) and myofibroblasts, which have 
characteristics of both fibroblasts and SMCs (Taylor et al., 2003; Sacks and Yoganathan, 
2007). Porcine skin fibroblasts and vascular SMCs were used in the cell seeding experiments. 
Differentiated cells such as fibroblasts and SMCs become senescent after prolonged culturing 
in vitro (Hayflick, 1965) due to the fact that they are already aged prior to isolation and, 
therefore, it may be difficult to generate sufficient numbers of cells for scaffold seeding. The 
potential senescence of differentiated cells could also limit their capacity for the repopulation 
and regeneration of the scaffold. In addition, in the clinical setting, it may be difficult to isolate 
fibroblasts and SMCs from the intended recipient of the implant. Due to the limitations 
associated with the use of differentiated cells, porcine bone-marrow-derived mesenchymal 
stem cells (MSCs) were also used in the experiments with the pericardial scaffolds. In the 
clinical setting, MSCs can be easily isolated from bone marrow biopsies and expanded to 
large numbers without loss of their proliferative capacity (Till and McCulloch, 1961). Once 
sufficient cell numbers are available, differentiation into the appropriate lineage(s) could then 
be induced by mechanical stimulation in a bioreactor (Banes et al., 1995; Sato et al., 1996; 
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Butt and Bishop, 1997; Hishikawa and Lüscher, 1997; Eastwood et al., 1998; Sirois et al., 
1998; Breen, 2000; Grinell, 2000; Altman et al., 2002; Väänänen, 2005; Ku et al., 2006). 
 
5.1.1 Aims and objectives 
Aims: 
The aim of the work presented in this chapter was to investigate the optimum cell density and 
culture time point for seeding the decellularised pericardium prior to dynamic seeding in a 
bioreactor. 
Objectives: 
 To characterise, through immunofluorescence, the phenotype of the cells used for 
seeding experiments 
 To investigate, through SEM, histology and a cell viability assay, the optimum cell 
density and static seeding time required to form a monolayer of cells on the 
pericardial scaffold prior to loading in a bioreactor.  
 
5.2 Materials  
5.2.1 Equipment 
The equipment used for the static cell seeding experiments is summarised in Table 5.1: 
Equipment Supplier Function 
Cylindrical cutting tool 
Bespoke design; manufactured 
in-house 
Dissection of pericardial scaffold 
discs (40 mm diameter) 
Tissue holder 
Bespoke design; manufactured 
in-house 
Clamping of pericardial scaffold 
discs for static culture 
Culture tub with filter Nalgene 
Culture of the cell-seeded 
pericardial disc clamped in the 
tissue holder 
Table 5.1: Equipment used for the static cell seeding of the decellularised pericardial scaffolds. 
 
The cutting tool and tissue holders were made of 316L stainless steel. The culture system 
comprising the tissue holder and culture tub are illustrated in Figure 5.1, the cutting tool was 
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used to obtain a scaffold patch of 4.6 cm in diameter, which was clamped between the top 
and bottom part of the tissue holder. The patch was clamped in between the two parts of the 
holder, which were held together by six screws (Figure 5.1b). 
Following clamping, the exposed portion of the scaffold patch was a 3 cm diameter disc. The 
bottom part of the tissue holder was a mesh (Figure 5.1a) to allow the cell culture medium to 
permeate the inferior surface of the-cell seeded scaffold. The size of the mesh holes (1.5 mm) 
was small enough to avoid any deformation of the pericardial scaffold disc, but large enough 
to ensure a supply of medium to most of the surface. The holder with the secured pericardial 
patch was placed in the culture tub (Figure 5.1c) by lifting it by the middle screws (Figure 
5.1b).  
 
Figure 5.1: Tissue holder (a, b) and culture tub (c) used in the static cell-seeding experiments. 
 
During the seeding experiments, culture medium was added (up to the mesh of the bottom 
part of the tissue holder) in the culture tub, which was fitted with a filter to allow oxygen 
exchange. A simple experiment was carried out to determine the optimum volume of culture 
medium to be added to the surface of the pericardial scaffold patch (in the well formed by the 
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tissue holder). A 4.6 cm diameter patch of native pericardium was loaded on the tissue holder, 
which was then positioned in the culture tub. The culture tub was filled with 105 ml of cell 
culture medium (Chapter 2, Section 2.5.4), up to the mesh of the lower part of the tissue 
holder, such that the medium contacted the inferior surface of the pericardial patch. Cell 
culture medium (2 ml) was added to the upper surface of the patch, in the well formed by the 
top part of the tissue holder. The tissue holder was incubated (37ºC in 5% v/v CO2 in air) 
overnight to observe the level of evaporation of the culture medium. The head volume of 2 ml 
was chosen in order to cover the top surface of the patch, to allow passive diffusion of 
oxygen, and to allow for potential evaporation of the culture medium without drying of the 
tissue patch. The head volume (V) corresponded to a culture medium height (h) in the well, 
which was calculated as follows: 
   patch area   medium height in well       r2   h       1.52   h   2 ml  h   2.8 mm  
where r was the radius of the sample. This height was similar to the height of the volume of 
cell culture medium in the flasks, used in cell culture.  
Following overnight incubation, there was some evaporation of the culture medium, but there 
was still enough culture medium in the well to cover the pericardial patch. 
5.2.2 Pericardial scaffolds 
Fresh pericardium was isolated and decellularised as described in Chapter 4, Section 4.2.1. 
5.2.3 Cells 
Porcine MSCs, dermal fibroblasts and SMCs were cultured on the mesothelial surface of 
decellularised pericardial scaffolds. Cells were cultured as described in Chapter 2, Section 
2.17.  
 
5.3 Methods 
5.3.1 Static seeding of decellularised pericardial scaffolds 
5.3.1.1 Sterilisation of tissue holders and culture tubs  
Prior to conducting the seeding experiments, all the equipment was sterilised. The upper and 
lower parts of the tissue holders were placed in a metal container, together with the allen keys 
and the cutting tool, and sterilised by dry heat sterilisation. A metal tray, which was also used 
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in the experiments as a working surface, was covered with tin foil and sterilised by dry heat. 
The air filters of the culture tubs were covered with tin foil and fixed with autoclave tape. The 
tubs was then closed loosely and sterilised by autoclaving. After autoclaving, the tubs were 
left to dry in a 45 °C drying room for 2 - 3 days prior to use.  
5.3.1.2 Scaffold mounting on tissue holders and cell seeding 
Porcine MSCs, dermal fibroblasts and SMCs were cultured on the mesothelial surface of 
pericardial scaffolds in order to determine the optimal cell density and static seeding time 
required to form a cell monolayer on the scaffold surface prior to dynamic conditioning in the 
bioreactor. Previous studies (Mirsadraee, 2005) have reported that cells, particularly 
fibroblasts, showed a better attachment on the mesothelial surface of decellularised 
pericardium compared to the epipericardial surface. Hence the mesothelial surface was 
chosen as the cell seeding surface.  
All work was carried out aseptically in a class II safety cabinet. Decellularised porcine 
pericardia were prepared as described in Chapter 4, Section 4.2.1 and 27 (one sample per 
cell density per cell type per time point) 46 mm in diameter circular patches were dissected 
aseptically using the cylindrical cutting tool. The lower part of each tissue holder was 
positioned on top of a sterile square petri dish, which was placed on a sterile metal tray. A 
scaffold patch was placed onto the lower part of each tissue holder, and the upper part 
screwed in place. The whole unit was then placed in a culture tub. A volume of cell culture 
medium equal to 105 ml was added to the culture tub, as described in Section 5.2.1. The 
various cell types were used at different passage numbers depending on the duration of 
culture on the pericardial scaffold: MSCs at passage 2 (24 h) and at passage 6 (3 days and 1 
week); porcine dermal fibroblasts at passage 4 (24 h), passage 5 (3 days) and passage 3 (1 
week); SMCs at passage 4 (24 h) and passage 5 (3 days and 1 week). Following resurrection, 
each cell type was cultured to the specific passage number, re-suspended and counted. The 
cell suspensions were then adjusted to the 3 required cell seeding densities, and 2 ml of each 
suspension was pipetted on 3 (for time point analysis) of the samples (in the well formed by 
each tissue holder). The seeding densities used for the three different cell types are 
summarised in Table 5.2. The cell densities were chosen on the basis of previous work on 
MSCs, fibroblasts (Mizrachi, 2009; Thomas et al., 2009) and Sinha (personal communication) 
for SMCs. The cell densities that were seeded on each sample were calculated as follows:  
Cell density (cells/cm2)   Sample area (cm2)    Number of cells 
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The sample area was calculated from: 
Sample area       r2 
where r is the radius of the circular patch equal to 15 mm (since the effective diameter of the 
patch was 30 mm). 
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Cell type 
Cell densities 
(cells·cm-2) 
Cells per sample (in 
2 ml cell suspension) 
Time points Type of assessment 
MSCs 
2×104 1.413×105 
24 hours SEM 
3 days H & E 
1 week H&E and live/dead 
1×105 7.065×105 
24 hours SEM 
3 days H & E 
1 week H&E and live/dead 
2×105 1.413×106 
24 hours SEM 
3 days H & E 
1 week H&E and live/dead 
Skin 
fibroblasts 
2×104 1.413×105 
24 hours SEM 
3 days H & E 
1 week H&E and live/dead 
1×105 7.065×105 
24 hours SEM 
3 days H & E 
1 week H&E and live/dead 
2×105 1.413×106 
24 hours SEM 
3 days H & E 
1 week H&E and live/dead 
SMCs 
2.5×104 1.766×105 
24 hours SEM 
3 days H & E 
1 week H&E and live/dead 
5×104 3.532×105 
24 hours SEM 
3 days H & E 
1 week H&E and live/dead 
1×105 7.065×105 
24 hours SEM 
3 days H & E 
1 week H&E and live/dead 
Table 5.2: Parameters used in the static seeding experiments with the decellularised pericardial 
scaffolds. One sample was used for each seeding density of each cell type at each time point (n = 
27). 
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The seeded scaffolds were incubated for either 24 hours, 3 days or 1 week under standard 
conditions. After 24 hours, 9 seeded scaffolds, corresponding to each cell density and cell 
type, were harvested and assessed for cell attachment by scanning electron microscopy 
(SEM). Nine more scaffolds, again corresponding to each cell density and cell type, were 
harvested after 3 days and assessed for cell penetration using histology and H&E staining. 
The final 9 samples were harvested after 1 week and assessed for cell penetration and 
amount of live/dead cells using histology (H&E) and live/dead staining, respectively (Table 
5.1). Cell culture medium (2 ml) was added to the top surface of the seeded scaffold every 2 
days during the 1-week incubations.  
5.3.2 SEM of cell seeded pericardial scaffolds 
The attachment of the different cell types to the pericardial scaffolds was assessed after 24 
hours using SEM. A rectangular piece was cut from the central area of each seeded scaffold, 
and processed for SEM as described in Chapter 2, Section 2.13. 
5.3.3 Histological analysis of recellularised pericardial scaffolds 
Cell seeded scaffolds were harvested for histological analysis after 3 days and 1 week to 
investigate the capacity of the cells to both form a monolayer on the surface of the scaffold 
and to penetrate its thickness. A rectangular piece was cut from the central area of each 
seeded scaffold, processed, and stained with H&E as described in Chapter 2, Section 2.11.1. 
 
5.4 Results 
5.4.1 Characterisation of porcine fibroblasts & SMCs 
Immunofluorescence labelling of porcine dermal fibroblasts and SMCs was performed using 
antibodies to -SMA, calponin (SMCs only), desmin and vimentin (fibroblasts only). The 
dermal fibroblasts isolated through collagenase digestion only expressed vimentin, whereas 
the SMCs explanted from porcine aorta were positive for calponin and desmin, and strongly 
positive for -SMA (Figure 5.2).  
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Figure 5.2: Immunofluorescence labelling of porcine fibroblasts and SMCs. Fibroblasts 
expressed vimentin only. SMCs expressed -SMA, calponin and desmin. The blank boxes indicate 
that cells were not phenotyped for that specific marker. Scale bars indicate 200 µm. pSMCs: porcine 
SMCs. 
 
5.4.2 Optimisation of cell seeding density 
Porcine MSCs, fibroblasts and SMCs were cultured on the mesothelial surface of pericardial 
scaffold samples to determine the optimal cell density and seeding time required to form a 
 156 
 
monolayer of cells on the surface of tissue prior to dynamic conditioning of the scaffolds in the 
bioreactor. The samples were analysed by SEM after 1 day, H&E staining after 3 days and 1 
week, and by live/dead staining after 1 week.   
5.4.2.1 Cell attachment after 24 hours culture visualised by SEM 
After 24 hours static culture, the fibroblasts and SMCs readily attached to the scaffold at all 
seeding densities. The SMCs and fibroblasts looked sparsely distributed at the lowest 
densities (2×104 cells·cm-2 and 2.5×104 cells·cm-2, respectively), with small cell patches 
observed on the surface of the scaffolds (Figure 5.3a, g). At the intermediate cell densities 
(1×105 cells·cm-2 for fibroblasts and 5×104
 
cells·cm-2 for SMCs), the cells started forming a 
monolayer (Figure 5.3b, h). At the high cell densities (2×105 cells·cm-2 for fibroblasts and 
1×105 cells·cm-2 for SMCs), the cells formed  monolayers (Figure 5.3c, i). The MSCs attached 
well onto the scaffold at both the intermediate and high densities (1×105 cells·cm-2 and 2×105 
cells·cm-2, Figure 5.3e, f). At the low density (2×104 cells·cm-2) only a few MSCs were 
observed, most of them round in shape, suggesting that the cells did not attach to the scaffold 
(Figure 5.3d). Generally, the attached cells demonstrated a characteristic spread morphology 
suggesting good attachment to the scaffolds (Figure 5.4a - f). 
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Figure 5.3: SEM of porcine fibroblasts, pMSCs and pSMCs seeded on porcine pericardial 
scaffolds after 24 hours culture. (a, d) 2×104 cells·cm-2; (b, e), 1×105 cells·cm-2; (c, f) 2×105 
cells·cm-2cm2; (g) 2.5 ×104 cells·cm-2;  (h) 5×104 cells·cm-2; (i) 1×105 cells·cm-2 . The red arrows and 
circles indicate cells. Scale bars indicate 200 µm. pMSCs: porcine MSCs; pSMCs: porcine SMCs. 
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Figure 5.4: SEM of porcine fibroblasts, pMSCs and pSMCs showing cell attachment onto 
porcine pericardial scaffolds after 24 hours culture. Fibroblasts and MSCs at 2×105 cells·cm-2 (a, 
b, c and d); SMCs at 1×105 cells·cm-2 (e, f). Scale bars indicate 30 µm. pMSCs: porcine MSCs; 
pSMCs: porcine SMCs. 
 
5.4.2.2 Cell attachment and, penetration and viability after 3 days and 1 week 
culture visualised by histology and live/ dead staining 
The histology images (3 days and 1 week) and live/dead (1 week only) staining results of the 
3 cell types seeded on the pericardial scaffolds are illustrated in Figures 5.5, 5.6 and 5.7. After 
3 days of static seeding, no fibroblasts or SMCs were observed through histology and H&E 
staining of sections on the mesothelial surface of scaffolds at the lowest and intermediate 
densities (2 ×104 and 1 ×105 cells·cm-2 for fibroblasts; 2.5 ×104 and 5 ×104 cells·cm-2 for 
SMCs), as shown in Figure 5.5a, b and 5.7a, b. Sparsely arranged cells were observed at the 
highest densities (2×105 cells·cm-2 for fibroblasts and 1×105 cells·cm-2 for SMCs), as shown in 
 159 
 
Figure 5.5c and 5.7c. In contrast , after 3 days of culture MSCs were observed as an early 
monolayer when seeded at the intermediate and highest densities (1×105 and 2×105 cells·cm-
2; Figure 5.6b and 5.6c, respectively), and they were seen to have penetrated into the 
scaffold, especially at the highest density. The penetration and migration of the MSCs into the 
scaffold was more apparent after 1 week of static seeding at both the intermediate and high 
seeding densities, whereas only sparsely arranged cells were observed on the scaffolds 
seeded at the low cell density. 
Following 1 week culture, the fibroblasts and SMCs became more confluent on the scaffold 
surface, especially when seeded at the intermediate and high cell densities, (Figures 5.5e, f 
and 5.7e, f), forming a continuous (fibroblasts) or almost continuous (pSMCs) monolayer at 
the highest cell seeding density (Figures 5.5f and 5.7f). In contrast to the fibroblasts and 
MSCs, the SMCs were not observed within the scaffolds after 1 week of culture, 
demonstrating a tendency to form agglomerates on the scaffold surface. The most favourable 
seeding densities for fibroblasts and MSCs were 2×105 cells·cm-2 and 1×105 cells·cm-2, 
respectively, representing the lowest densities at which the cells were found to populate the 
surface of the scaffold. Based on the same criterion, the most favourable static culture 
duration was 1 week for fibroblasts and 3 days for MSCs. 
The results for the live/dead staining (Chapter 2, Section 2.16) after 1 week static culture of 
the 3 cell types are shown in Figure 5.5g - i, 5.6g - i and 5.7g - i. All 3 cell types were mostly 
stained green when seeded on the pericardial scaffolds at all cell densities investigated, with 
the exception of MSCs at the lowest cell density, which were mostly stained red (Figure 5.6g). 
Counting of the live (green) and dead (red) cells (Chapter 2, Section 2.16.1) indicated that 
68% and 78% of fibroblasts and SMCs, respectively, were alive when seeded at the lowest 
cell density, whereas only 25% of MSCs were alive when seeded at the lowest cell density. 
Moreover, 91%, 81% and 74% of fibroblasts, pMSCs and SMCs, respectively, were alive after 
1 week following seeding onto the pericardial scaffolds at the intermediate cell density and 
89%, 74% and 77% viable when seeded at the high cell densities. 
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Figure 5.5: H&E stained sections (a - f) and live/dead (g - i) stained samples of decellularised 
pericardial scaffolds seeded with porcine fibroblasts at different cell densities at 3 days (a - c) 
and 1 week (d - i). (a, d, g) 2×104 cells·cm-2; (b, e, h) 1×105 cells·cm-2; (c, f, i) 2×105 cells·cm-2. At 3 
days, the fibroblasts appeared as a discontinuous monolayer when seeded at the high cell density (c). 
At 1 week, the cells were observed to form a continuous monolayer at the high cell seeding density, 
and were present through the thickness of the scaffold (f). Most of the cells that had been seeded at 
the intermediate (h) and high (i) cell densities were stained green, in contrast to the cells seeded at the 
low cell density (g). Arrows indicate cells. M: mesothelial surface. Scale bars indicate 200 µm. 
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Figure 5.6: H&E stained sections (a - f) and live/dead (g - i) stained samples of decellularised 
pericardial scaffolds seeded with porcine MSCs at different cell densities at 3 days (a - c) and 1 
week (d - i). (a, d, g) 2×104 cells·cm-2; (b, e, h) 1×105 cells·cm-2; (c, f, i) 2×105 cells·cm-2. Following 3 
days and 1 week, the MSCs attached well to the scaffold forming continuous monolayers at the middle 
and high densities (b, c, e, f). At the high density, the cells started infiltrating the scaffold after 3 days 
(c), whereas after 1 week they started migrating further into the scaffold. Most of the cells at the middle 
(h) and high (i) densities were stained green, in contrast to the low density (g) at which most of the 
cells were stained red. Arrows indicate cells. M: mesothelial surface. Scale bars indicate 200 µm. 
pMSCs: porcine MSCs. 
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Figure 5.7: H&E stained sections (a - f) and live/dead (g - i) stained samples of decellularised 
pericardial scaffolds seeded with porcine SMCs at different cell densities at 3 days (a - c) and 1 
week (d - i). (a, d, g) 2.5×104 cells·cm-2; (b, e, h) 5×104 cells·cm-2; (c, f, i) 1×105 cells·cm-2. Following 3 
days a low amount of cells was observed on the scaffold at the high density (c). After 1 week, the 
SMCs were observed to form a discontinuous layer at the middle density (e) and an almost continuous 
layer at the high density (f). Most of the cells at the low (g), middle (h) and high (i) densities were 
stained green. Arrows indicate cells. M: mesothelial surface. Scale bars indicate 200 µm. pSMCs; 
porcine SMCs.  
 
5.5 Discussion 
The studies described in this chapter aimed at verifying the phenotype of porcine fibroblasts 
and SMCs that were subsequently used in the seeding of decellularised pericardial scaffolds, 
and at investigating the cell density and static culture duration for the cell seeding of 
decellularised pericardial scaffolds prior to their dynamic conditioning under mitral-valve-
relevant mechanical stimulation in a bioreactor. The results from the immunofluorescence 
staining confirmed the phenotype of fibroblasts and SMCs. Fibroblasts were strongly positive 
for vimentin and negative for SMA and desmin, in accordance to the literature (Rensen et 
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al., 2007; Wilcox et al., 2005). In addition, -SMA, calponin and desmin are among the 
markers most commonly used to confirm SMC phenotype (Wilcox et al., 2005). The SMCs 
investigated in this study were all strongly positive for -SMA and most of them were positive 
for calponin and desmin. Rensen et al. (2007) reported that the expression levels of the 
contractile marker proteins, such as –SMA, calponin and desmin, gradually decrease when 
SMCs are cultured in vitro. This could explain the weak level of expression of calponin and 
desmin by the SMCs used in this study. 
Identification of an acceptable cell seeding density and time is essential for the effective 
cellularisation of scaffolds. The seeding density has an effect on cell proliferation rates 
(Fossett and Khan, 2012); both too high and too low seeding densities might lead to cell 
senescence, affecting the proliferation and differentiation capabilities of cells (Hayflick, 1965). 
High cell density may also cause contact inhibition which can lead to lower growth rates 
(Mochizuki et al., 2006), whereas low seeding densities may allow for a higher availability of 
nutrients per cell, improving cell growth (Both et al., 2007; Lode et al., 2008). However, if the 
cell density is too low, it could take longer for the cells to populate the scaffold, and a high 
number of cell doubling times will be required, potentially leading to cell senescence. Van den 
Bos et al. (1998) reported that human MSCs undergo programmed cell death at low seeding 
densities. This could explain the high number of dead MSCs observed when seeded onto the 
pericardial scaffold at the low cell density in this study. MSCs isolated from porcine bone 
marrow have been used in previous studies for the population of decellularised porcine 
pericardial scaffolds under static conditions. Thomas et al. (2009) investigated the use of 
different MSCs densities, ranging from 1×104, 1×105 and 2×105 cells·cm-2, at different time 
points to populate pericardial scaffolds produced by the same method as in the present study. 
Their findings showed that a cell density of 1×105 cells·cm-2 was the most favourable seeding 
density. This was in accordance to the results reported here, representing the lowest density 
at which the cells were capable of populating the scaffold and migrating through its thickness.  
Bone marrow derived MSCs have been used in several studies for the production of tissue 
engineered constructs, including bone, cartilage, vascular grafts and heart valves (Ponticiello 
et al. 2000; Meinel et al. 2004; Wang et al. 2005; Vincentelli et al., 2007). The affinity of bone 
marrow derived MSCs towards an osteogenic lineage might represent an issue when using 
these cells for cardiac tissue engineering. Yoon et al. (2004) reported that homologous MSCs, 
derived from the bone marrow of rats, caused myocardial calcification two weeks after 
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injection in rats with myocardial infarction. They reported that this was due to the high 
plasticity of bone marrow MSCs and the possible predilection for calcification in infarcted 
myocardium. The authors also suggested that during the isolation of the MSCs some bone 
precursor cells might have been isolated, since they used unselected MSCs. MSCs 
differentiation can be influenced by cell density which affects cell shape and cytoskeletal 
tension, guiding biochemical signalling (Mc Beath et al., 2004). The optimum density of 
porcine bone marrow MSCs found in the present study (1×105 cells·cm-2, corresponding to 
3.533×105 cells·ml-1) was lower compared to previous reports by Engelmayr et al. (2006), 
Hoerstrup et al. (2002) and Sutherland et al. (2005) for heart valve regeneration (8×106 
cells·ml-1, 4.5 to 5.5×106 cells·cm-2; 4×107 cells·ml-1, respectively).  
Following 1 week in static culture, the SMCs showed a tendency to agglomerate on the 
surface of the scaffold rather than penetrating through its thickness. This result indicated the 
possible need for prolonged culture times, and the possible technical error in mixing and 
separating the cell suspension before seeding. Co-workers at iMBE have previously 
investigated the seeding density and culture time for porcine vascular SMCs and skin 
fibroblasts on pericardial scaffolds, and reported that SMCs seeded at a density of 5×104 
cells·cm-2 required 2 weeks to fully populate the surface of the scaffold, whereas after 3 
weeks the number of cells in the scaffold had decreased. Remuzzi et al. (2004) also observed 
a decrease in SMCs numbers over time in cellularising polymeric scaffolds at cell densities 
higher than those described in this study (3.75×105 and 3×106 cells·cm-2 and 2.5×104, 5×104 
and 1×105 cells·cm-2, respectively). The authors hypothesized that the loss of cells was the 
consequence of an increasing number of cells undergoing apoptosis. The SMC viability could 
potentially be improved by dynamic conditioning, as described by Jeong et al. (2004), who 
reported that shear stress could enhance tissue development and retention of contractile cell 
phenotypes.  
Dermal fibroblasts have been used in various tissue engineered products for skin 
regeneration, such as Dermagraft (Advanced BioHealing, La Jolla, CA, U.S.A.) and Apligraf 
(Novartis, Basel, Switzerland) for the treatment of burns, chronic venous ulcers and several 
other clinical applications in dermatology and plastic surgery (Wong et al., 2007), and cells 
have been reported to enhance ECM deposition and wound healing. With regards to the 
fibroblasts used in the present study, coverage of the scaffold surface and initiation of cell 
infiltration was achieved after 1 week at a density of 2×105 cells·cm-2. On the other hand, 
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MSCs reached confluence and initial infiltration after only 3 days and at a density of 1×105 
cells·cm-2. The longer time and higher cell density required for populating the scaffold with 
both fibroblasts and SMCs might have been related to the nature of the differentiated cells, 
which might have already been aged. Co-workers at iMBE have previously reported that at 
least 3 weeks were needed in order to fully populate decellularised porcine pericardial 
scaffolds with porcine dermal fibroblasts at a density of 5×104 cells·cm-2. Previous studies by 
Masoumi et al. (2013b) and Weber et al. (2012) have reported higher dermal fibroblast 
densities (10×106 and 1.5×106 cells·cm-2, respectively) for heart valve tissue engineering 
compared to the seeding density found in the present study (2×105 cells·cm-2).  
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Chapter 6 
Biaxial bioreactor description & calibration 
6.1 Introduction 
This chapter describes the procedure followed for the calibration and commissioning of the 
biaxial bioreactor, which was used for the dynamic conditioning of the cell-seeded pericardial 
scaffolds. Bioreactors represent one of the main components in the development of tissue-
engineered heart valves in vitro. Heart valve bioreactors facilitate the dynamic conditioning of 
cell seeded scaffolds under valve-relevant mechanical stimulation, with a view to guiding the 
regeneration of tissue-engineered valves in vitro. The bioreactor system used in the present 
study for the engineering of mitral valve (MV)-leaflet-equivalents was able to simulate the 
mechanical environment that the native MV leaflets experience in vivo. In particular, the native 
MV apparatus is subjected to cyclic loading in vivo, which is characterised mainly by the 
inflation and deflation of the leaflets during the cardiac cycle (Nolan et al., 1969). 
The cyclic loading of heart valve leaflets, in general, can be decomposed into components of 
circumferential and radial stretch, compression, shear stress, and flexure (Berry et al., 2010). 
Several studies have investigated the influence of these loading components on cell seeded 
scaffolds (Jockenhoevel et al., 2002; Butcher et al., 2004, 2006; Englemayr et al., 2005, 2006, 
2008; Ku et al., 2006; Merryman et al., 2007; Balachandran et al., 2009). Accordingly, several 
bioreactors have been reported in the literature, which have been designed to simulate one or 
more of the loading components experienced by heart valves in vivo (Zeltinger et al., 2001; 
Weston and Yoganathan, 2001; Dumont et al., 2002; Hildebrand et al., 2004; Mol et al., 2005; 
Lichtenberg et al., 2006; Karim et al., 2006; Syedain and Tranquillo, 2009). The majority of 
bioreactors reported in the literature have the capacity to simulate either one of the loading 
components experienced by the heart valve apparatus, or the whole haemodynamic 
environment of the heart valve, as in the case of the aortic valve. The complex geometry and, 
indeed, the complex haemodynamics of the MV apparatus, make it difficult to simulate the 
local haemodynamic environment of the MV apparatus for tissue engineering purposes. This 
is especially the case, when engineering a construct for replacing/repairing an individual 
component of the MV apparatus, such as the MV leaflets. 
 167 
 
The present study employed a bioreactor that was able to exert variable biaxial strain and 
flexure on cultured constructs, representative of the cyclic inflation-deflation experienced by 
the native MV leaflets in vivo. Moreover, the present study employed physiological levels of 
strain for the conditioning of the cell-seeded pericardial scaffolds. Specifically, the cell-seeded 
scaffolds were conditioned under the maximum strain experienced by the native anterior MV 
leaflets during the cardiac cycle in vivo, which was obtained through finite element (FE) 
computational models of the whole MV apparatus, using a physiological MV geometry and 
input pressures (Roberts, 2012). In addition to relevant and highly controllable mechanical 
stimulation, the bioreactor system used also provided control over a number of additional 
parameters, including culture medium temperature, pH and oxygen tension, which are 
fundamental for the appropriate function of the cells seeded onto the scaffold. 
 
6.1.1 Aims and objectives 
Aims: 
The aims of the work presented in this chapter were to calibrate and commission the biaxial 
bioreactor, which was subsequently used for the dynamic conditioning of cell-seeded 
pericardial scaffolds. 
Objectives: 
 To set up the bioreactor in order to exert MV-leaflet-relevant biaxial strain fields to the 
conditioned constructs under cyclic conditions  
 To calibrate the main components of the bioreactor system 
 To develop the general methodology for conditioning and culturing the cell-seeded 
scaffolds in the bioreactor under aseptic conditions.  
 
6.2 Description of the biaxial bioreactor system 
The bioreactor system used for the dynamic culture of cell-seeded pericardial scaffolds was 
designed and constructed in iMBE by Dr Sotirios Korossis and Mr Lee Wetherill, respectively. 
The system was designed to mimic the biaxial loading that the native MV leaflets experienced 
in vivo. The bioreactor comprised four main parts, including: i) a linear actuator, which 
provided the mechanical stimulation exerted to the construct; ii) four construct stations, which 
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housed the cell-seeded scaffolds; iii) a chemostat system, which conditioned the culture 
medium in terms of temperature, pH and oxygen partial pressure (pO2).  
The electric linear actuator (Industrial Devices Ltd, UK; model N2-T31-10-05B-4-MF3-FT1M-
2PSR) was connected to a programmable single-axis digital stepper controller (Industrial 
Devices Ltd, UK; model SmartStep23), through which the desired cycling rate, stroke volume 
and waveform of the actuator could be set. A schematic of the linear actuator connected to 
the bioreactor chamber is shown in Figure 6.1. A piston, which was connected to the linear 
actuator, pushed the water inside the bioreactor chamber (Figure 6.1), generating a cyclic 
volume displacement within the bioreactor chamber. This volume displacement caused, in 
turn, the cyclic inflation/deflation of the silicone rubber diaphragms mounted at the bottom of 
each of the four bioreactor stations (Figure 6.1) which also acted as an impermeable barrier to 
maintain sterility of the culture medium in the chambers. The cyclic inflation/deflation of the 
silicone rubber diaphragms caused, in turn, the generation of a volume displacement of the 
culture medium in the lower part of the bioreactor stations and a synchronous 
inflation/deflation of the pericardial scaffolds mounted between the lower and upper parts of 
the stations (Figure 6.3). The stations were positioned symmetrically on top of the bioreactor 
chamber and, therefore, the volume displacement produced by the actuator was divided 
equally between the four stations. In order to generate the necessary volume displacement of 
water in the bioreactor chamber to accommodate the four bioreactor stations, an increased 
diameter piston head was used, the frictionless motion of which was supported by a rolling 
diaphragm inflated by pressurised air. The deformation of the scaffolds in the bioreactor 
stations duplicated the deformation of the MV leaflets in vivo, characterised by inflation during 
systole and deflation during diastole. The deformation of the MV leaflets during the cardiac 
cycle is shown in Figure 6.2. Although the actuator controller was able to generate a range of 
different waveforms, a simple (non-physiological) sinusoidal waveforms, with a frequency of 
1Hz, was chosen for the operation of the bioreactor in order to simplify the experiments and to 
limit the study to the effect of the physiological strain magnitude on the cell seeded scaffolds.   
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Figure 6.1: Schematic (a) and photograph (b) of the actuator connected to the bioreactor 
chamber.    
 
 
Figure 6.2: Schematic of the deformation of the MV leaflets in vivo. Adapted from Nolan et al. 
(1969). 
 
The bioreactor was able to accommodate four cell-seeded scaffolds at the same time; one in 
each station. Each station comprised an upper and lower part and a central disk onto which 
the pericardial membrane was loaded. The set-up of the bioreactor stations is illustrated in 
Figure 6.3. The parts of each station were interconnected via silicone tubing (Figure 6.3b), 
and also featured viewing ports for inspection of the culture medium and cell-seeded scaffolds 
during culture. Following preliminary trials, the initial design of the bioreactor stations was 
improved by adding a stopcock and a tube open to the atmosphere, in order to control the 
direction of the flow of the culture medium and to allow for better aeration during medium 
filling. The diameter of the circular sample loaded on the central disk of each station was 4.6 
cm, however the effective diameter of the scaffold (following mounting) that was mechanically 
stimulated was 3 cm (Figure 6.3d).  
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Figure 6.3: Setup of the bioreactor stations. The first version of the stations (a, b) was improved by 
adding a tube open to the atmosphere together with a stopcock in order to allow for a better release of 
the air trapped in the station (c). The scaffold was loaded on the central disk, which was then clamped 
between the upper (top) and lower (bottom) parts. The medium was pumped into the lower part of the 
station and overflowed into the upper part. It then flowed out of the station into a collection reservoir 
(c). (e) Station cross-section showing the scaffold stimulation principle (green: scaffold; red: silicone 
rubber membrane). (f) Image of the silicone rubber heating element which was wrapped around each 
bioreactor station.  
 
The circulation of the culture medium in the bioreactor system is illustrated in Figure 6.4. The 
culture medium was conditioned in a 2 L autoclavable chemostat vessel (Applikon 
Biotechnology, UK), attached to an ADI 1010 Bio Controller and ADI 1025 Bio Console 
(Applikon Biotechnology, UK). In the chemostat the medium was maintained at pH 7.2 - 7.4, 
and pO2 21%. A heating element, wrapped around the chemostat vessel, and controlled by 
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the Bio Controller, was used for temperature control. A stirrer attached to the vessel, provided 
continuously stirring of the medium at 100 rpm. Following mounting the cell-seeded scaffolds 
into the bioreactor stations, culture medium was pumped from the chemostat into the lower 
parts of the bioreactor stations using a four-channel peristaltic pump (Multichannel pump 
7536-04, Cole parmer). Culture medium was pumped into the stations until it completely filled 
the lower parts of the stations and overflowed into the upper parts through side ports (Figure 
6.3c). From there, the medium was allowed to freely flow out of the upper parts of the stations, 
through a side port, into a collection reservoir, assisted by gravity (as shown by the thick red 
arrows in Figure 6.3c). From the collection reservoir, the culture medium was pumped back 
into the chemostat vessel using a single-channel peristaltic pump (Easy load II77200-50, Cole 
parmer). The culture medium perfusion rate between the chemostat and the stations was 
balanced so that a constant culture medium level was maintained in both the chemostat 
vessel and the bioreactors stations. The temperature in the chemostat was maintained at 
42ºC, as described in Section 6.5. 
 
Figure 6.4: Schematic of the culture medium circulation in the bioreactor system. The culture 
medium was pumped from the chemostat vessel to the lower part of each bioreactor station using a 
four-channel peristaltic pump. Once the lower part of the stations was full, the medium flowed over to 
the upper part of the stations, before it was allowed to overflow out of the upper parts and into the 
collection reservoir, assisted by gravity. From the collection reservoir, the medium was driven back to 
the chemostat vessel using a single-channel peristaltic pump. 
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The temperature of the culture medium in the bioreactor stations was controlled by using a 
thermocouple attached to one of the bioreactor stations and 4 silicone rubber heating 
elements (Fig. 6.3f) wrapped around the four bioreactor stations (one for each station). The 
silicone-rubber heaters and thermocouple were connected to a temperature controller 
(Eurotherm, UK; Model 3216). The autoclavable thermocouple was fitted into the lower part of 
one of the stations and was in direct contact with the culture medium. The culture medium 
temperature in the other three stations was assumed to be equal to the temperature of the 
station fitted with the thermocouple (see Section 6.5). During the experiments, the 
temperature controller was set to maintain a culture medium temperature of 37ºC in all 
stations.  
6.3 Correlation of bioreactor actuator stroke to scaffold strain  
Prior to conditioning of the cell-seeded scaffolds, the bioreactor actuator required calibration in 
terms of the strain it exerted on the scaffolds. Specifically, the stroke (piston displacement) of 
the actuator required correlation to the volume displacement of water in the bioreactor 
chamber and this, in turn, to the strain experienced by the scaffolds in the bioreactor stations.  
Previous FE simulations of the whole MV apparatus, which were based on the physiological 
geometry and pressure conditions of the MV apparatus, predicted that the central regions of 
the anterior MV leaflets experienced a maximum tensile strain magnitude of around 10% 
(Roberts, 2012). Thus, the value of 10% tensile strain was chosen for the conditioning of the 
cell-seeded pericardial scaffolds.  
In order to obtain the relationship between the stroke of the actuator and the strain imposed 
onto the pericardial scaffolds, the deformed shape of the scaffolds was assumed to 
approximate a spherical cap (Figure 6.5).   Since the deformation of the scaffolds was caused 
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Figure 6.5: Deformed shape of the pericardial scaffold under the assumption of approximating 
a spherical cap. The blue coloured volume represents the stroke volume per bioreactor station (vcap). 
 
by the volume displacement (stroke volume) of the actuator, the volume enclosed by the 
spherical cap (Vcap) of each deformed scaffold mounted in each of the four bioreactor stations, 
corresponded to the volume per station displaced by the actuator. Therefore, the strain 
imposed onto the scaffolds was a function of the actuator stroke volume. The volume of the 
spherical cap (Vcap) was calculated according to: 
Vcap    
1
6
    h   (32   h2
 
) 
where  was the base radius (equal to 15 mm) and h the height of the spherical cap (Figure 
6.5). The actuator stroke necessary to exert the required stroke volume (Vcap) at all four 
stations was calculated according to: 
Stroke   
Vcap   No of stations 
Piston head area
 
where Piston head area was the area of the piston head of the actuator equal to 167.44 cm2, 
and No of stations the number of bioreactor stations in the system equal to 4. The relation 
between , h and R (radius of the sphere) was obtained by the Pythagorean Theorem: 
(R   h)2   2   R2    R   
(h
2
   2)
2h
 
Considering the 2D representation illustrated in Figure 6.5, the length of the arc AB represents 
the deformed (stretched) length of the scaffold. The length of the arc AB was calculated 
according to: 
Arc length AB   R   2  
the angle   was calculated according to: 
sin     

R
     sin 1

R
     in radians  
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Figure 6.6: Arc length (AB) of the deformed pericardial membrane. 
 
Therefore, the approximated engineering tensile strain in the pericardial scaffold was 
calculated according to: 
ε 
Deformed length   Original length
Original length
   
Arc length AB   2
2
   100% 
Based on the above formulation, the engineering tensile strain, stroke volume per station 
(Vcap), and actuator stroke were calculated for different values of h. These results are 
illustrated in Table 6.1. The table highlights the stroke volume per station and actuator stroke 
required to produce 10% strain in the cell-seeded scaffolds. The volume per station required 
to produce 10% strain was calculated to be 2.19 ml, and the corresponding actuator stroke 
was 0.52 mm. 
h 
(mm) 
R 
(mm) 
 
(radians) 
Arc length 
(mm) 
Strain 
(%) 
Stroke Volume 
(ml) 
Stroke 
(mm) 
5.00 25.00 0.64 32.18 7.25 1.83 0.44 
5.10 24.61 0.66 32.26 7.54 1.87 0.45 
5.20 24.23 0.67 32.35 7.83 1.91 0.46 
5.30 23.88 0.68 32.44 8.13 1.95 0.47 
5.40 23.53 0.69 32.53 8.43 1.99 0.48 
5.50 23.20 0.70 32.62 8.73 2.03 0.49 
5.60 22.89 0.71 32.71 9.05 2.07 0.49 
5.70 22.59 0.73 32.81 9.36 2.11 0.50 
5.80 22.30 0.74 32.91 9.69 2.15 0.51 
5.90 22.02 0.75 33.00 10.01 2.19 0.52 
6.00 21.75 0.76 33.10 10.35 2.23 0.53 
Table 6.1: Numerical correlation between h, R, , stroke volume per station and stroke.  
 
6.4 Calibration of the linear actuator 
Prior to operation, the linear actuator was calibrated in terms of correlating the actuator 
controller setting to the actual displacement (stroke) of the actuator piston. For this purpose, 
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the actuator connected to the piston head (Figure 6.1) was detached from the bioreactor 
system. During calibration, the actuator controller was set to produce a cycling rate of 1 Hz 
and a speed of 1 mm·s-1 of the actuator piston, as well as five different actuator stroke 
settings ranging from 0.5 to 1.5 at 0.25 intervals. At each setting, the displacement (stroke) of 
the actuator was measured three times using callipers and averaged. These results are 
presented in Table 6.2. The plot showing the linear relationship between the controller setting 
and the measured actuator stroke is illustrated in Figure 6.7. 
Controller setting Stroke (mm) 
0.50 0.11 
0.75 0.37 
1.00 0.63 
1.25 0.90 
1.50 1.15 
Table 6.2: Calibration of the actuator controller setting with respect to the actual actuator 
stroke amplitude. 
 
Figure 6.7: Calibration plot of the measured actuator stroke against the controller setting.   
 
Having obtained the calibration plot that correlated the controller setting to the actual stroke 
produced by the actuator, the controller setting that corresponded to the actuator stroke of 
0.52 mm (as calculated in Section 6.3), required to produce a strain of 10% in the cell-seeded 
scaffolds was calculated. For this purpose, linear regression was performed to the controller 
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setting against the actuator stroke data (Table 6.2, Figure 6.7), with a view to obtaining the 
mathematical relationship between the two parameters. The linear regression returned an 
equation of the form: 
y   mx   q  Stroke   1.04   Controller setting   0.41 
with a regression correlation coefficient R2 = 0.9999. Using the above equation, the controller 
setting for a stroke of 0.52 mm was calculated as: 
Controller setting   
Stroke   0.41
1.04
   
0.52   0.41
1.04
   0.89 
Therefore, using a controller setting of 0.89 for the actuator stroke, which corresponded to an 
actuator stroke amplitude of 0.52 mm, and a frequency of 1 Hz, the actuator was set to 
produce the following stroke waveform: 
Stroke (t)   
Strokeamplitude 
2
   [1   sin (2 t   
 
2
)] 
The graphical representation of the actuator stroke over time is illustrated in Figure 6.8.  
 
Figure 6.8: Actuator stroke waveform used for the conditioning of the cell-seeded pericardial 
scaffolds (two cycles).   
 
6.5 Calibration of the heating system and peristaltic pump 
During both static and dynamic culture experiments, the culture medium temperature within 
the bioreactor stations was maintained at 37ºC. In order to achieve this, the heating system of 
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the bioreactor was calibrated. For this purpose, the chemostat vessel was filled with distilled 
water and connected to the bioreactor station which was fitted with the thermocouple. The 
station was not fitted with its heating wrap. The chemostat vessel was wrapped with its 
silicone heater and the temperature was raised to 42°C. Temperature-conditioned water was 
then perfused from the chemostat vessel to the bioreactor station using one of the channels of 
the four -channel peristaltic pump at a rate of 10 ml·min-1. During the perfusion of water, the 
temperature in the bioreactor station was monitored. The water temperature in the station 
stabilised at 26.4°C, indicating a temperature drop of 15.6 °C between the chemostat and the 
station, probably due to the length of the tubing, which was not insulated. Subsequently, the 
station was wrapped with its heating element, and the heating controller was set to 37°C. The 
temperature of the chemostat vessel remained set at 42°C, to ensure that the medium in the 
stations would stabilised at 37°C relatively quickly. Using the selected perfusion rate of 10 
ml·min-1, the water temperature in the station stabilised at 37°C after 5 to 10 min. The 
additional three stations were then mounted in the bioreactor and wrapped with their heating 
elements, which were also connected to the heating controller. The three stations were also 
connected to the chemostat vessel and water was perfused to all four stations using the four-
channel peristaltic pump at a rate of 10 ml·min-1.  After the water was perfused for 10 min, the 
water temperature in the stations was measured manually using a thermometer. All stations 
reached a temperature of 37°C ± 0.3°C.    
In order to ensure that the four-channel peristaltic pump was running at an actual perfusion of 
10 ml·min-1, an empty universal was weighed (14.5 g) and then filled with water, which was 
pumped at a set rate of 10 ml·min-1 for 1 min, using the same silicone tubing (Masterflex) as 
in the experiments. After 1 min the peristaltic pump was stopped and the universal was 
weighed again (24.14 g). The volume of water collected after 1 min was equal to 9.63 ml. A 
second pump was used to return the culture medium from the medium collection reservoir to 
the chemostat vessel. During the bioreactor cultures, this pump was controlled by the 
chemostat controller and the level probe fitted in the chemostat vessel, which was maintaining 
a constant culture medium level in the chemostat vessel. 
6.6 Chemostat sterilisation, set-up, calibration and culture medium loading 
Prior to operation, the bioreactor stations and the chemostat vessel (Figure 6.9) including all 
the culture-medium-contacting components (pO2 probe, pH probe, stirrer propeller) and 
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ventilation filters, together with the silicone tubing, were sterilised by autoclaving at 121°C and 
15 lb. sq. in.  
Bioreactor stations sterilisation  
Prior to autoclaving, the bioreactor stations, upper and lower parts, central disk and tubes, 
were washed with 1% (v/v) Trigene (Figure 6.3a, b and c). All of the air filters were taken off 
the system during washes. The various parts of the bioreactor stations were then rinsed with 
running tap water until clear. The parts were then air-dried on the bench, and the air filters 
were assembled back in their correct position. Following air drying, the upper part of each 
station was screwed to the central disk and the lower part. All the ends of the quick 
connectors were covered with double layers of tin foil and fixed with autoclave tape, including 
the air filters and the lower part of each station which were covered with only one layer of tin 
foil and fixed with autoclave tape. Each station was finally put in an autoclave bag which was 
folded twice and fixed with autoclave tape. The bioreactor stations were left to completely dry 
in a 45°C drying room for 1 week after autoclaving.  
Chemostat vessel sterilisation and calibration  
The pH probe of the chemostat vessel was calibrated before autoclaving using pH standard 
solutions at pH 4 and 7. The values were taken when the reading reached a steady state. The 
values of pH were related to specific values of voltage.  Prior to autoclaving, the chemostat 
vessel connected to the reservoir and the tubes and bottles used for the cell culture medium 
loading procedure, were washed with 1% (v/v) Trigene. The various parts of the system were 
then rinsed with two washes of distilled water. A few millilitres of distilled water were left at the 
bottom of the chemostat to help the steam penetrate throughout all the tubes and bottles 
connected to the chemostat during the autoclaving process and to avoid drying of the pH 
probe. All the ends of the quick connectors were covered with double layers of tin foil and 
fixed with autoclave tape, including the air filters, which were covered with only one layer of tin 
foil. The chemostat vessel together with the various tubes and bottles was autoclaved once. 
Following autoclaving, the equipment was stored at room temperature for 1 week to dry, prior 
to loading the culture medium and calibrating the pO2 probe. After the drying period, the pO2 
and pH probes, attached to the chemostat vessel, were connected to the chemostat 
controller, and the gas inlet of the chemostat vessel was connected to the gas supply via a 
filter. In addition, the water inlet and outlet of the condenser, attached to the headplate of the 
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chemostat vessel, were also connected to the water supply and drainage, respectively, of the 
chemostat control unit (Figure 6.9). The chemostat vessel was then filled with 2.5 L of culture 
medium using a peristaltic pump, and wrapped with its silicone-rubber heater, which was 
connected to the chemostat controller. The thermocouple (PT100) monitoring the temperature 
in the vessel was also connected to the controller and then inserted inside a closed-end 
stainless steel sleeve, which was immersed in the chemostat vessel and its outer surface was 
in contact with the culture medium. Finally, the motor of the stirrer was attached to the 
chemostat vessel headplate and the stirrer was set running at 100 rpm. 
For all bioreactor studies involving cell-seeded scaffolds, the cell culture medium (Chapter 2, 
Section 2.5.4) was supplemented with 10 ml·L-1 of antifungal (amphotericin B). Initially, the 
cell culture medium was left in the chemostat vessel at 37°C for 3 days prior to the 
commencement of an experiment and its sterility was assessed by visual inspection of its 
transparency. If the culture medium in the chemostat was still transparent, the FBS was 
added to the medium on the day of the experiment. 
On the day of the commencement of the bioreactor experiments, the temperature in the 
chemostat vessel was raised to 42°C and the pO2 was calibrated. Prior to calibration, the pO2 
probe was left to equilibrate in the culture medium for at least 12 hours. The calibration was 
performed between 0% and 21% pO2. The 0% pO2 was set by pumping 100% N2 into the 
chemostat vessel through the sparger fitted at the bottom of chemosat vessel, and the 21% 
pO2 which was also used during the bioreactor cultures, was set by pumping 5% CO2 in air. 
During the experiments in the bioreactor, the level probe was switched on, and 5% (v/v) CO2 
in air was continuously pumped through the system at a flow rate of 0.1 L·min-1, to maintain a 
pH value of 7.4 and a pO2 level of 21%.  
 
 180 
 
 
Figure 6.9: The chemostat system with its vessel loaded with culture medium. 
 
6.7 Discussion 
This chapter described the design, set up and calibration of the biaxial strain bioreactor used 
in this project for the conditioning of cell seeded pericardial scaffolds. The bioreactor was 
calibrated in order to exert a tensile strain value of 10% at a frequency of 1 Hz to the cultured 
tissues under a mode of cyclic inflation/deflation. The tensile strain of 10% was chosen as 
being representative of the maximum physiological strain experienced by the MV leaflets 
during the cardiac cycle, obtained through computational modelling of the MV apparatus 
(Roberts, 2012). Dynamic flexure induced by cyclic inflation/deflation has been reported as 
being the major mode of deformation of heart valve leaflets (Vesely et al., 1989). 
Several studies have focused on the use of cyclic flexure for the development of tissue 
engineered heart valves. Engelmayr et al. (2003) developed a bioreactor to study the effects 
of uniaxial cyclic flexure on the stiffness of non-cell-seeded polyglycolic acid (PGA) scaffolds. 
This bioreactor used a linear actuator to exert dynamic flexural deformation on the samples at 
1 Hz in order to emulate the cardiac cycle. Their finding indicated that dynamically flexed 
scaffolds were 72% (after three weeks) and 76% (after five weeks) less stiff than static 
controls and that they developed directional anisotropy after 3 weeks of conditioning. These 
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results suggested that dynamic flexure can produce significant changes in the mechanical 
properties of scaffolds. The same system was used by the same group in an additional study 
with ovine SMCs seeded on PGA and poly-L-lactic acid (PLLA) scaffolds (Engelmayr et al., 
2005). Seeded and unseeded scaffolds were subjected to cyclic uniaxial three-point flexure at 
1 Hz and amplitude of 6.35 mm for up to 3 weeks. They reported that cyclic flexure increased 
stiffness, collagen production, and transmural cell distribution compared to static controls. 
In another study, Engelmayr et al. (2006) investigated the effects of cyclic flexure and laminar 
flow on PGA and PLLA scaffolds seeded with ovine MSCs and conditioned in a flex-stretch-
flow bioreactor for 1 and 3 weeks. The laminar flow was provided by culture medium 
recirculation within the bioreactor, whereas cyclic flexure was applied at 1 Hz and a curvature 
of 0.554 mm-1. This value of curvature was obtained from a previous study on the opening and 
closing of trileaflet heart valves in vitro (Iyengar et al., 2001). The results from this study 
suggested that cyclic flexure and laminar flow could accelerate tissue formation within the cell 
seeded scaffolds. Merryman et al. (2007) investigated the influence of both biomechanical 
(cyclic tension) and biochemical factors on the phenotype and collagen biosynthesis of aortic 
valve interstitial cells by applying cyclic tension (15%) and transforming growth factor beta-1 
(TGF-β1). The choice of the tension magnitude was based on a previous study by Billiar and 
Sacks, (2000), which measured the physiological range of tension in aortic valve cusps. The 
study suggested that the presence of TGF- β1 and cyclic mechanical stimuli in vivo might lead 
to altered ECM architecture, compromised valve function, and ultimately degenerative valvular 
disease.  
Other studies have reported the use of similar strain values to the one used in the present 
study (10%). Balachandran et al. (2009) used the same bioreactor described by Engelmayr et 
al. (2003) to stimulate rectangular samples of porcine aortic cusps under cyclic tensile stretch 
at three levels of strain, including 10% (physiological; Thubrikar et al., 1980), 15% 
(pathological/hypertensive), and 20% (hyperpathological/severely hypertensive) at 1.167 Hz 
(70 beats/min), for 24 and 48h. The study investigated whether the elevated cyclic stretch 
could cause increased expression and activity of proteolytic enzymes in the valve cusp. The 
results indicated an altered cell turnover and increased expression of metalloproteinase and 
cathepsin, potentially leading to valve degeneration. In another study, Gupta et al. (2008) 
seeded collagen gels with MV interstitial cells or chordal cells and subjected them to 10% 
strain at 1.167 Hz for 24 h, followed by a static phase (relaxation) for 24 h. The results 
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showed that GAG secretion was significantly upregulated during cyclic stretch and 
downregulated during relaxation. 
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Chapter 7  
Bioreactor cultures 
7.1 Introduction 
Prior to the dynamic conditioning of the decellularised cell-seeded pericardial scaffolds in the 
biaxial strain bioreactor, it was necessary to optimise the culture conditions in terms of oxygen 
supply, pH and temperature maintenance, tissue sterility and cell viability. This chapter 
describes the series of experiments performed during the optimisation of the static cultures, 
as well as the results from short-term (1 day) dynamic conditioning of decellularised 
pericardial scaffolds seeded with porcine mesenchymal stem cells (pMSCs). Initially, fresh 
porcine pericardia were cultured under static conditions in the bioreactor stations and in 
separate tissue holders, in order to optimise the static culture in terms of pO2, pH and 
temperature. Subsequently, decellularised pericardia were seeded with pMSCs and cultured 
in the bioreactor under static and then 10% dynamic strain with a view to investigating the 
effect of this strain on the cell viability in the construct. Pericardial scaffolds seeded with 
pMSCs were also maintained in static culture, in both the bioreactor and in separate tissues 
holders, and used as controls.  
 
7.1.1 Aims and objectives 
Aims: 
The aim of the work presented in this chapter was to investigate the static and dynamic 
culture of decellularised pericardial scaffolds seeded with pMSCs, and to investigate the effect 
of 10% cyclic biaxial strain on the viability of the pMSCs.  
Objectives: 
The specific objectives were to:  
 Investigate the disinfection of fresh porcine pericardium using Cambridge antibiotic 
solution 
 Investigate the static culture of fresh pericardium under sterile conditions 
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 Investigate the static and dynamic culture of cell-seeded pericardial scaffolds in the biaxial 
bioreactor under sterile conditions 
 Investigate the effect of 10% dynamic strain on pMSC-seeded decellularised pericardial 
scaffolds. 
 
7.2 Disinfection of fresh pericardium  
Studies of the static culture conditions were firstly carried out using fresh pericardium. 
Therefore, it was necessary to ensure that the fresh pericardium was not contaminated with 
microbes that might affect the cell viability of the fresh tissue obtained from the abattoir. 
Cambridge antibiotic disinfection solution was used since it is the one most frequently used in 
tissue banks in the UK. The cell viability of the tissue treated with this solution was determined 
by the MTT assay (Chapter 2, Section 2.15). 
 
7.2.1 Materials and methods 
7.2.1.1 MTT assay validation 
The MTT assay was performed and validated as described in Chapter 2, Section 2.15 and 
2.15.1, respectively. The amount of tissue to be used was chosen on the basis of the standard 
absorbance curve (Section 7.2.2.1). 
7.2.1.2 Cambridge antibiotic treatment 
Fresh porcine pericardia were treated in Cambridge antibiotics for 3 different durations (30 
min, 1 and 2 h) to investigate the optimal time for effectively disinfecting the tissue without 
affecting its cell viability. The Cambridge antibiotics solution was supplied by the NHS Blood & 
Transplant Tissue Bank, Speke, Liverpool, UK. This antibiotic solution comprised of i) medium 
199 ii) HEPES (14.7 g·L-1; Sigma M2520), iii) vancomycin HCl USP (0.2 g·L-1; Sigma V8138), 
iv) polymyxin B sulphate (0.2 g·L-1; Sigma P0972), v) nystatin (2.5 million units·L-1; irradiated), 
vi) imipenem/cilastatin sodium (0.25 g·L-1), vii) gentamicin sulphate (4 g·L-1). 
7.2.1.3 Tissue disinfection  
Thirty-six fresh porcine pericardial tissue samples with a size of 9 x 6 cm2 were dissected, 
(Chapter 2, Section 2.8), providing 12 samples for each duration of antibiotic treatment (30 
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min, 1 and 2 h). For each time, 3 samples were treated at 37° C in 60 ml each of Cambridge 
antibiotics; 3 were processed for MTT assay immediately after dissection (positive control at 0 
min treatment); 3 were kept in 60 ml each of cell culture medium at 37°C (positive control) 
and 3 in 60 ml each of 10% (v/v) NBF (negative control) at 37°C. Triplicates of tissue 
weighing 50 mg (wet weight) were used for each pericardium of each group for MTT assay. In 
addition, one piece of tissue (5 mm2) of each of the pericardial samples treated in Cambridge 
antibiotics was cut prior and after treatment and processed for sterility assessment, as 
described in Chapter 4, Section 4.2.2.4.  
 
7.2.2 Results 
7.2.2.1 MTT assay validation  
Following the MTT assay, the absorbance was read at 570 nm with a reference filter at 630 
nm and plotted against the corresponding weights of fresh pericardial samples (Figure 7.1). 
For weights above 100 mg, the optical density decreased. Thus, it was decided to perform a 
dilution of 1 in 2 in order to investigate whether the decrease was related to a high signal from 
the samples weighing more than 100 mg. The results after the dilution showed that the values 
of optical density above 100 mg still decreased; there was a plateau between 100 and 150 mg 
and then the optical density decreased (Figure 7.2). The decrease in absorbance for samples 
weighing above 100 mg was probably related to the large amount of tissue, which did not 
allow for adequate permeation of the MTT solution throughout the inner mass of tissue. Thus, 
only the optical densities corresponding to sample weights between 0 and 100 mg were 
included in the final standard absorbance curve (Figure 7.3). A tissue weight of 50 mg was 
chosen for subsequent experiments. 
 186 
 
 
Figure 7.1: Optical density against wet weight (mg) of fresh pericardial samples following MTT 
assay. Data expressed as means (n=3) ± 95% C.I. 
 
Figure 7.2: Optical density after 1 in 2 dilution against wet weight (mg) of fresh pericardial 
samples following MTT assay. Data expressed as means (n=3) ± 95% C.I. 
 
 
Figure 7.3: Standard curve of optical density vs wet weight of tissue for the MTT assay. Data 
expressed as means (n=3) ± 95% C.I. 
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7.2.2.2 Tissue disinfection   
Following treatment with the Cambridge antibiotics solution for different durations (30 min, 1 h 
and 2 h), the fresh pericardial samples were assayed for cell viability using the MTT assay 
and the absorbance was read at 570 nm with a reference filter at 630 nm.  The optical density 
values of the test and control groups are illustrated in Figure 7.4, 7.5 and 7.6. 
After 30 min treatment in Cambridge antibiotics, fresh pericardial tissue were sterile; no 
significant difference was observed between the levels of MTT conversion by the fresh 
pericardium treated in Cambridge and both fresh pericardium treated in cell culture medium 
(positive control) and fresh pericardium processed immediately after dissection (positive 
control at 0 min treatment), as shown in Figure 7.4. Fresh pericardium treated in 10% (v/v) 
NBF (negative control) showed significantly lower levels of MTT conversion compared to all 
the other groups (p < 0.05; MSD = 0.005). 
Similar observations were apparent following 1 h treatment of the pericardium (p < 0.05; MSD 
= 0.002), as shown in Figure 7.5. However, the samples treated in Cambridge antibiotics for 1 
hour, showed significantly lower levels of MTT conversion compared to those in culture 
medium (positive control). 
 
Figure 7.4: Cell viability of fresh pericardium treated in Cambridge antibiotics for 30 min (FP 
treated). Data expressed as means (n=3) ± 95% C.I. Asterisk and connectors indicate significant 
difference between originator and end-arrow column, as determined by ANOVA and calculation of 
MSD (p < 0.05; MSD = 0.005). FP in Formalin (-): fresh pericardium treated in 10% NBF (-ve control); 
FP (+): fresh pericardium treated in culture medium (+ve control); FP (+, 0min): fresh pericardium 
processed straight after dissection (+ve control at t = 0 min). 
 
 188 
 
 
 
Figure 7.5: Cell viability of fresh pericardium treated in Cambridge antibiotics for 1 h (FP 
treated). Data expressed as means (n=3) ± 95% C.I. Asterisk and connectors indicate significant 
difference between originator and end-arrow column, as determined by ANOVA and calculation of 
MSD (p < 0.05; MSD = 0.002). FP in Formalin (-): fresh pericardium treated in 10% NBF (-ve control); 
FP (+): fresh pericardium treated in culture medium (+ve control); FP (+, 0min): fresh pericardium 
processed straight after dissection (+ve control at t = 0 min). 
 
After the 2 h treatment with Cambridge antibiotics, the samples were also sterile, and the 
levels of MTT conversion by the samples treated in 10% (v/v) NBF were significantly lower 
compared to the other groups (Figure 7.6; p < 0.05, MSD = 0.004). The level of MTT 
conversion by the samples treated in culture medium (positive control) were significantly 
higher compared to both the samples processed immediately after dissection (positive control 
at t = 0 min) and the samples treated in Cambridge antibiotics. Therefore, the optimum time 
point for the disinfection of fresh pericardium was 30 min, which represented the shortest 
duration for disinfecting the tissue without affecting its viability.  
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Figure 7.6: Cell viability of fresh pericardium treated in Cambridge antibiotics for 2 h (FP 
treated). Data expressed as means (n=3) ± 95% C.I. Asterisk and connectors indicate significant 
difference between originator and end-arrow column, as determined by ANOVA and calculation of 
MSD (p < 0.05; MSD = 0.004). FP in Formalin (-): fresh pericardium treated in 10% NBF (-ve control); 
FP (+): fresh pericardium treated in culture medium (+ve control); FP (+, 0min): fresh pericardium 
processed straight after dissection (+ve control at t = 0 min). 
 
7.3 Static culture of fresh pericardium 
7.3.1 Overview 
Fresh pericardial samples were cultured statically in the bioreactor stations and in separate 
tissue holders, in order to validate the bioreactor system in terms of sterility and culture 
medium perfusion. The bioreactor was originally designed to operate with two dynamically-
conditioned samples and two statically-maintained samples as controls. In order to increase 
the number of dynamically-conditioned samples per experiment to four, this series of 
experiments was carried out to investigate whether there was a difference between samples 
maintained statically in the bioreactor stations and static controls maintained in separate 
tissue holders. The experiments were designed to investigate the sterility, viability and 
histoarchitecture of samples maintained in static cultures for 1 day. The 1 day experiments 
were repeated three times (method 1, 2 & 3) to optimise the system in terms of both tissue 
viability and maintenance of sterility. Fresh pericardial samples were cultured in tissue 
holders, which were housed in culture tubs and placed in an incubator, and in bioreactor 
stations for 1 day. The stations were mounted to the bioreactor and wrapped with their heating 
element to maintain a temperature of 37°C.  
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7.3.2 Materials and methods 
7.3.2.1 Sterilisation and calibration of equipment  
Prior to each experiment, the tissue holders and bioreactor stations were sterilised as 
described in Chapters 5 Section 5.3.1.1 and Chapter 6, Section 6.6, respectively.  
7.3.2.2 Pericardium dissection and disinfection 
For each experiment, 12 fresh pericardial samples were dissected, as described in Chapter 2, 
Section 2.8, from 12 different pericardia (Figure 7.7). Four of the samples were loaded to the 
bioreactor stations, 4 to the tissue holders (positive control for MTT assay, live/dead staining, 
and histology) and 4 were treated in 10% (v/v) NBF (negative control for MTT assay). The 
positive control and the samples loaded on the bioreactor stations were cut in a rectangular 
shape, (9 x 6 cm2 in size), and crosswise at one of the edges to identify the mesothelial 
surface; they were then treated in 60 ml of Cambridge antibiotics for 30 min at 37°C and cut 
to size for loading on either the tissue holders or the bioreactor stations. The tissue remaining 
after the cutting of each pericardial sample (tissue remnant) before treatment in antibiotic 
solution, was used as the positive control at t = 0 for (i) MTT assay (50 mg) (ii), histological 
analysis (iii), live/dead staining (with the exception of the samples for method 1) and (iv) 
sterility assessment, (Chapter 2 Section 2.15, 2.11.1, 2.16, and Chapter 4, Section 4.2.2.4, 
respectively) (Figure 7.7).  
 
Figure 7.7: Isolation of fresh porcine pericardial samples. The samples (9 × 6 cm2) were cut 
crosswise at one of their edges to identify the mesothelial surface. The remaining tissue (tissue 
remnant), was used as a positive control for MTT assay, H&E and live/dead staining (with the 
exception of the samples for method 1 which were not processed for live/dead staining). 
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7.3.2.3 Loading of bioreactor stations and tissue holders 
Unless otherwise stated, all work was carried out in class II laminar flow cabinet. Following 
disinfection, the bioreactor station and tissue holder samples were transferred aseptically into 
individual sterile pots filled with 60 ml culture medium, and then loaded onto the bioreactor 
stations and tissue holders. The samples were loaded on the tissue holders and then placed 
in culture tubs, as described in Chapter 5, Section 5.2.1. Prior to loading on the bioreactor 
station, tissue was cut to size with the sterile cutting guide. The procedure for loading samples 
on the bioreactor stations is illustrated in Figure 7.8c: the upper station part was separated 
from the bottom and placed on the sterile loading guide (Figure 7.8a, b and d). The upper part 
was then separated from the central disk (Figure 7.8e) and the sample was placed onto the 
central disk. The upper station part was then placed back onto the central disk and screwed to 
it (Figure 7.8f). The upper part of the station was then screwed back to the lower part. The 
procedure of loading the culture medium in the stations varied at each experiment, due to 
continuous optimisation of the system.   
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Figure 7.8: Loading tissue and cell culture medium on the bioreactor stations. The loading guide 
and the various components of the bioreactor station are illustrated in the Figure (a, b and c, d, e).   
 
7.3.2.4 One day static culture (method 1) 
Fresh pericardial samples were dissected, disinfected and loaded to the bioreactor stations 
and holders as described in Sections 7.3.2.2 and 7.3.2.3. The bioreactor stations were then 
filled with culture medium using a peristaltic pump, in order to facilitate the escape of the air 
trapped in the lower part of the station. Prior to loading the medium, the external port of the 
upper part of the station was sealed off. Culture medium was then pumped into the lower part 
of the station until it filled the interconnected upper part up to height of approximately 3 mm 
(Figure 7.9). The tube connected to the bottom part of the station was sealed off. Each of the 
stations were then mounted to the main bioreactor and wrapped with their heating element in 
order to maintain the temperature at 37°C. 
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Figure 7.9: Filling of the bioreactor stations with culture medium (method 1). Photograph (a) and 
schematic (b) of the bioreactor station. During filling, the top tube was sealed off (b) and the culture 
medium was pumped into the lower part until the level in the top part was 3 mm above the samples.  
 
After 1 day of static culture, the bioreactor station (Bior. Stations group) and tissue holder (T. 
Holders group) samples were harvested aseptically and assessed for their viability (MTT 
assay), sterility, and histoarchitecture (H&E). In addition, samples from the remnants of the 
pericardia used to isolate the station (Bior. Remn. Group; positive control) and holder (T. H. 
Remn. group; positive control) samples, together with samples treated in 10% (v/v) NBF 
(Tissue in formalin group; negative control), were also assessed for their viability, sterility and 
histoarchitecture. 
7.3.2.5 One day static culture (method 2) 
The 1 day static culture experiment was repeated due to issues with air entrapment in the 
stations, underneath the tissue, using method 1 (Section 7.3.2.4) for the culture medium 
loading procedure. For this reason, the design of the station was slightly changed by adding a 
stopcock and a tube open to the atmosphere, (Figure 7.10). Fresh pericardial samples were 
isolated, disinfected and loaded to the bioreactor stations and tissue holders as described in 
Sections 7.3.2.2 and 7.3.2.3. The cell culture medium was bubbled with 5% (v/v) CO2 in air for 
10 min, and then it was loaded in a sterile bottle fitted with a filter and a tube, used for 
subsequent filling of the station. The tube of the sterile bottle was then attached to a peristaltic 
pump and primed to remove the air in it; then it was connected to the bioreactor station. 
During filling, the station was kept horizontally, with the stopcock opened to the atmosphere 
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(Figure 7.10) and medium was pumped in the station through the port of the bottom part. 
When medium started leaking, the stopcock was turned to seal the port from the atmosphere 
(the tube itself was also sealed off by clamping) and direct the flow towards the upper part of 
the station. The medium was then allowed to flow in the upper part until a head of 3 mm was 
developed above the samples. Following filling, the stations were mounted to the main 
bioreactor and wrapped with their heating element in order to maintain the temperature at 
37°C during the culture. 
 
Figure 7.10: Filling of the bioreactor stations with culture medium (method 2). Photograph (a) 
and schematic (b) of the bioreactor station. During filling, the port of the upper part was sealed off (b), 
and the stopcock was opened to the atmosphere. Culture medium was pumped into the lower part, 
which was kept horizontally. When medium started leaking, the stopcock was turned to seal the port 
from the atmosphere and direct the flow towards the upper part. 
 
After 1 day of static culture, the bioreactor station (Bior. Stations group) and tissue holder (T. 
Holders group) samples were harvested and assessed for viability (MTT assay and live/dead 
staining), sterility and histoarchitecture (H&E). In addition, samples from the remnants of the 
pericardia used to isolate the station (Bior.Remn. group; positive control) and holder 
(T.H.Remn. group; positive control) samples, together with samples treated in 10% (v/v) NBF 
(Tissue in formalin group; negative control), were assessed for their viability, sterility and 
histoarchitecture. 
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7.3.2.6 One day static culture (method 3) 
The 1 day time point for static culture was repeated in order to improve the maintenance of 
the viability of samples in the stations with a better control of pO2 and pH. Fresh pericardial 
samples were isolated, disinfected and loaded to the bioreactor stations and tissue holders as 
described in Sections 7.3.2.2 and 7.3.2.3. The number of replicates for the tissue remnants 
groups (Bior.Remn. group and T.H.Remn. group; positive controls) was increased in order to 
decrease the high level of variability previously observed within each positive control group, 
so to improve the accuracy of measurements for the MTT assay. Four pieces of tissue were 
cut out of each pericardium and then averaged to obtain one positive control for each 
pericardial sample (Figure 7.11).  
HEPES (hydroxyethyl-piperazineethane-sulfonic acid buffer from Lonza; 25ml·L-1) was added 
to the cell culture medium to improve the maintenance of the pH at 7.2 during the 1 day static 
culture; then, it was bubbled with 5% (v/v) CO2 in air for 10 min, and finally loaded in the lower 
stations, as described in Section 7.3.2.5. After loading the bottom station, cell culture medium 
was added to the top station by using a different procedure so to improve the passive diffusion 
of the oxygen. The air filter at the top of the stations was then temporarily removed and 2 ml 
of culture medium was added in the upper top part with a syringe through the filter port. This 
ensured a head volume of culture medium of 2.8 mm above the samples, which allowed 
passive oxygen diffusion (Chapter 5, Section 5.2.1).  
 
Figure 7.11: Isolation of fresh porcine pericardial samples. The samples (9 × 6 cm2) were cut 
crosswise at one of their edges to identify the mesothelial surface. In the last 1 day static culture 
experiment (method 3), 4 pieces of tissue were taken from different regions of the same pericardium 
and used as the +ve control (tissue remnant) for MTT assay. 
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After 1 day of static culture, the bioreactor station (Bior. Stations group) and tissue holder (T. 
Holders group) samples were harvested and assessed for viability (MTT assay and live/dead 
staining), sterility and histoarchitecture (H&E). In addition, samples from the remnants of the 
pericardia used to isolate the station (Bior.Remn. group; positive control) and holder 
(T.H.Remn. group; positive control) samples, together with samples treated in 10% (v/v) NBF 
(Tissue in formalin group; negative control), and were assessed for their viability, sterility and 
histoarchitecture. 
 
7.3.3 Results 
7.3.3.1 One day static culture (method 1) 
Sterility assessment 
Following treatment in Cambridge antibiotics, the fresh pericardial samples used in the 
experiment were sterile. The sterility of the samples was maintained during the 1 day time 
static culture in the bioreactor stations and tissue holders, despite a leakage that was 
developed in one of the bioreactor stations. The leakage was developed at one of the 
polyvinylidene fluoride (PDVF) luer fittings used to connect the silicone tubing. These fittings 
could get damaged quite easily when they were screwed in the stations made of stainless 
steel. These fittings were replaced with stainless steel fittings in subsequent experiments. 
Cell viability- MTT assay 
The measured cell viability of the groups used in this experiment was averaged over the 
number of samples in each group (n = 4). The results are illustrated in Figure 7.12. The 
Tissue in Formalin group (negative control) demonstrated significantly lower cell viability 
compared to all the other groups, with the exception of the Bior.Stations group (p < 0.05; MSD 
= 0.009). The Bior.Stations group showed significantly lower viability compared to the 
T.H.Remn. group (positive control). The reduced viability of the Bior.Stations group was 
related to air entrapped underneath the samples in the bioreactor stations. Indeed, in spite of 
filling the stations with culture medium by employing a peristaltic pump, the samples were 
doming during the filling process, which was evidence of air entrapment. This caused 
inadequate supply of medium to both the top and bottom surfaces of the samples. 
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Figure 7.12: Cell viability (MTT assay) after 1 day static culture of fresh pericardium in 
bioreactor stations (Bior. Stations) and tissue holders (T. Holders) (method 1). The data also 
shows the viability of the remnants of the pericardia used to isolate the station (Bior.Remn.; +ve 
control) and holder (T.H.Remn.; +ve control) samples, together with the group treated in 10% (v/v) 
NBF (Tissue in formalin; -ve control). Data expressed as means (n=4) ± 95% C.I. Asterisk/connectors 
indicate significant difference between originator and end-arrow column (ANOVA and calculation of 
MSD) (p < 0.05; MSD = 0.009). 
 
Histological analysis 
The general histoarchitecture of the fresh pericardial samples cultured in both the bioreactor 
stations and the tissue holders appeared to be intact (Figure 7.13). The mesothelial cell layer 
was partially intact in most of the bioreactor station samples (Figure 7.13b, l, p). One of the 
station samples showed a complete loss of mesothelium, and the same was observed for its 
correspondent positive control (Figure 7.13f and e, respectively). A high loss of the 
mesothelium was observed in 3 of the tissue holder samples. However, this was also 
apparent in their positive controls (Figure 7.13h, n, r and g, m, q respectively). 
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Figure 7.13: H&E stained sections of pericardial samples (n = 4) after 1 day static culture in the 
bioreactor stations (Bior. Stations; b, f, l and p) and tissue holders (T. Holder; d, h, n and r) 
(method 1). The figure also includes H&E-stained sections of the remnants of the pericardia used to 
isolate the station (Bior.Remn. (+); a, e, i and o) and holder (T.H.Remn. (+); c, g, m and q) samples. E: 
epipericardial surface; M: mesothelial surface. Scale bar indicates 200 µm. 
 
7.3.3.2 One day static culture (method 2) 
Sterility assessment 
Following treatment in Cambridge antibiotics, the pericardial samples used in the experiment 
were sterile. The sterility of the samples was maintained during the 1 day static culture. 
Cell viability - MTT assay 
The averaged viability of the samples cultured statically for 1 day according to method 2, 
together with their controls, is shown in Figure 7.14. The viability of the Tissue in Formalin 
group was significantly reduced compared to the Bior.Remn and T.H.Remn groups, but not 
compared to the Bior.Stations and T.Holders ones (p < 0.05; MSD = 0.006). The Bior.Stations 
group showed significantly lower viability compared to the T.H.Remn. group. The cause for 
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the drop in viability of the Bior.Stations group was related to a not appropriate oxygen and pH 
control. Also, a high variability in the viability values of samples was observed. 
 
 
Figure 7.14: Cell viability (MTT assay) after 1 day static culture of fresh pericardium in 
bioreactor stations (Bior. Stations) and tissue holders (T. Holders) (method 2). The data also 
shows the viability of the remnants of the pericardia used to isolate the station (Bior.Remn.; +ve 
control) and holder (T.H.Remn.; +ve control) samples, together with the group treated in 10% (v/v) 
NBF (Tissue in formalin; -ve control). Data expressed as means (n=4) ± 95% C.I. Asterisk/connectors 
indicate significant difference between originator and end-arrow column (ANOVA and calculation of 
MSD) (p < 0.05; MSD = 0.006). 
 
Histological analysis 
Following the 1 day culture, the general histoarchitecture of the bioreactor station and tissue 
holder samples appeared to be intact, (Figure 7.15). Absence of mesothelium was observed 
in 2 of the station samples (Figure 7.15b, f). However, the positive controls for these samples 
(Figure 7.15a, e) were also absent of mesothelium. Mesothelium presence was observed in 
all 4 positive controls of the tissue holder samples (Figure 7.15c, g, m q). However, only 2 of 
the tissue holder samples (Figure 7.15h, n) maintained their mesothelium after 1 day static 
culture.  
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Figure 7.15: H&E stained sections of pericardial samples (n = 4) after 1 day static culture in the 
bioreactor stations (Bior. Stations; b, f, l and p) and tissue holders (T. Holder; d, h, n and r) 
(method 3). The figure also includes H&E-stained sections of the remnants of the pericardia used to 
isolate the station (Bior.Remn. (+); a, e, i and o) and holder (T.H.Remn. (+); c, g, m and q) samples. E: 
epipericardial surface; M: mesothelial surface. Scale bar indicates 200 µm. 
 
Cell viability - Live/dead staining 
The live/dead staining of the samples cultured in the stations and holders according to Method 
3, together with their controls, is shown in Figure 7.16. Most cells were stained red (dead) on 
the mesothelial surface, which also demonstrated a high level of green autofluorescence. 
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Figure 7.16: Live/dead stained pericardial samples (n = 4) after 1 day static culture in bioreactor 
stations (Bior. Stations; b, f, l and p) and tissue holders (T. Holder; d, h, n and r) (method 2). 
The figure also shows the live/dead stained remnants of the pericardia used to isolate the station 
(Bior.Remn. (+); a, e, i and o) and (T.H.Remn. (+); c, g, m and q) samples. Dead cells were stained 
red and live cells green. Scale bars indicate 200 µm. 
 
7.3.3.3 One day static culture (method 3) 
Sterility assessment 
Following treatment in Cambridge antibiotics, the pericardial samples used in the experiment 
were sterile. The sterility of the samples was maintained during the 1 day static culture. 
Cell viability - MTT assay 
The averaged viability of the bioreactor station and tissue holder groups cultured statically for 
1 day according to Method 3, together with their controls, is shown in Figure 7.17. All groups, 
except the Bior.Stations. group, demonstrated significantly higher viabilities compared to the 
Tissue in Formalin group (negative control) (p < 0.05; MSD = 0.005). In spite of using control 
samples from 4 different regions of each pericardium used to isolate each of the bioreactor 
station and tissue holder samples (Figure 7.17), there was still a high variability in the 
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Bior.Remn and T.H.Remn. groups. Indeed, a high level of variability was observed in the cell 
viability values of the 4 different portions of tissue cut out of the same pericardium, suggesting 
that, depending on the area considered of the same pericardium, there were different levels of 
viability. Also, within the T.Holders group, some of the samples showed low values of viability, 
similar to those obtained for the bioreactor stations group.  
This suggested uneven cell viability/cell distribution across the fresh pericardia used in the 
study, and indicated the use of a tissue in which the cell viability was better controlled. It was 
decided that a cell-seeded decellularised pericardial scaffold might offer better control over 
cell number/viability.  
 
Figure 7.17: Cell viability (MTT assay) after 1 day static culture of fresh pericardium in 
bioreactor stations (Bior. Stations) and tissue holders (T. Holders) (method 3). The data also 
shows the viability of the remnants of the pericardia used to isolate the station (Bior.Remn.; +ve 
control) and holder (T.H.Remn.; +ve control) samples, together with the group treated in 10% (v/v) 
NBF (Tissue in formalin; -ve control). Data expressed as means (n=4) ± 95% C.I. Asterisk/connectors 
indicate significant difference between originator and end-arrow column (ANOVA and calculation of 
MSD) (p < 0.05; MSD = 0.005). 
 
Histological analysis 
In general, the histoarchitecture and mesothelium of the test and control samples appeared to 
be intact (Figure 7.18). However, sample 1 of the Bior.Stations group (Figure 7. 18b) and 
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sample 3 of the T.Holders group (Figure 7.18n) were void of a mesothelium, in contrast to 
their control. 
 
 
Figure 7.18: H&E stained sections of pericardial samples (n = 4) after 1 day static culture in the 
bioreactor stations (Bior. Stations; b, f, l and p) and tissue holders (T. Holder; d, h, n and r) 
(method 3). The figure also includes H&E-stained sections of the remnants of the pericardia used to 
isolate the station (Bior.Remn. (+); a, e, i and o) and holder (T.H.Remn. (+); c, g, m and q) samples. E: 
epipericardial surface; M: mesothelial surface. Scale bar indicates 200 µm. 
 
Cell viability - Live/dead staining 
The live/dead staining of the samples cultured in the stations and holders according to Method 
3, together with their controls is shown in Figure 7.19. Most cells were stained red (dead) on 
the mesothelial surface, which also demonstrated a high level of green autofluorescence. 
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Figure 7.19: Live/dead staining of pericardial samples (n = 4) after 1 day static culture in 
bioreactor stations (Bior. Stations; b, f, l and p) and tissue holders (T. Holder; d, h, n and r) 
(method 3). The figure also shows the live/dead stained remnants of the pericardia used to isolate the 
station (Bior.Remn. (+); a, e, i and o) and holder (T.H.Remn. (+); c, g, m and q) samples. Dead cells 
were stained red and live cells green. Scale bars indicate 200 µm. 
 
7.4 Static and dynamic bioreactor cultures of cell-seeded scaffolds 
7.4.1 Overview 
The purpose of this part of the study was to investigate the cell viability and histoarchitecture 
of pMSC-seeded decellularised porcine pericardial scaffolds, cultured either dynamically in 
the bioreactor or statically in tissue holders for 1 day. Dynamic experiments with fresh 
pericardium to optimise the dynamic cultures could not be performed due to the high 
variability in the cell viability of the available tissue. The culture medium loading technique, 
and pO2 and pH control, developed during the static cultures with fresh pericardium were used 
during the experiments with the seeded scaffolds. The experiments were designed to 
investigate the sterility, viability and histoarchitecture of the seeded pericardial scaffolds 
maintained in static and dynamic cultures. The experiments that were performed are 
summarised below: 
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A. One day static culture: Decellularised pericardial samples were seeded with pMSCs and 
cultured statically in either bioreactor stations or tissue holders to investigate any potential 
differences in the viability between samples cultured in bioreactor stations and in tissue 
holders. This was necessary in order to assess whether samples cultured in the tissue 
holders could be used as static controls.    
B. One day dynamic cultures (methods 1 & 2): Decellularised pericardial samples were 
seeded with pMSCs and cultured either in the bioreactor dynamically, or in tissue holders 
statically to investigate the effect of dynamic culture on pMSCs viability and alignment, and 
scaffold histoarchitecture.    
 
7.4.2 Materials and methods  
7.4.2.1 Sterilisation and calibration of the equipment 
Prior to each experiment, the tissue holders and bioreactor stations were sterilised as 
described in Chapters 5, Section 5.3.1.1 and Chapter 6, Section 6.6, respectively. The 
chemostat was sterilised and calibrated as described in Chapter 6. The chemostat was used 
only during the dynamic experiments, in order to avoid the waste of a large amount of medium 
in case of contamination or failure of the static experiment. The culture medium (2.5 L) added 
to the chemostat was prepared as described in Chapter 6, Section 6.6. 
7.4.2.2 Decellularisation and seeding of pericardium 
Unless otherwise stated, all work was carried out in class II laminar flow cabinet. For each 
experiment, 8 fresh pericardial samples were decellularised as described in Chapter 4, 
Section 4.2.1.2, then cut into size and mounted to tissue holders, as described in Chapter 5, 
Section 5.3.1.2. The holders were then placed in culture tubs, filled with 105 ml of medium 
and the scaffolds were seeded with pMSCs at P5 and at a density of 1×105 cells·cm-2 
(Chapter 5, Section 5.3.1.2), and cultured statically for 3 days at 37°C in an incubator with an 
atmosphere of 5% (v/v) CO2 in air. The remaining decellularised tissue was used as negative 
control for the MTT assay. 
7.4.2.3 Loading of bioreactor stations and tissue holders 
All work was carried out in class II laminar flow cabinet. Following the 3 days of static culture 
in the tissue holders, half of the samples (n = 4 for each experiment) were aseptically 
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unloaded from the tissue holders and transferred to the bioreactor stations as described in 
Section 7.3.2.3, and cultured statically or dynamically for 1 day. The other 4 samples were 
maintained in the tissue holders in the incubator (positive control). The bioreactor stations 
were filled with culture medium as described in Section 7.3.2.6 for both static and dynamic 
studies, but only during dynamic studies the stations were filled directly from the chemostat, 
and HEPES and 5% (v/v) CO2 in air were not added to the cell culture medium. 
7.4.2.4 One day static culture 
Following the 3-day static seeding of the pericardial scaffolds (Section 7.4.2.2), 4 out of the 8 
samples were maintained in static culture in the tissue holders in the incubator (T.Holders 
group), and the other 4 were transferred to stand-alone bioreactor stations (Bior.Stations), as 
described in Section 7.4.2.3. Subsequently, the stations were filled as described in Section 
7.3.2.6, and mounted on the main bioreactor, and then they were wrapped with their heaters 
to maintain 37°C. After 1 day of static culture, the samples from both groups were harvested 
and assessed for their sterility, cell viability (MTT assay and live/dead assay), and 
histoarchitecture (H&E). 
7.4.2.5 One day dynamic culture (method 1) 
The chemostat vessel was filled with 2.5 L of culture medium, which was prepared and 
calibrated as described in Chapter 6, Section 6.6, with the addition of antifoam (0.05% v/v; 
Sigma). Following the 3-day static seeding of the pericardial scaffolds (Section 7.4.2.2), 4 out 
of the 8 samples were maintained in static culture in the tissue holders in the incubator 
(T.Holders group), and the other 4 were transferred to stand-alone bioreactor stations 
(Bior.Stations), as described in Section 7.4.2.3. The stations were then filled directly from the 
chemostat using the 4-channel peristaltic pump. Four tubes were loaded on the peristaltic 
pump, one per each station; one tube only was used for filling all the 4 stations while the 
others were sealed off. The technique used for filling the station was similar to that described 
in Section 7.3.2.6. The upper station was filled by pumping the medium to just above the 
height of the inlet port of the tube connecting the upper and lower station, to avoid air 
entrapment during dynamic motion of the medium. After filling, each station was mounted to 
the main bioreactor and connected to the inlet tube from the chemostat and to the outlet tube 
to the reservoir. The stations were then wrapped with their heaters to maintain a temperature 
of 37°C. Subsequently, the bioreactor actuator was set to produce 10% dynamic strain, and 
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the samples were dynamically conditioned for 1 day. During the experiment, medium from the 
chemostat was continuously perfused to the stations using the 4-channel peristaltic pump. 
After 1 day, the statically-maintained and dynamically-conditioned samples were harvested 
and assessed for their sterility, cell viability (MTT assay and live/dead assay), and 
histoarchitecture (H&E). 
7.4.2.6 One day dynamic culture (method 2)  
Due to persisting issues with air entrapment in both the bioreactor stations and the bioreactor 
chamber (Figure 6.1), which was filled with water and transferred the volume displacement 
generated by the actuator to the bioreactor chambers, the dynamic experiment (Section 
7.4.2.5) was repeated. The method of filling the stations was performed with the outmost care 
to remove the air entrapped underneath the seeded pericardial membrane. The height of the 
medium above the pericardial membrane was also monitored during mechanical conditioning 
of the samples; if the height reduced the medium pump speed was increased to avoid air 
escaping from the upper to the lower station. The medium flow rate was finally set at 10 
ml·min-1. The presence of air in the bioreactor chamber, underneath the bottom silicone 
membrane of some stations, caused an unequal volume displacement between the 4 stations 
and, therefore, slightly different strain levels between the samples. During this experiment, 
outmost care was taken to avoid air trapped within the bioreactor chamber. This was achieved 
by pumping some additional water in the bioreactor chamber, after mounting the stations, until 
all the air trapped underneath the silicone membranes of the 4 stations was removed. 
 
7.4.3. Results 
7.4.3.1 One day static culture 
Sterility assessment 
The pMSC-seeded scaffolds in both the tissue holders and bioreactor stations were sterile 
after 1 day of culture.  
Cell viability - MTT assay 
The calculated cell viability values of the test and control groups had to be discarded due to a 
technical fault with the Micro plate spectrophotometer used for measuring the optical densities 
of the samples.  
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Histological analysis 
After 1 day of culture, the histoarchitecture of the pMSC-seeded scaffolds maintained 
statically in both the bioreactor stations and tissue holders was intact (Figure 7.20 and 7.21, 
respectively). All samples of both the Bior.Stations and T.Holders groups demonstrated an 
almost continuous layer of pMSCs on the mesothelial surface (seeding surface). In addition, 
there was evidence of cells penetrating the thickness of the scaffold. 
 
 
Figure 7.20: H&E stained sections of pMSC-seeded scaffolds (n = 4) after 1 day static culture in 
the bioreactor stations (Bior.Stations; a - d). Cells started penetrating through the thickness of the 
scaffold, as indicated by the red arrows. M: mesothelial surface. Scale bar indicates 200 µm. 
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Figure 7.21: H&E stained sections of pMSC-seeded scaffolds (n = 4) after 1 day static culture in 
the tissue holders (T.Holders; a - d). Cells started penetrating through the thickness of the scaffold, 
as indicated by the red arrows. M: mesothelial surface. Scale bar indicates 200 µm. 
 
Cell viability - Live/dead staining 
The pMSCs in both the bioreactor station and tissue holder samples appeared to be stained 
green (live) after 1 day of static culture (Figure 7.22 and 7.23), with the exception of one of the 
tissue holder samples, which showed a high amount of dead red cells (Figure 7.23a). The 
high amount of dead cells in this sample might have been related to cell senescence or 
inadequate cell attachment to the scaffold. Cells counting revealed similar numbers of live 
cells in the two groups, with the Bior.Stations group scoring 80-94 % live cells, and the 
T.Holders group 81-88 %. The tissue holder sample that demonstrated the high amount of 
red-stained cells, scored only 20% live cells. These results suggested that there was no 
difference in terms of viability between the constructs cultured statically in the tissue holders 
and bioreactor stations. Thus, the tissue holders could be used as static controls during the 
dynamic experiments. 
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Figure 7.22: Live/dead stained pMSC-seeded scaffolds (n = 4) after 1 day of static culture in the 
bioreactor stations (Bior.Stations; a - d). Dead cells were stained red and live cells green. Scale 
bars indicate 200 µm. 
 
 
Figure 7.23: Live/dead stained pMSC-seeded scaffolds (n = 4) after 1 day of static culture in 
tissue holders (T.Holders; a - d). Dead cells were stained red and live cells green. Scale bar 
indicates 200 µm 
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7.4.3.2 One day dynamic culture (method 1) 
Sterility assessment 
After 1 day of culture, both the statically-maintained and dynamically-conditioned pMSC-
seeded scaffolds were sterile. 
Cell viability - MTT assay 
The averaged viability of the dynamically-conditioned (Bior.Stations; Method 1) and statically-
maintained (T.Holders) pMSC-seeded constructs after 1 day of culture, together with the 
negative control (decellularised pericardium), is shown in Figure 7.24. The T.Holder 
constructs demonstrated significantly increased viability compared to both the Bior.Station 
constructs and negative control (p < 0.05; MSD = 0.005). No significant difference was found 
between the Bior.Station constructs and negative control. This result was due to the high 
variability in the Bior.Station constructs viability values. Indeed, 2 samples showed very low 
viabilities, which were close to the mean of the negative control, whereas the other 2 showed 
viabilities similar to the T.Holder group. The decreased viability of the 2 dynamically-
conditioned samples was most likely due to the fact that during conditioning, the level of the 
culture medium in the bottom part of the stations hosting these two constructs dropped, 
probably due to air trapped in the bioreactor stations. This resulted to the bottom surface of 
the constructs not being in contact with the culture medium, and being deprived of nutrients 
during the dynamic culture.  
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Figure 7.24: Cell viability (MTT assay) of pMSC-seeded pericardial scaffolds after 1 day 
dynamic culture in bioreactor stations (Bior. Stations), and 1 day static culture in tissue 
holders (T.Holders) (method 1). The data also shows the viability of decellularised pericardium 
(dCELL pericardium; -ve control). Data expressed as means (n=4) ± 95% C.I. Asterisk/connectors 
indicate significant difference between originator and end-arrow column (ANOVA and calculation of 
MSD) (p < 0.05; MSD = 0.003). 
 
Histological analysis 
The histoarchitecture of both the statically-maintained and dynamically-conditioned pMSC-
seeded scaffolds was intact (Figure 7.25 and 7.26) after 1 day of culture. All samples of both 
groups demonstrated an almost continuous layer of pMSCs on the mesothelial surface 
(seeding surface). In addition, there was evidence of cells started penetrating the thickness of 
the scaffold, especially in the case of the T.Holders group.  
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Figure 7.25: H&E stained sections of pMSC-seeded scaffolds (n = 4) after 1 day of dynamic 
culture in the bioreactor stations (Bior.Stations; a - d) (method 1). Cells started penetrating 
through the thickness of the scaffold. M: mesothelial surface. Scale bars indicate 200 µm. 
 
Figure 7.26: H&E stained sections of pMSC-seeded scaffolds (n = 4) after 1 day of static culture 
in the tissue holders (T.Holders; a - d) (method 1). Cells started penetrating through the thickness 
of the scaffold, as indicated by the red arrows. M: mesothelial surface. Scale bars indicate 200 µm. 
 
Cell viability - Live/dead staining 
Two of the pMSC-seeded scaffolds, which were dynamically conditioned in the bioreactor, 
appeared to be stained heavily green, with a percentage of viable cells between 57 – 76% 
(Figure 7.27a, b). In these two samples, the cells appeared to be aligned along specific 
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directions. The other two dynamically-conditioned samples demonstrated only 4% - 21% 
viable cells (Figure 7.27c, d). The high amount of dead cells in these two samples was in 
accordance with the MTT assay results. In contrast to the bioreactor station samples, all 
tissue holder samples demonstrated a higher amount of live cells, with percentages between 
86 - 98% (Figure 7.28). 
 
Figure 7.27: Live/dead stained pMSC-seeded scaffolds (n = 4) after 1 day of dynamic culture in 
the bioreactor stations (Bior.Stations; a - d) (method 1). Dead cells were stained red and live cells 
green. Red arrows indicate cells aligned along specific directions. Scale bar indicates 200 µm. 
 
Figure 7.28: Live/dead stained pMSC-seeded scaffolds (n = 4) after 1 day of static culture in 
tissue holders (T.Holders; a - d) (method 1). Dead cells were stained red and live cells green. Scale 
bars indicate 200 µm. 
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7.4.3.3 One day dynamic culture (method 2)  
Sterility assessment 
After 1 day of culture, both the statically-maintained and dynamically-conditioned pMSC-
seeded scaffolds were sterile. 
Cell viability - MTT assay 
The averaged viability of the dynamically-conditioned (Bior.Stations; Method 2) and statically-
maintained (T.Holders) pMSC-seeded constructs after 1 day of culture, together with the 
negative control (decellularised pericardium), is shown in Figure 7.29. The T.Holders group 
demonstrated high variability due to 2 samples registering significantly lower viability values 
compared to the other 2 (almost half). This was in disagreement with the live/dead staining 
that showed all four T.Holder constructs expressing mostly viable cells (Figure 7.33). The 
probable cause of this discrepancy was the time taken to process these 2 samples. Indeed, 
these 2 samples were the first to be cut and put in the eppendorf with PBS only, waiting for 
the other samples to be harvested and cut before addition of the MTT solution. Thus, these 2 
samples were excluded from the analysis. Both the Bior.Stations and T.Holder groups 
demonstrated significantly increased viabilities compared to negative control (p < 0.05; MSD = 
0.002). No significant difference was found between the Bior.Stations and T.Holder groups.  
 
Figure 7.29: Cell viability (MTT assay) of pMSC-seeded pericardial scaffolds after 1 day 
dynamic culture in bioreactor stations (Bior. Stations; n = 4), and 1 day static culture in tissue 
holders (T. Holders; n = 2) (method 2). The data also shows the viability of decellularised 
pericardium (dCELL pericardium; -ve control; n = 4). Data expressed as means ± 95% C.I. 
Asterisk/connectors indicate significant difference between originator and end-arrow column (ANOVA 
and calculation of MSD) (p < 0.05; MSD = 0.003). 
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Histological analysis 
The histoarchitecture of both the dynamically-conditioned and statically-maintained pMSC-
seeded scaffolds was intact (Figure 7.30 and 7.31) after 1 day of culture. All samples of both 
groups demonstrated a layer of pMSCs on the mesothelial surface (seeding surface). In 
addition, there was evidence of cells penetrating the thickness of the scaffold. 
 
Figure 7.30: H&E stained sections of pMSC-seeded scaffolds (n = 4) after 1 day of dynamic 
culture in the bioreactor stations (Bior.Stations; a - d) (method 2). Cells started penetrating 
through the thickness of the scaffold, as indicated by the arrows. M: mesothelial surface. Scale bar 
indicates 200 µm. 
 
Figure 7.31: H&E stained sections of pMSC-seeded scaffolds (n = 4) after 1 day of static culture 
in the tissue holders (T.Holders; a - d) (method 2). Cells started penetrating through the thickness 
of the scaffold, as indicated by the arrows. M: mesothelial surface. Scale bar indicates 200 µm. 
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Cell viability - Live/dead staining 
Most of the pMSCs in both the dynamically-conditioned (Figure 7.32) and statically-
maintained (tissue holders) constructs (Figure 7.33) appeared to be stained green (live) after 
1 day of culture. The cell counting revealed 69 - 84% live cells for the dynamically-conditioned 
constructs and 96 - 97% live cells for the statically maintained constructs. Under the 
mechanical stimulation, the constructs in the bioreactor stations demonstrated significant cell 
alignment along specific directions (Figure 7.32a, c). 
 
Figure 7.32: Live/dead stained pMSC-seeded scaffolds (n = 4) after 1 day of dynamic culture in 
the bioreactor stations (Bior.Stations; a - d) (method 2). Dead cells were stained red and live cells 
green. Red arrows indicate cells aligned along specific directions. Scale bars indicate 200 µm. 
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Figure 7.33: Live/dead stained pMSC-seeded scaffolds (n = 4) after 1 day of static culture in 
tissue holders (T.Holders; a - d) (method 2). Dead cells were stained red and live cells green. Scale 
bars indicate 200 µm. 
 
7.5 Discussion 
This chapter described the culture of fresh and pMSC-seeded decellularised pericardium 
under static and dynamic conditions in tissue holders and bioreactor stations, with a view to 
developing the use of the bioreactor system and investigating the effect of MV-leaflet relevant 
mechanical stimulation on the cell-seeded scaffolds. This investigation was based on 
assessing the sterility and histoarchitecture of the cultured samples, as well as on the 
qualitative and quantitative assessment of their cell viability using live/dead staining and the 
MTT assay, respectively. The MTT assay is an enzyme-based assay and it depends on the 
mitochondrial activity and not cell viability per se, (Mosmann, 1983; Twentyman and 
Luscombe, 1987). Therefore, and since the MTT assay results might be misleading, live/dead 
staining was used in conjunction with the MTT assay. 
Prior to the tissue cultures, it was necessary to ensure sterility of the fresh pericardium in 
order to be used in the cultures. The Cambridge antibiotics solution, which included a cocktail 
of different antibiotics, was used for disinfection of the fresh pericardium, since it is the most 
commonly used disinfection solution employed by the NHS Tissue Bank. Fresh pericardium 
treated in Cambridge antibiotics was sterile at every time point considered (30mins, 1h and 
2h); all the groups had significantly higher viability compared to the negative control at each 
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time point, thus, the lowest time point (30 min) was chosen as the optimum to be used for 
future experiments. The viability of the positive control stored in cell culture medium was 
higher than that of tissue treated in Cambridge after 1 and 2 hours, as well as of the tissue 
remnants, after 2 hours; these results were probably affected by the use of cell culture 
medium which improved the viability of tissue. The high variability in terms of viability 
observed in each group was most likely affected by the different time of death of the various 
pigs from which the hearts were dissected.  
In preliminary studies the bioreactor stations were filled with cell culture medium without using 
a peristaltic pump; results showed a high decrease in cell viability compared to the positive 
control. This was attributed to the entrapment of air, which was observed underneath most of 
the samples in the bioreactor stations, probably due to the procedure followed for filling the 
stations with medium. In the first 1 day static culture experiment (method 1) a peristaltic pump 
was used to fill the bioreactor stations with culture medium, with a view to avoiding the air 
entrapment underneath the tissue. Sterility was maintained after 1 day of static culture in the 
stations mounted in the main bioreactor, despite a small leakage that was developed. 
However, the viability of the tissue in the bioreactor stations was significantly reduced due to 
the persisting air entrapment underneath the tissue.  
The 1 day static culture experiment was repeated (method 2) again by changing the set-up of 
the bioreactor stations, and by introducing a new technique for filling the stations with culture 
medium. The new culture medium filling technique helped to avoid air entrapment in the 
stations. However, the fresh pericardial samples in the bioreactor stations again demonstrated 
low viability, which was not significantly different to the negative control. This drop in cell 
viability was attributed to inadequate oxygen and pH control. Previous studies have shown 
that, if the oxygen supply is inadequate, the mitochondria are unable to effectively synthesise 
ATP, leading to increased glycolysis, and subsequent increased production of pyruvate. The 
pyruvate is then converted to lactate, which can cause pH drop, inhibiting cell growth 
(Hochachka and Mommsen, 1983) and potentially leading to cell swelling and death (Staub et 
al., 1990). The 1 day static culture experiment with fresh pericardium was repeated once more 
(method 3), by introducing a pH-stabilising buffer (HEPES), and a better control of the head 
volume of culture medium on top of the samples in the bioreactor stations. In addition, the 
number of replicates for the positive control for the MTT assay was increased to improve the 
accuracy of the results. In spite of these changes, a high variability was still observed in the 
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cell viability results. This was probably due to the quality of the fresh tissue. It has been 
reported that some cellular organelles start deteriorating shortly after death, affecting and 
decreasing the cell viability of the tissues (Alessandrini et al., 1994). Owing to this, it was 
decided to use a tissue whose cell viability was more controllable, such as the pMSC-seeded 
pericardial scaffolds, in the subsequent dynamic cultures. 
Porcine MSC-seeded pericardial scaffolds were cultured statically in both bioreactor stations 
and tissue holders to investigate any potential differences in the viability and histoarchitecture 
maintenance between samples cultured in stations and in tissue holders. This investigation 
was performed to assess whether samples cultured in the tissue holders could be used as 
static controls. The protocol previously optimised for the static culture of fresh pericardia in the 
bioreactor stations (method 3) was used during static culture in the stations of the pMSC-
seeded pericardial scaffolds. Results after 1 day static culture showed that the 
histoarchitecture was intact for both tissue holders and bioreactor stations group, and all 
samples demonstrated an almost continuous layer of pMSCs on the mesothelial surface 
(seeding surface). Samples cultured in the stations showed viability similar to most of the 
samples of the tissue holders group; only one sample of the tissue holders group showed a 
high number of dead cells probably due to cell senescence or inadequate cell attachment to 
the scaffold. In conclusion, the tissue holders could be used as positive control during 
dynamic experiments.  
Porcine MSC-seeded pericardial scaffolds were then cultured dynamically (method 1) in the 
bioreactor stations and statically in the tissue holders for up to 1 day to investigate the effects 
of dynamic culture on cell viability, directionality and sample histoarchitecture. The results of 
the MTT assay after 1 day dynamic conditioning showed that 2 out of 4 samples of the 
bioreactor stations group had low values of viability, close to the values of the negative 
control. This was related to air entrapment issues; indeed, the level of medium underneath the 
2 samples was not into contact with the tissue after 1 day dynamic stimulation, probably due 
to some air trapped in the system during the dynamic motion of the cell culture medium. 
Nevertheless, the histoarchitecture of samples was intact and pMSCs formed an almost 
continuous monolayer of cells on the seeding surface and started penetrating the matrix. Also, 
cell alignment was observed in the bioreactor stations samples. Unfortunately, it was not 
possible to define along which direction cells were aligning (circumferential or radial). 
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Finally, the 1 day dynamic culture was repeated (method 2) again to overcome the issues in 
terms of air entrapment in some of the bioreactor stations and the bioreactor chamber, the 
latter to have a more homogeneous strain level distribution on the sample. The bioreactor 
stations samples showed viability similar to the tissue holders and significantly higher than the 
negative controls. The histoarchitecture of samples was intact, and pMSCs started forming an 
almost continuous monolayer of cells on the seeded surface, as well as started penetrating 
through the thickness of samples. The alignment of cells along specific directions was obvious 
again in the samples cultured dynamically in the bioreactor stations. Cell alignment can guide 
the deposition of ECM proteins, such as collagen and elastin, along specific directions, 
guiding the formation of specific histoarchitecture, as reported in previous studies (Kim et al., 
1999; Altman et al., 2002; Mol et al., 2003). It has been described that the realignment of the 
ECM is driven by the cytoskeleton of cells, to which the ECM is connected via protein 
complexes; cells probably align the ECM proteins by pulling the collagen fibers and aligning 
them in a direction parallel to their bodies (Grenier et al., 2005).  
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Chapter 8 
Discussion, conclusions & future work 
Valvular heart disease represents a major cause of mortality worldwide. In the USA alone 
there are approximately 100,000 valve replacement or repair operations and 20,000 
associated deaths per year (Otto and Bonow, 2009). Mitral valve (MV) dysfunction, 
manifested by valve regurgitation and/or stenosis, represents the second major valvular 
disorder in the Western world, after aortic valve dysfunction (Chockalingam et al., 2004). 
Current strategies for MV dysfunction are mainly focused on the repair of the diseased valve 
or its replacement with a mechanical, bioprosthetic, homograft (semilunar or MV) or autograft 
(pulmonary) valve (Moon et al., 2001). However, both strategies only deliver biocompatible 
solutions that cannot regenerate or grow with the patient, causing serious disadvantages 
especially for young patients (Chauvaud et al., 2003; Dumont et al., 2007). Tissue engineering 
approaches have the potential to deliver solutions to the problems associated with 
conventional MV repair and replacement through the development of tailor-made MV 
replacements or reconstruction materials. In addition, particularly for the pediatric population, 
tissue-engineered heart valves could represent the optimal solution for valve reconstruction 
due to their potential for growth, repair and remodelling (Sapirsten and Smith, 2001; Booth, et 
al., 2002; Vesely, 2005). 
The overall aim of this study was to investigate the functional tissue engineering of MV 
leaflets. The approach adopted was to utilise decellularised porcine pericardium seeded with 
porcine cells. The long term strategy was envisaged as the production of decellularised 
xenogeneic donor pericardial scaffolds seeded with the patient’s own MSCs, isolated from the 
bone marrow, and mechanically conditioned in a bioreactor, to allow for the remodelling of the 
scaffold in order to obtain a MV-leaflet-equivalent tissue prior to implantation. Human cells 
were not used in this study due to the limited availability of human tissue. 
During the course of this study, the biomechanical and biological properties of porcine MV 
leaflets were studied with a view to understanding the histoarchitectural, biomechanical and 
functional requirements of the tissue engineered (TE) constructs. The properties of native and 
decellularised porcine pericardium were also studied to assess the effects of decellularisation 
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on the histoarchitecture, biomechanics and function of the pericardium, as well as to assess 
the suitability of pericardium for MV leaflet repair. The biocompatibility and DNA content of 
pericardium after decellularisation were investigated.  
The decellularised pericardia were then seeded with different cells types (porcine smooth 
muscle cells (pSMCs), porcine skin fibroblasts and porcine mesenchymal stem cells (pMSCs)) 
to investigate the seeding density and time point to culture the samples statically, prior to 
loading on the bioreactor for dynamic stimulation. A novel bioreactor system was described, 
calibrated and optimised for static and dynamic experiments with both fresh and cell-seeded 
decellularised porcine pericardium. In particular, fresh pericardium was used to validate the 
system, in terms of oxygen and pH control, during static culture; subsequently, 1 day static 
and dynamic (at 10% strain) experiments were performed in the bioreactor using 
decellularised pericardium seeded with pMSCs.   
Porcine MV leaflets were used in this study for comparative purposes due to the limited 
availability of human tissue. Previous studies have demonstrated that the anatomic structure 
of human and porcine MV apparatus is similar (Kunzelman et al., 1994). Decellularised 
pericardium was chosen as the natural scaffold for the regeneration of MV leaflets; the reason 
for the choice of this specific tissue was that pericardium has been commonly used in the 
clinic for the repair of MV leaflets (Maranto and Schoen, 1988; Chauvad et al., 1991; Duran 
and Gometza, 1993; Muhercke et al., 1997; Chauvad et al., 2001; Dillon et al., 2013). In 
addition to this, a natural scaffold was chosen over a synthetic alternative due to its inherent 
properties; natural scaffolds present natural histoarchitecture and biochemical cues, which 
can potentially favour cell adhesion, migration and proliferation (Mendelson and Schoen, 
2006). Synthetic materials have limitations in terms of their mechanical properties, which are 
usually poor and make them unlikely candidates for implantation to the demanding valvular 
environment in the body (Rabkin and Schoen, 2002).  
Another option amongst the natural scaffolds was a reconstituted extracellular matrix (ECM) 
protein-based scaffold; in particular, a recombinant human collagen scaffold might represent a 
good alternative to a decellularised biological scaffold for MV leaflet reconstruction. Indeed, 
collagen is the major component of the ECM and it provides mechanical strength to tissues; 
recombinant human collagen has the same amino acid sequence as human tissue-derived 
collagen and can be produced with a similar degree of stability as natural collagen (Yang et 
al., 2004). Recombinant human collagens types I and III have been used as corneal 
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substitutes for implantation in in vivo studies (Merret et al., 2008). This approach for the 
production of collagen has some advantages in comparison to collagen derived from an 
animal, such as better quality and purity as well as no risk of transmission of infectious 
agents. Nevertheless, collagen constructs, as well as reconstituted protein scaffolds in 
general, have limitations in terms of both excessive shrinkage of the construct after cell 
seeding and insufficient mechanical properties (Shi and Vesely, 2004; Mendelson and 
Schoen, 2006). The dynamic conditioning of collagen constructs seeded with cells might help 
to overcome problems of shrinkage of the scaffold; the mechanical stimuli could potentially 
withstand the contractile forces developed by the cells.  
The histological examination of fresh pericardium revealed its characteristic trilaminar 
structure. The histoarchitecture was maintained after decellularisation; nevertheless, a high 
loss of glycosaminoglycans (GAGs), mainly concentrated in the mesothelial region, was 
observed. Histological analysis of MV leaflets showed the collagen fibre alignment along the 
circumferential direction and revealed their characteristic quadrilaminar structure. The 
conclusions from the histological analysis were that the fibrous layer of fresh and 
decellularised pericardium was quite comparable to the fibrosa of the MV leaflets, rich in 
densely packed collagen fibres and with small and few elastic fibres, however, the collagen 
fibre orientation in the pericardium was more multidirectional compared to that in the fibrosa of 
the leaflets which was mainly aligned along the circumferential direction.  
The biochemical analysis of the tissues showed that both fresh and decellularised pericardium 
had a lower GAG content compared to both the anterior and posterior MV leaflet, and the 
hydroxyproline (HXP) content of decellularised pericardium was higher compared to that of 
both the anterior and posterior leaflets.  
The biomechanical characterisation of the porcine MV leaflet specimens showed the 
characteristic anisotropic behaviour of the anterior and the rather isotropic behaviour of the 
posterior leaflets. The anterior leaflets demonstrated a higher collagen phase slope and 
ultimate tensile strength (indicative of a stiffer tissue) in the circumferential direction compared 
to the radial direction, as well as compared to the circumferential and radial directions of the 
posterior leaflets. This behaviour of the anterior leaflet is related to its distinct histoarchitecture 
that features circumferentially-aligned collagen fibres, and compensates for the significantly 
higher stress that the anterior leaflet experiences during the cardiac cycle (Jensen, 2006; 
Kunzelman et al., 1993a; May-Newman and Yin, 1995; Roberts, 2012). Both fresh and 
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decellularised pericardium demonstrated rather isotropic mechanical behaviours, in contrast 
to the anisotropic properties observed for the MV anterior leaflets. In addition, both fresh and 
decellularised pericardium were less compliant and stiffer compared to the leaflets.  
These findings showed that MV leaflets and porcine pericardium presented different biological 
and mechanical properties. Despite these limitations, decellularised porcine pericardium was 
still considered a good choice for this project.  
This was because mechanical stimulation of cell-seeded decellularised pericardium in vitro in 
a bioreactor, could potentially guide the histoarchitectural, biochemical and biomechanical 
remodelling of the scaffold towards a more leaflet-like histoarchitecture, biochemistry and 
biomechanics. 
In addition to histochemical and mechanical analysis, the DNA content and biocompatibility of 
decellularised pericardium were determined. A reduction in the DNA content of 99% was 
observed following decellularisation and the cytotoxicity assays showed that porcine 
fibroblasts and pMSCs grew well in contact with the scaffold and with scaffold extracts, 
demonstrating adequate removal of the chemicals used during the decellularisation process.   
Prior to static and dynamic experiments with the bioreactor, the potential of decellularised 
pericardial samples to support cell attachment was investigated. Cells needed to attach to and 
form a continuous monolayer on the surface of the scaffold, prior to dynamic culture in the 
bioreactor, in order to avoid dislodging of the cells during mechanical stimulation (Ye et al., 
2009). The cells chosen for seeding were SMCs and dermal fibroblasts which expressed a 
phenotype close to the VICs of the MV leaflets in vivo and MSCs due to their relative ease of 
isolation from the bone marrow of the patient and their differentiation potential towards the 
VICs phenotype under mechanical stimuli in vitro. Following confirmation of cell phenotype, 
the seeding density and time point for culturing the cells on the scaffolds prior to loading on 
the bioreactor were investigated. Results obtained with fibroblasts and pSMCs showed the 
need for a longer culture duration and higher cell density for seeding the scaffold compared to 
pMSCs, probably due to their limited lifespan, being terminally differentiated. Owing to these 
results, only pMSCs were used in the subsequent dynamic cultures. 
It has been reported that bone marrow derived MSCs have a propensity to default towards an 
osteogenic lineage (Yoon et al., 2004). This issue could potentially be overcome by careful 
use of selection methods, such as magnetic-activated cell sorting (MACS) or fluorescence-
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activated cell sorting (FACS) (Deschaseaux et al., 2003), or using a different source for 
MSCs, such as adipose tissue, which can be isolated in fairly large quantities using minimally 
invasive procedures (Pansky et al., 2007). Other stem cells which have been reported in the 
literature for possible use in heart valve tissue engineering are embryonic stem cells and 
induced pluripotent stem cells (iPCs). These cell types were not chosen for this study due to 
their limitations. Embryonic stem cells are allogeneic and may be rejected by the patient and 
undifferentiated embryonic stem cells may be tumorogenic (Forsberg and Hovatta, 2012). In 
addition there are ethical concerns associated with their harvesting which is embryo-
destructive (Forsberg and Hovatta, 2012). Induced pluripotent stem cells, in contrast to 
embryonic stem cells, do not raise ethical concerns; nevertheless, research using these cells 
is still at a relatively early stage and there are concerns about their safety in terms of 
carcinogenic potential of virally or non-virally transduced lines, in the latter case, due to 
genome instability (Weber et al., 2012). Long term animal studies need to be performed to 
evaluate the safety when using such cells for tissue regeneration.  
The bioreactor represents a major component required for the development of tissue 
engineered heart valves. The bioreactor system used in this study was designed in order to 
mimic in vitro the biaxial strain that the MV leaflets experience in vivo, which is mainly 
characterised by an inflation and deflation of the leaflets during the cardiac cycle (Nolan et al., 
1969). During the dynamic cultures, the seeded scaffolds were subjected to biaxial strain 
amplitude of 10%. This strain level was obtained from previously-developed, near-
physiological computational models (fluid-solid-interaction) of the MV apparatus (Roberts, 
2012), and represented the maximum strain predicted for the central region of the MV anterior 
leaflets during the cardiac cycle. To date, the only study reported in the literature on the tissue 
engineering of MV leaflets was by Flanagan et al. (2006). Unfortunately the study of Flanagan 
et al. (2006) did not include any mechanical conditioning of the tissue engineered constructs.  
The study progressed to validate the bioreactor system in terms of its ability to maintain cell 
viability using fresh pericardial patches, which were disinfected using an optimised Cambridge 
antibiotic protocol and cultured statically for 1 day. Numerous problems were encountered 
when setting up the pericardium in the bioreactor stations. Initially problems were encountered 
with air entrapment beneath the pericardium which led to a rapid loss of viability during static 
culture. This problem was overcome by careful attention to the technique used to fill the 
stations with medium plus improving the design of the bioreactor stations by adding a 
stopcock and a tube open to the atmosphere. It would however be useful for future studies to 
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redesign further aspects of the bioreactor stations. For example, the inlet and the outlet of the 
lower station consisted of small holes located just below the pericardial membrane; their size 
should be increased to allow for a better removal of the air during filling with medium. 
Furthermore, it was observed that while filling the lower station, the medium was partly going 
towards the lower station and partly towards the upper station, probably due to air 
entrapment. To overcome this issue, the inlet port of the lower station should be redesigned to 
guide the flow of medium towards the lower station during filling. Since it was not practicable 
to make these changes during the course of this study due to time pressure, it was necessary 
to change the technique for filling the station to solve this issue. Another problem was 
represented by the soft material of the luer fittings; during initial static experiments a leakage 
was observed in a bioreactor station, developing at one of the polyvinylidene fluoride (PDVF) 
luer fittings used to connect the silicone tubing. This problem was resolved by replacing with 
stronger stainless steel fittings.  
Problems were also encountered with loss of tissue viability due to inadequate oxygen and pH 
control and insufficient passive diffusion of the oxygen through the head volume when the 
chemostat was not used for physiological control. Unfortunately the bioreactor had been 
designed to be fed via a 2 L chemostat through which medium conditions were controlled. It 
was considered wasteful to utilise this volume of expensive medium for short term 
experiments. This was another design feature that could be improved prior to further studies 
using the bioreactor. In spite of numerous changes to the methodology used for the culture 
and analysis of fresh pericardium it was finally concluded that this tissue had an inherent 
variability in viability that could not be easily overcome. This was most likely related to the 
quality of the fresh tissue, indeed it has been reported that cell viability of tissue is affected by 
the deterioration of some cellular organelles shortly after death (Alessandrini et al., 1994). The 
original idea was to culture the fresh pericardial samples statically and also dynamically in the 
bioreactor in order to optimise the strain value to be used during dynamic experiments with 
cell-seeded decellularised pericardial samples, in order to maintain the ECM integrity and cell 
viability during mechanical conditioning in the bioreactor. Unfortunately, it was impossible to 
further proceed with the dynamic experiments with fresh pericardium, due to the high level of 
variability in the viability of the tissue that was available. The viability of tissues could possibly 
be improved if tissues could be immediately submerged in tissue transport medium containing 
proteinase inhibitors such as aprotinin following removal from the carcases at the abattoir. 
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Unfortunately, this was not possible during the course of this study due to the reluctance of 
the abattoir staff to change their working practice.   
Studies therefore progressed to utilise pMSC-seeded scaffolds. Initially, the pMSC-seeded 
scaffolds were seeded statically in bioreactor stations and in tissue holders housed in tissue 
pots, with the view to investigating potential differences between the two conditions to be used 
as static controls for the dynamic cultures. After one day, the pMSC-seeded scaffolds in both 
the bioreactor stations and the tissue holders maintained their viability. Subsequently, pMSC-
seeded scaffolds were conditioned under 10% cyclic strain in the bioreactor, whereas 
additional pMSC-seeded scaffolds were maintained statically in the tissues holders. Again, 
with dynamic cultures, problems were encountered with air entrapment beneath the scaffolds. 
Moreover, air was observed underneath the bottom silicone membrane of some stations, 
causing an unequal volume displacement between the 4 stations. Unfortunately, it was difficult 
to visualise the level of the medium in the upper stations, with respect to the inlet port due to 
the small size of the glass window. In addition to this, it was also impossible to visualise the 
level of the medium in the lower station, and so, it was not possible to observe if the medium 
was into contact with the bottom surface of samples during the dynamic culture. These issues 
were finally overcome during the final one day dynamic experiment, by adjusting the flow rate 
of the medium pumped from the chemostat to the stations so that the level of medium in the 
upper station was constantly maintained above the inlet port, and by pumping some additional 
water in the bioreactor chamber, after mounting the stations, until all the air trapped 
underneath the silicone membranes of the four stations was removed.  
The one day dynamic experiment was repeated with the improvements and results showed 
that cells were viable both after one day dynamic culture in the bioreactor and one day static 
culture in the tissue holders. Cells started aligning along specific directions when cultured 
dynamically; unfortunately, it was not possible to define along which direction (circumferential 
or radial). It has been reported that cell alignment can guide the deposition of ECM proteins, 
such as collagen and elastin, along specific directions, guiding the formation of specific 
histoarchitecture (Altman et al., 2002; Mol et al., 2003; Grenier et al., 2005).  
In conclusion, prior to future studies the stations should be fabricated using a transparent 
material to allow for visualisation of the samples. Transparent materials such as 
polycarbonate, and plexiglass combined with silicone have been used in previous studies 
(Hoerstrup et al., 2000b; Mol et al., 2005), these materials allowed for the visualisation of the 
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engineered valve under culture and can be sterilised using ethylene oxide. Glass could also 
be used for the fabrication of a large cylindrical window, but it could not be used for the 
production of more complex components.  
In addition to the material used in the fabrication of the bioreactor stations, as indicated 
above, the design of the bioreactor stations should be changed to make the system more 
user-friendly. The volumes of the upper and lower parts of the stations could be reduced by 
half without compromising nutrient supply to the constructs. In addition to using a transparent 
material, the material of choice would be much lighter than stainless steel. The upper surface 
of the chamber onto which the bioreactor stations are loaded should be large enough to easily 
accommodate the many tubing connections of the stations and it should be lower in height. 
The stations would be easier to incorporate if they did not screw into the rosette, but rather 
appropriate slots provided with o rings should be designed in the rosette in order to position 
and “clamp” the stations. The stations should then be connected through a system of pumps 
to a reservoir for the supply and collection of medium. The whole system could be housed in 
an incubator to avoid the use of the heaters for the maintenance of the temperature (37ºC) in 
the stations.  
Hoerstrup et al. (2000b) created a simple and compact heart valve bioreactor which could be 
fitted in a standard incubator and which consisted of an air chamber, a reservoir filled with cell 
culture medium and a perfusion chamber which held the heart valve, sewn inside a 
transparent silicon tube. A silicon diaphragm was placed between the air chamber and the 
perfusion chamber, and the air chamber was connected to a respirator pump. The pulsatile 
flow was achieved by pumping air into the lower chamber and displacing the silicone 
diaphragm between the liquid chamber and the lower air chamber periodically. The limitation 
of this system was that it only held one sample; however, this design could be modified to 
have at least four samples in series.  
Further limitations were observed during the use of the chemostat for the monitoring and 
supply of the oxygen and the 5% (v/v) CO2. Chemostats were originally developed for the 
growth of microorganisms. The chemostat was rather complicated to use during the bioreactor 
experiments; the high number of connections and the long length of the tubes connected to 
the stations and the reservoir made the chemostat system too bulky and introduced further 
risks of contamination. The whole set up of the system was not user friendly. In the designs 
suggested above, the chemostat would be replaced by a reservoir, which could be provided 
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with an air filter and connected to a gas cylinder with 5% (v/v) CO2 in air for the continuous 
supply of oxygen and for the pH control. The culture medium could then be pumped from the 
reservoir to the stations and then from the stations back to the reservoir in a closed loop 
system. 
Despite the encouraging results from the short-term dynamic cultures of pMSC-seeded 
decellularised pericardial scaffold, in terms of viability maintenance and cell alignment, future 
studies need to focus on longer term dynamic cultures, in order to investigate MSC 
differentiation and phenotype, ECM remodelling and tissue remodelling (Hoerstrup et al., 
2002; Rabkin et al., 2002; Mol et al., 2005; Engelmayr et al., 2006; Ku et al., 2006; 
Balachandran et al., 2009;) as well as on the experimental validation of the strains 
experienced by the engineered construct during dynamic conditioning (Engelmayr et al., 
2003). Seeded constructs could be cultured for one week and 21 days to investigate tissue 
remodelling over time; similar time points have been used previously, showing ECM 
production and remodelling at 21 days (Engelmayr et al., 2005 and 2006; Weber et al., 2013). 
Biological characterisation of samples should include histology (H&E) for the visualisation of 
cell distribution and immunohistochemistry for collagen I and III and chondroitin sulphate, to 
investigate the ECM remodelling and deposition. The qualitative results of the 
immunohistochemical analysis could be compared to quantitative assays for the 
measurements of HXP and GAG content. Qualitative and quantitative analysis have been 
used in previous studies to assess ECM remodelling (Engelmayr et al., 2005, 2006; Masoumi 
et al., 2013a, 2013b; Weber et al., 2013).  
The differentiation of MSCs could be investigated and assessed through immunocytochemical 
labelling of alpha-SMA, calponin and vimentin to investigate differentiation towards fibroblast 
or myofibroblast phenotype, and smooth muscle myosin to distinguish between the 
differentiation towards myofibroblast or SMC phenotype (Perez-Montiel et al., 2013). Von 
Kossa staining as well as osteocalcin could be used as bone marker to investigate potential 
calcification of the seeded construct as well as potential differentiation of the cells towards an 
osteoblast phenotype (Mizuno et al., 2001; Nakamura et al., 2009). Cell differentiation and 
levels of up-regulation of gene expression after dynamic conditioning of samples could be 
investigated through reverse-transcriptase polymerase chain reaction (RT-PCR) analysis; in 
particular the levels of up-regulation mRNA for the alpha-SMA, calponin, vimentin and smooth 
muscle myosin genes should be studied for cell differentiation, as well as mRNA for COL3A1 
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gene (type III collagen) and COL1A1 gene (type I collagen) for ECM production, as reported 
in previous studies (Ku et al., 2006). Mechanical tests, such as uniaxial tensile tests, should 
be performed to investigate the change in the mechanical properties of seeded constructs in 
comparison to the original scaffold and anisotropic properties of native MV leaflets. In 
addition, the actual strains experienced by the seeded constructs during mechanical 
conditioning would require validation as described by Engelmayr et al. (2003). The authors 
developed a cyclic flexure bioreactor system, which involved the recording of images during 
flexural deformation of samples. Prior to the start of the experiments, they created a 
calibration grid to couple the data in pixels to the physical dimensions of the sample, in mm. 
During the experiments, they recorded and calculated the positions and coordinates of some 
markers positioned on the sample, together with the applied load during one flexure cycle, 
through a custom C program. They processed all the data using a custom Matlab program to 
calculate the applied moment and the resulting change in curvature of the sample.  
The clinical application of this project to the tissue engineering of the MV would involve the 
use of xenogeneic porcine pericardial scaffolds that have been treated to remove the 
immunogenic cells, and then reseeded with the patient’s own cells and mechanically 
conditioned in vitro, with a view to producing biological and biomechanical functionality of the 
graft prior to implantation. Another possible tissue engineering approach would involve the 
implantation of unseeded scaffolds, with a view to attracting endogenous cell repopulation in 
vivo, after implantation. The potential use of unseeded decellularised scaffolds for MV leaflet 
reconstruction in the clinic might be limited by the variability of the patient response in terms of 
recellularisation, especially in the elderly. The ECM proteins would be continuously degraded 
in vivo due to cyclic loading and the presence of functional cells in the scaffold at the time of 
implantation would create an immediate remodelling potential in vivo.  
Nevertheless, the clinical translation of cell seeded constructs represents a major challenge. 
The seeded constructs will need to be tested in a relevant large animal prior to implantation in 
human. For example, the decellularised porcine pericardium could be seeded with ovine cells, 
dynamically conditioned in a bioreactor and then, the seeded construct could be implanted 
into the sheep from which the cells were isolated. This approach would be representative of 
the homogeneic model of human (autologous) cells seeded to xenogeneic decellularised 
scaffolds, and physically conditioned in a bioreactor prior to implantation. If the results from 
the animal study were successful, showing the effective remodelling of the seeded construct 
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and the maintenance of the valve dynamics in vivo, then the same approach could be tested 
in an initial clinical trial in a small number of patients. If the results from the clinical trial were 
successful, then this approach could be established in specialist hospitals. In addition, if the 
bioreactor system was better optimised and simplified, it could be commercialised.  
Bioreactors would have to be located in Good Manufacturing Practice (GMP) laboratories in or 
close to the hospitals, so that cells, isolated from the patient through specific protocols 
developed for the isolation of the MSCs, could be firstly expanded, using dedicated 
equipment, and then cultured on the scaffold dynamically up to a specific time point, chosen 
on the basis of previous studies. The cells would have to be cultured and expanded using 
specific protocols under ISO standards to ensure quality assurance and safety. These 
standards and regulations are set by the European Union Tissue and Cells Directives 
(EUTCD); in particular, in the UK, the Human Tissue Authority, one of the competent 
authorities under the EUTCD, has responsibility for regulating cells, as well as tissues, and for 
the registration of the facilities where the expansion and culture of the cells is carried out. 
Such Authority establishes the regulations for the procurement, testing, processing, storage 
and distribution of cells and tissues for human application.  
In addition, the process would require the use of traceable quality assured reagents and 
equipment, used during the production process. Quality assurance of the final product (the 
seeded construct) would also have to be carried out in order to ensure that the whole 
procedure was safe and that the construct was fit for its intended use and did not place the 
patient at risk or render the cells harmful or clinically ineffective. It would be necessary to 
develop non-invasive methods to ensure the quality of the constructs.  The implant would also 
need to be monitored after implantation; echocardiography has been reported as being the 
method of choice for the evaluation of the function of the valve (Pibarot and Dumesnil, 2009). 
To date, no MV leaflets have been produced or commercialised for clinical application, using a 
tissue engineering approach. A recent interesting example of tissue engineered scaffold 
reseeded in vitro with the patient’s autologous cells, and cultured under mechanical 
stimulation, for clinical application, was described in the study of Macchiarini et al. (2008). In 
this study, a decellularised human trachea free of cells and major histocompatibility complex 
(MHC) antigens was produced, then the scaffold was cultured with epithelial cells and 
chondrocytes derived from MSCs, taken from the patient, under mechanical conditioning in a 
bioreactor. The graft was then used to replace the patient’s bronchus. The results were 
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successful, showing an improved quality of life of the patient, the formation of a functional 
airway with normal appearance and mechanical properties after 4 months. Also, no 
immunosuppressive drugs were used. These results are encouraging, showing that by using 
the appropriate techniques and methodology it could be possible to provide tissue engineered 
constructs, cultured with the patient’s own cells and dynamically conditioned, to successfully 
treat patients with serious clinical disorders. 
In this study, decellularised pericardial scaffolds were seeded dynamically for up to one day in 
vitro in a novel MV leaflet bioreactor. Results were encouraging showing that the viability of 
cells could be maintained in the system and cells started aligning along preferred directions 
under dynamic stimulation. Overall the approach used for the mechanical stimulation of the 
reseeded biological scaffolds has good potential for the development of a tissue engineered 
construct that could be used in the clinic for the reconstruction of MV leaflets in a limited 
number of patients.   
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APPENDIX 
Stress-strain behaviour of the leaflet anterior 
groups 
The stress-strain behaviour of the leaflet anterior groups, circumferential and radial, are 
illustrated in Figure A.1-A.6 and Figure A.7-A.12, respectively.  
Only the data corresponding to the final loading ramp to failure, following preconditioning, 
were used in the subsequent analysis. The recorded force-extension histories of the samples 
were converted to stress strain in Microsoft Excel XP, as described in Section 2.18.3, and the 
stress-strain behaviour of the specimens was plotted. The six mechanical parameters were 
calculated as follows. The ultimate tensile strength (σuts) and the failure strain corresponded to 
the Y and X coordinates at the failure point of the curve. All the values of stress and strain 
from the σuts and failure strain onwards were discarded. Then, a line was drawn to fit and 
identify the linear region of the collagen phase and the elastin phase (Figure A.1). The elastin 
(El-E) and collagen phase slope (Coll-E) were calculated by selecting the stress and strain 
values correspondent to the linear region of the curve, and then the same interval was 
selected and processed on Origin Pro 8 to calculate the slope by using the function Fit-Linear. 
The transition strain corresponded to the X coordinate at which the line of the Coll-E crossed 
the X axsis, and the transition stress corresponded to the Y coordinate of the projection of the 
transition strain on the stress-strain curve (Figure A.1). The six parameters for each specimen 
were finally averaged over the number of specimens in the group, and analysed statistically, 
as described in Section 2.19. 
The same analysis was performed for the leaflet posterior groups and the fresh and 
decellularised pericardial groups. 
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Figure A.1: Leaflet anterior circumferential – sample 1. The red and black lines indicate the elastin 
and collagen phase region, respectively. σt: transition stress; εt: transition strain; UTS: ultimate tensile 
strength. 
 
Figure A.2: Leaflet anterior circumferential – sample 2. The red and black lines indicate the elastin 
and collagen phase region, respectively. 
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Figure A.3: Leaflet anterior circumferential – sample 3. The red and black lines indicate the elastin 
and collagen phase region, respectively. 
 
Figure A.4: Leaflet anterior circumferential – sample 4. The red and black lines indicate the elastin 
and collagen phase region, respectively. 
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Figure A.5: Leaflet anterior circumferential – sample 5. The red and black lines indicate the elastin 
and collagen phase region, respectively. 
 
Figure A.6: Leaflet anterior circumferential – sample 6. The red and black lines indicate the elastin 
and collagen phase region, respectively. 
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Figure A.7: Leaflet anterior radial – sample 1. The red and black lines indicate the elastin and 
collagen phase region, respectively. 
 
Figure A.8: Leaflet anterior radial – sample 2. The red and black lines indicate the elastin and 
collagen phase region, respectively. 
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Figure A.9: Leaflet anterior radial – sample 3. The red and black lines indicate the elastin and 
collagen phase region, respectively. 
 
Figure A.10: Leaflet anterior radial – sample 4. The red and black lines indicate the elastin and 
collagen phase region, respectively. 
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Figure A.11: Leaflet anterior radial – sample 5. The red and black lines indicate the elastin and 
collagen phase region, respectively. 
 
Figure A.12: Leaflet anterior radial – sample 6. The red and black lines indicate the elastin and 
collagen phase region, respectively. 
 
